LRRK2 inhibitors
Novel 5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine compounds provide a promising solution to inhibit LRRK2, addressing the neuronal loss in Parkinson's disease by enhancing brain penetration and selectivity, thus offering therapeutic benefits.
Patent Information
- Application Number
- JP2024524998
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-13
- Filing Date
- 2022-10-26
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current therapeutic interventions for Parkinson's disease, such as increasing dopamine levels, fail to address the underlying cause of the disease, namely the progressive loss of dopaminergic neurons, and existing LRRK2 inhibitors face challenges in achieving brain penetration, potency, and selectivity.
Development of novel 5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine compounds that act as potent and selective LRRK2 inhibitors, demonstrating low clearance and high brain penetration with good pharmacokinetics.
These compounds effectively inhibit LRRK2 activity, potentially slowing the progression of Parkinson's disease by targeting the underlying neuronal loss and offering therapeutic benefits with minimal side effects.
Smart Images

Figure 2024541934000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to compounds that are LRRK2 inhibitors and are therefore useful in therapy, and to pharmaceutical compositions comprising said compounds. [Background technology]
[0002] Parkinson's disease (PD) is a neurodegenerative disorder. It is the second most common neurodegenerative disorder after Alzheimer's disease, affecting more than 1% of the population aged 65 years or older. Clinically, PD is characterized by resting tremor, bradykinesia, muscle rigidity, and postural instability. In addition to motor symptoms, many patients also experience other symptoms, such as neuropsychiatric symptoms, and Parkinson's disease dementia commonly develops in the later stages of the disease. Pathologically, the disease is characterized by the loss of dopaminergic neurons, resulting in a decrease in brain dopamine levels, and the aggregation of α-synuclein protein in dopaminergic neurons. These aggregates, called Lewy bodies, are composed of insoluble α-synuclein phosphorylated at serine 129 and ubiquitin.
[0003] Current intervention strategies for Parkinson's disease aim to increase dopamine levels by administering levodopa or monoamine oxidase B inhibitors. Alternatively, dopamine agonists are administered to stimulate dopaminergic receptors, achieving a similar effect to increasing dopamine levels. While these treatments provide significant symptomatic benefits to patients, they also have adverse side effects and often become ineffective after long-term treatment and progression of the underlying disease. Importantly, none of the existing treatments address the underlying, disease-causing problem: the progressive loss of dopaminergic neurons.
[0004] Leucine-rich repeat kinase 2 (LRRK2) is a 2527 amino acid protein involved in catalyzing protein phosphorylation. Increasing evidence implicates LRRK2 in the pathogenesis of Parkinson's disease. Single nucleotide polymorphisms that alter amino acids in the functional domain of LRRK2 have been shown to cause common, sporadic forms of Parkinson's disease. Several such pathogenic variants have been identified, including G2019S, I2020T, N1437H, R1441C, R1441G, R1441H, and Y1699C (Shu et al., A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease, Front Aging Neurosci., 11:13, 2019; Chittoor-Vinod et al., Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism, Int. J. Mol. Sci., 2021, 22, 1045). The most common pathogenic form of LRRK2-related Parkinson's disease is the amino acid substitution G2019S within the kinase domain of the LRRK2 protein. G2019S Parkinson's disease is inherited in an autosomal dominant manner, suggesting a gain-of-function mutation in the LRRK2 protein. In support of this concept, biochemical studies have shown that both G2019S and other pathogenic LRRK2 mutations lead to increased LRRK2 kinase activity (West et al., Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity, Proc. Nat. Acad. Sci, 102, 16842-16847, 2005; Chittoor-Vinod et al., Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism, Int. J. Mol. Sci., 2021, 22, 1045).The clinical and pathological features of LRRK2 gene mutation-associated Parkinson's disease are very similar to those of idiopathic Parkinson's disease (Trinh et al., A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism, Neurobiol. Aging., 35(5), 1125-31, 2014). This strongly suggests that overactivity of LRRK2 is involved in the pathogenesis of Parkinson's disease in patients with such activating LRRK2 mutations, and suggests that LRRK2 inhibitors may be used as disease-modifying treatments for the common Parkinson's disease.
[0005] In addition to the rare highly penetrant exonic LRRK2 variants described above, there are also common LRRK2 variants with a low but significant association with Parkinson's disease, indicating that LRRK2 also contributes to idiopathic Parkinson's disease. These include a highly common single-nucleotide polymorphism in the LRRK2 promoter region, where Parkinson's disease-associated variants appear to be associated with increased LRRK2 expression in at least some cell types (Nalls et al., Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies, Lancet Neurol, 2019, 18, 1091-1102; Sun et al., Genetic Variants Associated With Neurodegenerative Diseases Regulate Gene Expression in Immune Cell CD14+ Monocytes, Front Genet., 2018, 18, 9:666; Langston et al., Association of a Common Genetic Variant with Parkinson's Disease is Propagated through Microglia, bioRxiv, 2021), suggesting that inhibition of LRRK2 may be involved. Furthermore, investigation of common exonic polymorphisms has revealed several LRRK2 Parkinson's disease risk variants, including A419V and G2385R, which are common in Asians (Shu et al., A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease, Front Aging Neurosci., 11:13, 2019).There are also protective LRRK2 mutations with reduced kinase activity, such as the LRRK2 N551K R1398H mutant (Wang et al., "Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10," Scientific Reports, 2021, 11:12900). This indicates that wild-type LRRK2 activity is suboptimal in the context of Parkinson's disease, further supporting the potential of LRRK2 inhibition in idiopathic Parkinson's disease. Functionally, LRRK2 influences the trafficking of lysosomes and other vesicles through phosphorylation of RAB GTPases, and PD-associated genes are enriched for genes involved in lysosomal function and autophagy (Chang et al., "A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci," Nat Genet., 2017, 49(10):1511-1516). Two genes associated with Parkinson's disease, VPS35 and RAB29, have been shown to directly interact with LRRK2 biology by increasing its activity (Taylor et al., Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease, Curr Opin Cell Biol., 2020, 63:102-113), and as mentioned above, LRRK2-associated Parkinson's disease closely resembles idiopathic PD. Taken together, these findings strongly support the relevance of LRRK2 inhibition in the treatment of idiopathic PD.
[0006] Several lines of evidence suggest that LRRK2 activity may influence α-synuclein pathogenesis following α-synuclein seeding (O'Hara et al., LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?, Front Neurosci., 2020, 17;14:577).
[0007] In addition to strengthening the evidence for the potential of LRRK2 inhibitors in the treatment of Parkinson's disease, this also points to the potential of LRRK2 inhibitors in the treatment of other synucleinopathies, including dementia with Lewy bodies and multiple system atrophy.
[0008] LRRK2 is highly expressed in leukocytes and the spleen, suggesting that LRRK2 inhibitors may be useful for treating abnormal immune responses. This is further supported by the genetic association of LRRK2 with such diseases, particularly inflammatory bowel diseases such as Crohn's disease and leprosy (Liu et al., Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations, Nat Genet., 2015, 47(9):979-986; Rastegar et al., Leucine Rich Repeat Kinase 2 and Innate Immunity, Front Neurosci., 2020, 10;14:193). Therefore, LRRK2 inhibitors may be a potential therapeutic agent for these diseases.
[0009] Because of the promise of LRRK2 in the treatment of Parkinson's disease, there has been significant interest from both the pharmaceutical industry and academic research institutions in developing potent and selective LRRK2 inhibitors.
[0010] The historical development of LRRK2 inhibitors is well documented (Delgado et al., N-bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders, European Journal of Medicinal Chemistry 97(2015)719-731; Xiao Ding & Feng Ren(2020)Leucine-rich repeat kinase 2 inhibitors: a patent review(2014-present), Expert Opinion on Therapeutic Patents,30:4,275-286). Despite much attention being paid to the design of new LRRK2 inhibitors in the pharmaceutical industry and academic research institutions, the challenge of designing brain-penetrant, potent, and selective LRRK2 inhibitors remains a challenging task for the medicinal chemistry community (Delgado et al., N-bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders, European Journal of Medicinal Chemistry 97(2015)719-731).
[0011] Despite significant efforts from the pharmaceutical industry and academic research institutions, only two molecules (DNL201 and DNL151) from Denali Therapeutics have reached the clinical stage (Xiao Ding & Feng Ren (2020) Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present), Expert Opinion on Therapeutic Patents, 30:4, 275-286).
[0012] Against this background, there remains an unmet need to provide LRRK2 inhibitors with good pharmacokinetic properties while maintaining high potency and good selectivity. Summary of the Invention
[0013] The present inventors have surprisingly discovered that certain 5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine compounds are LRRK2 inhibitors. Accordingly, in a first aspect of the present invention, there is provided a compound of formula I: [ka] (Wherein R1 is CH2R4 or R4; R2 is C1-C3 alkyl, isotopically labeled C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 haloalkyl; R3 is halogen, cyano, O—C1-C3 haloalkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, or C1-C3 alkyl; R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; or R4 is a bicyclic 8-membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen; wherein each heterocycle or cycloalkyl is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0014] In some embodiments of the present invention, R1 is CH2R4.
[0015] In some embodiments of the present invention, R1 is R4.
[0016] In some embodiments of the invention, the compound has formula Ia: [ka] or a pharmaceutically acceptable salt thereof.
[0017] In some embodiments of the invention, R2 is selected from C1-C3 alkyl, isotopically labeled C1-C3 alkyl, or C3-C6 cycloalkyl.
[0018] In some embodiments of the present invention, R2 is selected from -CH3, -CH2CH3, -CD3, or cyclopropyl.
[0019] In some embodiments of the present invention, R2 is C1-C3 alkyl.
[0020] In some embodiments of the invention, R2 is methyl.
[0021] In some embodiments of the invention, R2 is ethyl.
[0022] In some embodiments of the invention, R2 is an isotopically labeled C1-C3 alkyl.
[0023] In some embodiments of the invention, R2 is selected from the group consisting of -CD3 or -CD2CD3.
[0024] In some embodiments of the invention, R2 is -CD3.
[0025] In some embodiments of the invention, R2 is cyclopropyl.
[0026] In some embodiments of the present invention, R3 is C1-C3 haloalkyl.
[0027] In some embodiments of the present invention, R3 is CF3.
[0028] In some embodiments of the present invention, R3 is halogen.
[0029] In some embodiments of the invention, R3 is chloro.
[0030] In some embodiments of the invention, R3 is bromo.
[0031] In some embodiments of the invention, R3 is cyano.
[0032] In some embodiments of the present invention, R3 is C3-C6 cycloalkyl.
[0033] In some embodiments of the invention, R3 is cyclopropyl.
[0034] In some embodiments of the present invention, R4 is a 4-6 membered heterocycle having one oxygen atom, wherein the 4-6 membered heterocycle is unsubstituted or substituted with one group selected from the group consisting of cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl.
[0035] In some embodiments of the present invention, R4 is a 4-6 membered heterocycle having one oxygen atom, wherein the 4-6 membered heterocycle is unsubstituted or substituted with one group selected from the group consisting of deuterium, halogen, C1-C3 alkyl, or isotopically labeled C1-C3 alkyl.
[0036] In some embodiments of the present invention, R4 is a 6-membered heterocycle having one oxygen atom, wherein the 6-membered heterocycle is unsubstituted or substituted with one group selected from the group consisting of deuterium, halogen, C1-C3 alkyl, or isotopically labeled C1-C3 alkyl.
[0037] In some embodiments of the present invention, R4 is a 6-membered heterocycle having one oxygen atom, wherein the 6-membered heterocycle is unsubstituted or substituted with two groups independently selected from the group consisting of deuterium, halogen, C1-C3 alkyl, or isotopically labeled C1-C3 alkyl.
[0038] In some embodiments of the invention, R4 is [ka] is selected from the group consisting of:
[0039] In some embodiments of the present invention, R4 is CH3, [ka] [ka] is selected from the group consisting of:
[0040] In some embodiments of the present invention, R4 is tetrahydropyran.
[0041] In some embodiments of the invention, R4 is unsubstituted tetrahydropyran.
[0042] In some embodiments of the invention, R4 is tetrahydro-2H-pyran-4-yl.
[0043] In some embodiments of the invention, R4 is tetrahydro-2H-pyran-3-yl.
[0044] In some embodiments of the present invention, R4 is 4-oxaspiro[2.5]octan-7-yl.
[0045] In some embodiments of the present invention, the 8-membered heterocycle is an unsubstituted 8-membered spirocyclic heterocycle.
[0046] In some embodiments of the present invention, the bicyclic 8-membered heterocycle contains one oxygen.
[0047] In some embodiments of the present invention, the bicyclic 8-membered heterocycle contains one oxygen and is a spirocyclic heterocycle.
[0048] In some embodiments of the invention, the compound has formula Ib: [ka] (wherein R2 is C1-C3 alkyl, isotopically labeled C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 haloalkyl; R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; wherein each heterocycle or cycloalkyl is unsubstituted or substituted with one group selected from cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0049] In some embodiments of the present invention, R2 is selected from -CH3, -CH2CH3, -CD3, or cyclopropyl.
[0050] In some embodiments of the invention, the compound has formula Ic: [ka] (wherein R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; Each heterocycle or cycloalkyl is unsubstituted or substituted with one group selected from cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0051] In some embodiments of the invention, the compound has formula Id: [ka] (wherein R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; Each heterocycle or cycloalkyl is unsubstituted or substituted with one group selected from cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0052] In some embodiments of the present invention, the 4-7 membered heterocycle is an unsubstituted 6-7 membered spirocyclic heterocycle.
[0053] In some embodiments of the present invention, the 4-7 membered heterocycle is an unsubstituted 6-7 membered bridged heterocycle.
[0054] In some embodiments of the invention, the compound is [ka] [ka] or a pharmaceutically acceptable salt thereof.
[0055] In some embodiments of the invention, the compound is 8-Chloro-2,3-dimethyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo-[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 3-Methyl-2-(tetrahydro-2H-pyran-4-yl)-8-(trifluoromethyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Bromo-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Cyclopropyl-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 3,8-Dimethyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 3-Methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-8-carbonitrile; 8-Chloro-3-cyclopropyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 2-((2-oxabicyclo[2.1.1]hexan-1-yl)methyl)-8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-((3-methyloxetan-3-yl)methyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-(3-methyloxetan-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-4-yl-4-d)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; and 8-chloro-3-(1-fluorocyclopropyl)-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
[0056] In some embodiments of the invention, the compound is [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof.
[0057] In some embodiments of the invention, the compound is 8-Chloro-3-ethyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-((2R,4R)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-((2S,4S)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-11,11,12,12,13,13-d6; 8-chloro-3-methyl-2-((3R,4S)-3-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-((3S,4R)-3-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-((3S,4S)-3-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-((3R,4R)-3-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((1r,4r)-4-fluorocyclohexyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-(4,4-difluorocyclohexyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-methyl-2-(oxepan-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-Chloro-3-methyl-2-(oxepan-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-methyl-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-Chloro-3-methyl-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 3-(8-chloro-3-methyl-12,13-dihydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecin-2(4H)-yl)bicyclo[1.1.1]pentane-1-carbonitrile; 8-chloro-3-methyl-2-(2-oxaspiro[3.3]heptan-6-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-11,11,12,12,13,13-d6; 1-(8-chloro-3-methyl-12,13-dihydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecin-2(4H)-yl)cyclopropane-1-carbonitrile; 8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 2-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-2-(2,2-difluorocyclopropyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-chloro-2-(2,2-difluorocyclopropyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-chloro-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 2-((1R,3s,5S)-8-oxabicyclo[3.2.1]octan-3-yl)-8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-11,11-d2; 8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-13,13-d2; 8-chloro-2-((3R,4S)-3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3S,4R)-3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-(methyl-d3)-2-((2R,4R)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-(methyl-d3)-2-((2S,4S)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-methyl-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-chloro-3-methyl-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-ethyl-2-((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-ethyl-2-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-ethyl-2-((1r,4r)-4-methoxycyclohexyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-(methyl-d3)-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-chloro-3-(methyl-d3)-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-Chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-(methyl-d3)-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; and (S)-8-chloro-3-(methyl-d3)-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; or a pharmaceutically acceptable salt thereof.
[0058] In some embodiments of the invention, the compound is [ka] or a pharmaceutically acceptable salt thereof.
[0059] In some embodiments of the invention, the compound is [ka] is.
[0060] In some embodiments of the invention, the compound is [ka] or a pharmaceutically acceptable salt thereof.
[0061] In some embodiments of the invention, the compound is [ka] or a pharmaceutically acceptable salt thereof.
[0062] In some embodiments of the invention, the compound is [ka] is.
[0063] In some embodiments of the invention, the compound is [ka] or a pharmaceutically acceptable salt thereof.
[0064] In some embodiments of the invention, the compound is [ka] or a pharmaceutically acceptable salt thereof.
[0065] In some embodiments of the invention, the compound is [ka] or a pharmaceutically acceptable salt thereof.
[0066] In some embodiments of the invention, the compound is [ka] or a pharmaceutically acceptable salt thereof.
[0067] In some embodiments of the invention, the compound is [ka] or a pharmaceutically acceptable salt thereof.
[0068] In some embodiments of the invention, the compound is [ka] is.
[0069] In some embodiments of the invention, the compound is [ka] is.
[0070] In some embodiments of the invention, the compound is [ka] is.
[0071] In some embodiments of the invention, the compound is [ka] is.
[0072] In some embodiments of the invention, the compound is [ka] is.
[0073] In some embodiments of the invention, the compound is [ka] is.
[0074] In some embodiments of the invention, the compound is [ka] is.
[0075] In some embodiments of the invention, the compound is [ka] is.
[0076] In some embodiments of the invention, the compound is [ka] is.
[0077] In a further aspect, the present invention provides pharmaceutical compositions comprising a compound of Formula I, Ia, Ib, Ic, Id, A or Aa as disclosed herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
[0078] In a further aspect, the present invention provides a compound of Formula I, Ia, Ib, Ic, Id, A or Aa, or a pharmaceutically acceptable salt thereof, as disclosed herein, for use in therapy.
[0079] In a further aspect, the present invention provides a compound of Formula I, Ia, Ib, Ic, Id, A or Aa, or a pharmaceutically acceptable salt thereof, as disclosed herein, for use in treating an LRRK2-related disorder, such as Parkinson's disease.
[0080] In a further aspect, the invention relates to the use of a compound of Formula I, Ia, Ib, Ic, Id, A or Aa, as disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an LRRK2-related disorder, such as Parkinson's disease.
[0081] In a further aspect, the present invention relates to a method for treating an LRRK2-related disease, such as Parkinson's disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, Ia, Ib, Ic, Id, A or Aa as disclosed herein, or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION
[0082] Detailed Description of the Invention The inventors of the present disclosure have surprisingly identified novel compounds that are LRRK2 inhibitors. The compounds are listed in Table 1. As can be seen from the examples of the present disclosure, the compounds have been demonstrated to have low clearance and high brain penetrability while maintaining high potency and selectivity for LRRK2 and possessing favorable pharmacokinetics. As presented above, and as demonstrated in the historical literature on LRRK2 inhibitors, identifying compounds with such characteristics is by no means straightforward.
[0083] [Table 1-1]
[0084] [Table 1-2]
[0085] [Table 1-3]
[0086] [Table 1-4]
[0087]
Table 1-5
[0088]
Table 1-6
[0089]
Table 1-7
[0090]
Table 1-8
[0091]
Table 1-9
[0092]
Table 1-10
[0093]
Table 1-11
[0094]
Table 1-12
[0095]
Table 1-13
[0096]
Table 1-14
[0097]
Table 1-15
[0098]
Table 1-16
[0099]
Table 1-17
[0100]
Table 1-18
[0101]
Table 1-19
[0102]
Table 1-20
[0103]
Table 1-21
[0104]
Table 1-22
[0105]
Table 1-23
[0106]
Table 1-24
[0107] [Table 1-25]
[0108] [Table 1-26]
[0109] [Table 1-27]
[0110] a.Definition In the present context, "alkyl" is intended to denote a straight or branched chain saturated hydrocarbon. 1~ C alkyl is intended to indicate a hydrocarbon having 1, 2, or 3 carbon atoms in the longest continuous carbon chain. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, and the like.
[0111] As used herein, the term "isotopically labeled alkyl group" refers to an alkyl group in which either a carbon or hydrogen atom is isotopically labeled with an isotopically labeled alkyl group. 13 C and / or 14 C, hydrogen atoms are replaced with corresponding isotopes such as deuterium or tritium. In one embodiment of the present invention, all hydrogen atoms of the alkyl group are replaced with deuterium. Representative examples of isotopically labeled alkyl include, but are not limited to, -CD3 and -CD2CD3. In a preferred embodiment, isotopically labeled C 1~ A C3 alkyl is CD3.
[0112] As used herein, the term "alkylene" refers to a divalent group derived from a straight or branched chain hydrocarbon of 1 to 10 carbon atoms, for example, 2 to 5 carbon atoms. Representative examples of alkylene include, but are not limited to, -CH-, -CHCH-, -CHCHCH-, -CHCH(CH)CH-, -CHCHCHCH-, -CHCH(CH)CHCH-, -CH(CH)-, and -CHCHCHCHCHCH-.
[0113] As used herein, the term "alkoxy" refers to a group of formula -O-alkyl, where alkyl is defined as above. In particular, C1-C3 alkoxy is intended to refer to a hydrocarbon having 1, 2, or 3 carbon atoms. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, isobutoxy, t-butoxy, and the like.
[0114] The terms "haloalkyl" or "haloalkoxy" are intended to refer to an alkyl or alkoxy group, as defined above, in which one, two, or three hydrogens have been replaced with a halogen. Representative examples include CHF 、 Examples include, but are not limited to, CHF2CF3, OCF3, OCH2F, and OCHF2. In this application, a "haloalkoxy" may also be referred to as an "O-haloalkyl," such as, for example, "O-C1-C3 haloalkyl."
[0115] Similarly, the term "fluoroalkyl" is intended to refer to an alkyl group as defined above in which one, two, or three hydrogens have been replaced with fluoro. Representative examples include, but are not limited to, -CF.
[0116] In the present context, "halogen" is intended to denote a member of the seventh main group of the periodic table of the elements, such as fluorine, bromine, chlorine, etc.
[0117] The term "heteroatom" is intended to mean sulfur, oxygen, or nitrogen.
[0118] As used herein, the term "cyano" means that at least one --CN group is appended to the parent molecular moiety.
[0119] As used herein, the term "cyanoalkyl" is intended to refer to an alkyl group, as defined herein, wherein at least one --CN group is appended to the parent molecular moiety.
[0120] As used herein, the term "cyclic" refers to any ring structure, including heterocyclic, aromatic, and heteroaromatic non-fused ring systems. The term "membered" is intended to indicate the number of skeletal atoms that constitute the ring. Thus, for example, pyridyl, pyranyl, and pyrimidinyl are six-membered rings, and pyrrolyl and tetrahydrofuranyl are five-membered rings.
[0121] As used herein, the term "cycloalkyl" refers to a carbocyclic ring system containing 3 to 10 carbon atoms, no heteroatoms, and no double bonds. Cycloalkyls can be monocyclic or bicyclic, and bicyclic rings can be bridged, fused, or spirocyclic.
[0122] As used herein, the terms "heterocycle," "heterocyclic," and "heterocyclyl," alone or in combination, refer to a saturated or unsaturated non-aromatic ring containing 4 to 7 ring atoms, in which one or more ring atoms are heteroatoms. Heterocycles can be monocyclic or bicyclic, and bicyclic rings can be bridged, fused, or spirocyclic. In some embodiments, when explicitly stated, the terms "heterocycle," "heterocyclic," and "heterocyclyl" can refer to a saturated or unsaturated non-aromatic ring containing 8 ring atoms, in which one or more ring atoms are heteroatoms. Such 8-membered heterocycles are bicyclic rings, in which the bicyclic rings are bridged, fused, or spirocyclic.
[0123] In the present context, the term "therapeutically effective amount" of a compound is intended to indicate an amount sufficient to reduce or partially prevent the clinical signs of a given disease and its complications in a therapeutic intervention involving the administration of said compound. An amount sufficient to achieve this is defined as a "therapeutically effective amount." The effective amount for each purpose will depend on the severity of the disease or injury, as well as the weight and general condition of the subject. It will be understood that determining the appropriate dosage may be achieved using routine experimentation, for example, by constructing a matrix of values and testing different points within the matrix, all of which is within the ordinary skill of a trained physician.
[0124] In the present context, the terms "treatment" and "treating" refer to the management and care of a patient for the purpose of combating disease. The term is intended to include any treatment for a given disease from which a patient is suffering, such as the administration of active compounds to alleviate the symptoms or complications, slow the progression of the disease, reduce or alleviate the symptoms and complications, and / or cure or eliminate the disease. The patient to be treated is preferably a mammal, in particular a human. In the present context, "disease" may be used synonymously with disorder, pathology, dysfunction, dysfunction, and the like.
[0125] Use of the terms "a," "an," and "the," and similar referents in the context of describing the present invention should be construed to include both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. For example, the phrase "compound" should be understood to refer to various "compounds" of the present invention or specific described embodiments, unless otherwise indicated.
[0126] Any description of any embodiment or aspects of the invention herein using terms such as "comprising," "having," "including," or "containing" in reference to an element or group of elements is intended to provide support for similar embodiments or aspects of the invention that "consist," "consist essentially of," or "consist substantially of" that particular element or group of elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood to also describe a composition consisting of that element, unless otherwise stated or clearly contradicted by context).
[0127] b. Embodiments of the invention In the following, embodiments of the present invention are disclosed, where the first embodiment is denoted as E1, the second embodiment is denoted as E2, and so on.
[0128] E1. Formula I, [ka] (Wherein R1 is CH2R4 or R4; R2 is C1-C3 alkyl, isotopically labeled C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 haloalkyl; R3 is halogen, cyano, O—C1-C3 haloalkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, or C1-C3 alkyl; R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; or R4 is a bicyclic 8-membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen; Each heterocycle or cycloalkyl is unsubstituted or substituted with one, two, or three groups independently selected from the group consisting of cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0129] E2. A compound according to embodiment E1, or a pharmaceutically acceptable salt thereof, wherein R1 is CH2R4.
[0130] E3. The compound has formula Ia: [ka] or a pharmaceutically acceptable salt thereof.
[0131] E4. A compound according to any one of embodiments E1-E3, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from C1-C3 alkyl, isotopically labeled C1-C3 alkyl, or C3-C6 cycloalkyl.
[0132] E5. A compound according to any one of embodiments E1-E4, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from -CH3, -CH2CH3, -CD3, or cyclopropyl.
[0133] E6. A compound according to any one of embodiments E1 to E4, or a pharmaceutically acceptable salt thereof, wherein R2 is C1-C3 alkyl.
[0134] E7. A compound according to any one of embodiments E1-E4, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl.
[0135] E8. A compound according to any one of embodiments E1-E4, or a pharmaceutically acceptable salt thereof, wherein R2 is ethyl.
[0136] E9. A compound according to any one of embodiments E1-E4, or a pharmaceutically acceptable salt thereof, wherein R2 is isotopically labeled C1-C3 alkyl.
[0137] E10. A compound according to embodiments E1-E4, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of -CD3 or -CD2CD3.
[0138] E11. The compound according to embodiment E10, or a pharmaceutically acceptable salt thereof, wherein R2 is -CD3.
[0139] E12. A compound according to any one of embodiments E1 to E4, or a pharmaceutically acceptable salt thereof, wherein R2 is cyclopropyl.
[0140] E13. A compound according to any one of embodiments E1 to E12, or a pharmaceutically acceptable salt thereof, wherein R3 is C1-C3 haloalkyl.
[0141] E14. A compound according to embodiment E13, or a pharmaceutically acceptable salt thereof, wherein R3 is CF3.
[0142] E15. A compound according to any one of embodiments E1 to E12, or a pharmaceutically acceptable salt thereof, wherein R3 is halogen.
[0143] E16. A compound according to embodiment E15, or a pharmaceutically acceptable salt thereof, wherein R3 is chloro.
[0144] E17. The compound according to embodiment E15, or a pharmaceutically acceptable salt thereof, wherein R3 is bromo.
[0145] E18. A compound according to any one of embodiments E1 to E12, or a pharmaceutically acceptable salt thereof, wherein R3 is cyano.
[0146] E19. A compound according to any one of embodiments E1 to E13, or a pharmaceutically acceptable salt thereof, wherein R3 is C3-C6 cycloalkyl.
[0147] E20. A compound according to embodiment E19, or a pharmaceutically acceptable salt thereof, wherein R3 is cyclopropyl.
[0148] E21. The compound according to any one of embodiments E1-E20, or a pharmaceutically acceptable salt thereof, wherein R4 is a 4-6 membered heterocycle having one oxygen atom, and the 4-6 membered heterocycle is unsubstituted or substituted with two groups independently selected from the list consisting of cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, or C1-C3 haloalkyl.
[0149] E22. The compound according to any one of embodiments E1-E20, or a pharmaceutically acceptable salt thereof, wherein R4 is a 4-6 membered heterocycle having one oxygen atom, and wherein the 4-6 membered heterocycle is unsubstituted or substituted with one group selected from the group consisting of cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl.
[0150] E23. A compound according to any one of embodiments E1 to E20, or a pharmaceutically acceptable salt thereof, wherein R4 is a 4-6 membered heterocycle having one oxygen atom, and wherein the 4-6 membered heterocycle is unsubstituted or substituted with one group selected from the group consisting of deuterium, halogen, C1-C3 alkyl, or isotopically labeled C1-C3 alkyl.
[0151] E24. A compound according to any one of embodiments E1 to E20, or a pharmaceutically acceptable salt thereof, wherein R4 is a 6-membered heterocycle having one oxygen atom, and wherein the 6-membered heterocycle is unsubstituted or substituted with one group selected from the group consisting of deuterium, halogen, C1-C3 alkyl, or isotopically labeled C1-C3 alkyl.
[0152] E25. In the formula, R4 is [ka] A compound according to any one of embodiments E1 to E20 selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
[0153] E26. In the formula, R4 is CH3, [ka] [ka] A compound according to any one of embodiments E1 to E20 selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
[0154] E27. A compound according to any one of embodiments E1 to E20, or a pharmaceutically acceptable salt thereof, wherein R4 is unsubstituted tetrahydropyran.
[0155] E28. A compound according to any one of embodiments E1 to E20, or a pharmaceutically acceptable salt thereof, wherein R4 is tetrahydro-2H-pyran-4-yl.
[0156] E29. A compound according to any one of embodiments E1 to E20, or a pharmaceutically acceptable salt thereof, wherein R4 is tetrahydro-2H-pyran-3-yl.
[0157] E30. A compound according to any one of embodiments E1 to E20, or a pharmaceutically acceptable salt thereof, wherein R4 is 4-oxaspiro[2.5]octan-7-yl.
[0158] E31. A compound according to any one of embodiments E1 to E20, or a pharmaceutically acceptable salt thereof, wherein the 8-membered heterocycle is an unsubstituted 8-membered spirocyclic heterocycle.
[0159] E32. A compound according to embodiment E31, or a pharmaceutically acceptable salt thereof, wherein the bicyclic 8-membered heterocycle contains one oxygen.
[0160] E33. A compound according to embodiment E31, or a pharmaceutically acceptable salt thereof, wherein the bicyclic 8-membered heterocycle contains one oxygen and is a spirocyclic heterocycle.
[0161] E34. The compound has formula Ib, [ka] (wherein R2 is C1-C3 alkyl, isotopically labeled C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 haloalkyl; R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; Each heterocycle or cycloalkyl is unsubstituted or substituted with one group selected from cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0162] E35. A compound according to embodiment E34, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from -CH3, -CH2CH3, -CD3, or cyclopropyl.
[0163] E36. The compound has formula Ic, [ka] (wherein R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; Each heterocycle or cycloalkyl is unsubstituted or substituted with one group selected from cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0164] E37. The compound of formula Id, [ka] (wherein R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; Each heterocycle or cycloalkyl is unsubstituted or substituted with one group selected from cyano, deuterium, halogen, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0165] E38. The compound according to any one of embodiments E30-E31, or a pharmaceutically acceptable salt thereof, wherein the 4-7 membered heterocycle is an unsubstituted 6-7 membered spirocyclic heterocycle.
[0166] E39. The compound according to any one of embodiments E30-E31, or a pharmaceutically acceptable salt thereof, wherein the 4-7 membered heterocycle is an unsubstituted 6-7 membered bridged heterocycle.
[0167] E40. The compound is [ka] [ka] The compound of embodiment E1 which is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
[0168] E41. The compound is 8-Chloro-2,3-dimethyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo-[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 3-Methyl-2-(tetrahydro-2H-pyran-4-yl)-8-(trifluoromethyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Bromo-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Cyclopropyl-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 3,8-Dimethyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 3-Methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-8-carbonitrile; 8-Chloro-3-cyclopropyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 2-((2-oxabicyclo[2.1.1]hexan-1-yl)methyl)-8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-((3-methyloxetan-3-yl)methyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-(3-methyloxetan-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-4-yl-4-d)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; and 8-Chloro-3-(1-fluorocyclopropyl)-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine The compound of embodiment E1 which is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
[0169] E42. The compound is [ka] [ka] [ka] [ka] [ka] The compound of embodiment E1 which is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
[0170] E43. The compound is 8-Chloro-3-ethyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-((2R,4R)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-((2S,4S)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-11,11,12,12,13,13-d6; 8-chloro-3-methyl-2-((3R,4S)-3-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-((3S,4R)-3-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-((3S,4S)-3-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-((3R,4R)-3-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((1r,4r)-4-fluorocyclohexyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-(4,4-difluorocyclohexyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-methyl-2-(oxepan-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-Chloro-3-methyl-2-(oxepan-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-methyl-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-Chloro-3-methyl-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 3-(8-chloro-3-methyl-12,13-dihydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecin-2(4H)-yl)bicyclo[1.1.1]pentane-1-carbonitrile; 8-chloro-3-methyl-2-(2-oxaspiro[3.3]heptan-6-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-11,11,12,12,13,13-d6; 1-(8-chloro-3-methyl-12,13-dihydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecin-2(4H)-yl)cyclopropane-1-carbonitrile; 8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 2-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-2-(2,2-difluorocyclopropyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-chloro-2-(2,2-difluorocyclopropyl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-chloro-2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 2-((1R,3s,5S)-8-oxabicyclo[3.2.1]octan-3-yl)-8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-11,11-d2; 8-Chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine-13,13-d2; 8-chloro-2-((3R,4S)-3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3S,4R)-3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-methyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-(methyl-d3)-2-((2R,4R)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-Chloro-3-(methyl-d3)-2-((2S,4S)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-methyl-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-chloro-3-methyl-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-ethyl-2-((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-ethyl-2-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-3-ethyl-2-((1r,4r)-4-methoxycyclohexyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-(methyl-d3)-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-chloro-3-(methyl-d3)-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (S)-8-Chloro-3-(methyl-d3)-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; 8-chloro-2-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-3-(methyl-d3)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; (R)-8-chloro-3-(methyl-d3)-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine; and (S)-8-Chloro-3-(methyl-d3)-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine The compound of embodiment E1 which is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
[0171] E44. The compound is [ka] or a pharmaceutically acceptable salt thereof The compound of embodiment E1, wherein:
[0172] E45. The compound is [ka] or a pharmaceutically acceptable salt.
[0173] E46. The compound is [ka] or a pharmaceutically acceptable salt thereof.
[0174] E47. The compound is [ka] or a pharmaceutically acceptable salt thereof.
[0175] E48. The compound is [ka] The compound of embodiment E1, wherein:
[0176] E49. The compound is [ka] or a pharmaceutically acceptable salt thereof.
[0177] E50. The compound is [ka] or a pharmaceutically acceptable salt thereof.
[0178] E51. The compound is [ka] The compound of embodiment E1, wherein:
[0179] E52. The compound is [ka] The compound of embodiment E1, wherein:
[0180] E53. The compound is [ka] The compound of embodiment E1, wherein:
[0181] E54. The compound is [ka] The compound of embodiment E1, wherein:
[0182] E55. The compound is [ka] The compound of embodiment E1, wherein:
[0183] E56. The compound is [ka] The compound of embodiment E1, wherein:
[0184] E57. The compound is [ka] The compound of embodiment E1, wherein:
[0185] E58. The compound is [ka] The compound of embodiment E1, wherein:
[0186] E59. A pharmaceutical composition comprising a compound according to any one of the preceding embodiments E1-E58 and one or more pharmaceutically acceptable carriers.
[0187] E60. A compound according to any one of embodiments E1-E58, or a pharmaceutically acceptable salt thereof, for use in therapy.
[0188] E61. A compound according to any one of embodiments E1 to E58, or a pharmaceutically acceptable salt thereof, for use in treating a disease or disorder of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, and Parkinson's disease.
[0189] E62. The compound of embodiment E61, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying the G2019S mutation in LRRK2, or Parkinson's disease in patients with one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
[0190] E63. The compound of embodiment E61, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, or Parkinson's disease in patients carrying one or more mutations in LRRK2 selected from G2019S, I2020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, I2020T, and Y2189C.
[0191] E64. The compound according to embodiment E61, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, or Parkinson's disease in patients carrying the G2019S mutation in LRRK2.
[0192] E65. The compound according to embodiment E61, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
[0193] E66. A compound according to any one of embodiments E1 to E58, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder characterized by increased LRRK2 kinase activity; or by expression of one or more mutant forms of LRRK2 selected from G2019S, I2020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, I2020T, and Y2189C; or by one or more LRRK2 non-coding mutants alone or in combination with a selection from rs76904798-T and Rs1491942-G.
[0194] E67. Use of a compound according to any one of embodiments E1 to E58, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or disorder of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, or Parkinson's disease.
[0195] E68. A method for treating a disease or disorder of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, or Parkinson's disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of embodiments E1 to E58, or a pharmaceutically acceptable salt thereof.
[0196] The compounds of the present invention may possess one or more asymmetric centers, and any optical isomers (i.e., enantiomers or diastereomers) are intended to be included within the scope of the present invention as separated pure or partially purified optical isomers and as any mixtures thereof, including racemic mixtures, i.e., mixtures of stereoisomers.
[0197] In this context, when specifying an enantiomeric form, it is understood that the compound is in enantiomeric excess, e.g., in essentially pure form. Thus, one embodiment of the present invention relates to a compound of the present invention having an enantiomeric excess (ee) of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%.
[0198] Racemic forms can be resolved into their optical antipodes by known methods, such as separation of diastereomeric salts with an optically active acid and liberating the optically active amine compound by treatment with a base. Another method for optically resolving racemates into their optical antipodes is based on chromatography on an optically active matrix. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. Additional methods for the resolution of optical isomers known to those skilled in the art may also be used. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions," John Wiley and Sons, New York (1981). Optically active compounds can also be prepared from optically active starting materials. The absolute stereochemistry may be determined by methods known to those skilled in the art, such as vibrational circular dichroism (VCD) spectroscopy.
[0199] Furthermore, when double bonds or fully or partially saturated ring systems are present in a molecule, geometric isomers may be formed. It is intended that the separate geometric isomers, pure or partially purified geometric isomers, or mixtures thereof, are included within the scope of the present invention. Similarly, molecules with bonds that are restricted in rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.
[0200] Furthermore, some of the compounds of the present invention may exist in different tautomeric forms, and it is intended that any tautomeric form that the compounds are able to form is included within the scope of the invention.
[0201] Also included in the present invention are isotopically labeled compounds in which one or more atoms are represented by atoms of the same element having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (e.g., 2 H, 11 C. 13 C. 15 N, 18 F, etc.). 2Particular mention is made of H-substituted compounds, ie compounds in which one or more H atoms are represented by deuterium.
[0202] In one embodiment of the present invention, a compound of Formula I, Ia, Ib, Ic, Id, A, or Aa is isotopically labeled. In a further embodiment of the present invention, one or more of the hydrogen atoms of a compound of Formula I, Ia, Ib, Ic, Id, A, or Aa is represented by deuterium. It is recognized that elements exist in natural isotopic abundance in most synthetic compounds, resulting in the intrinsic incorporation of deuterium. However, the natural isotopic abundance of hydrogen isotopes such as deuterium is insignificant (approximately 0.015%) compared to the degree of stable isotopic substitution of the compounds presented herein. Therefore, as used herein, designating an atom as deuterium at a position indicates that the abundance of deuterium is significantly greater than the natural abundance of deuterium. An atom not designated as a specific isotope is intended to represent any stable isotope of that atom, as would be apparent to one of ordinary skill in the art.
[0203] In one embodiment, the designation of a position in a compound as "D" has a minimum deuterium incorporation of greater than about 60% at that position, e.g., greater than about 70% at that position, e.g., greater than about 80% at that position, e.g., greater than about 85% at that position. In a further embodiment, the designation of a position in a compound as "D" has a minimum deuterium incorporation of greater than about 90% at that position, e.g., greater than about 95% at that position, e.g., greater than about 97% at that position, e.g., greater than about 99% at that position.
[0204] c. Pharmaceutically acceptable salts The compounds of the present invention are generally utilized as the free substance or as its pharmaceutically acceptable salt. When the compound of Formula I, Ia, Ib, Ic, Id, A, or Aa contains a free base, such salts may be prepared in a conventional manner by treating a solution or suspension of the free base of Formula I, Ia, Ib, Ic, Id, A, or Aa with a molar equivalent of a pharmaceutically acceptable acid. Representative examples of suitable organic and inorganic acids are listed below.
[0205] Pharmaceutically acceptable salts in this context are intended to refer to non-toxic, i.e., physiologically acceptable, salts. The term pharmaceutically acceptable salts includes salts formed with inorganic and / or organic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, and sulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and benzenesulfonic acid. Some of the acids listed above are di- or tri-acids, i.e., acids containing two or three acidic hydrogens, such as phosphoric acid, sulfuric acid, fumaric acid, and maleic acid. Diacids and triacids may form 1:1, 1:2 or 1:3 (triacid) salts, ie, salts formed between two or three molecules of a compound of the invention and one molecule of an acid.
[0206] The term "pharmaceutically acceptable salt" includes salts formed with inorganic and / or organic bases, such as alkali metal bases, such as sodium hydroxide, lithium hydroxide, and potassium hydroxide; alkaline earth bases, such as calcium hydroxide and magnesium hydroxide; and organic bases, such as trimethylamine. Some of the bases listed above are dibasic or tribasic, i.e., bases capable of accepting two or three acidic hydrogens, such as calcium hydroxide and magnesium hydroxide. Dibasic and tribasic salts may form 1:1 or 1:2 salts, i.e., salts formed between two molecules of a compound of the present invention and one molecule of a base.
[0207] Additional examples of acids and bases useful for forming pharmaceutically acceptable salts can be found, for example, in Stahl and Wermuth (Eds.) "Handbook of Pharmaceutical Salts. Properties, Selection, and Use," Wiley-VCH, 2008.
[0208] d. Pharmaceutical compositions The compound or pharmaceutically acceptable salt may be present in the composition as the sole active ingredient or in combination with other active ingredients. In addition, one or more pharmaceutically acceptable carriers or diluents may be present in the composition.
[0209] The pharmaceutical compositions may be specially formulated for administration by any suitable route, such as oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous, and intradermal) routes, with the oral route being preferred. It will be understood that the preferred route will depend on the general condition and age of the subject being treated, the nature of the condition being treated, and the active ingredient selected.
[0210] Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules, which may be prepared with coatings, if appropriate.
[0211] Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups, and elixirs.
[0212] Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted with sterile injectable solutions or dispersions before use.
[0213] Other suitable administration forms include suppositories, sprays, ointments, creams, gels, inhalants, skin patches, implants, and the like.
[0214] Conveniently, the compounds of the invention are administered in unit dosage form containing from about 0.1 to 500 mg of the compound of the invention, for example 10 mg, 50 mg, 100 mg, 150 mg, 200 mg or 250 mg.
[0215] For parenteral administration, a solution of the compound of the present invention in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E, or sesame or peanut oil may be used. Such aqueous solutions should be suitably buffered, if necessary, and the liquid diluent should first be rendered isotonic with sufficient saline or glucose. Aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. The sterile aqueous media used are all readily available by standard techniques known to those skilled in the art.
[0216] Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene, and water. The pharmaceutical composition formed by combining the compound of the present invention with a pharmaceutically acceptable carrier can then be easily administered in various dosage forms suitable for the disclosed administration route.
[0217] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, which may include a suitable excipient. Further, the orally available formulation may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
[0218] If a solid carrier is used for oral administration, the preparation may be, for example, a powder in a hard gelatin capsule, or in tablet form, such as in pellet form, or in the form of a troche or lozenge. The amount of solid carrier may vary but will usually be from about 25 mg to about 1 g.
[0219] If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
[0220] Tablets may be prepared by mixing the active ingredient with conventional adjuvants and / or diluents, followed by compressing the mixture in a conventional tablet machine. Examples of adjuvants or diluents include corn starch, potato starch, talc, magnesium stearate, gelatin, lactose, gums, etc. Any other auxiliary or additive normally used for purposes such as coloring, flavoring, preservatives, etc. may also be used, provided that they are compatible with the active ingredient.
[0221] e. Treatment of disease As established above, LRRK2 inhibitors may be used to treat Parkinson's disease, particularly those associated with LRRK2 mutations such as Gly2019Ser. Furthermore, LRRK2 inhibitors are expected to be useful in treating other LRRK2-related diseases. LRRK2 has been identified as a core component of Lewy bodies, and thus may be useful in the treatment of dementia with Lewy bodies [Neuropathol. Appl. Neurobiol., 34, 272-283, 2008]. LRRK2 mRNA expression is highly abundant in the brain, lung, kidney, spleen, and blood, suggesting that the functional effects of increased LRRK2 activity may be most relevant to pathogenic and pathological conditions associated with these regions. Support for this concept can be found in studies demonstrating an increased risk of non-skin cancers, particularly kidney and lung cancer, in LRRK2 Gly2019Ser mutation carriers [Mov. Disorder, 25, 2536-2541, 2010]. Overexpression of LRRK2 due to chromosomal amplification has also been confirmed in papillary renal cell carcinoma and thyroid cancer. Genetic association of LRRK2 has also been reported in diseases involving abnormal immune system responses. This is also true for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, as well as leprosy [Nat. Genet. 42, 1118-1125, 2010; Inflamm. Bowel Dis. 16, 557-558, 2010; N. Engl. J. Med. 361, 2609-2618, 2009; Inflamm. Bowel Dis.].
[0222] Thus, in one embodiment there is provided a compound according to the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to the invention, for use in the treatment of a disease of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, or Parkinson's disease.
[0223] In one embodiment, the disease of the central nervous system is Parkinson's disease.
[0224] In one embodiment, the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, or Parkinson's disease in patients carrying the G2019S mutation of LRRK2.
[0225] In one embodiment, the Parkinson's disease is idiopathic Parkinson's disease.
[0226] In one embodiment, the Parkinson's disease is sporadic Parkinson's disease.
[0227] In one embodiment, Parkinson's disease is present in a patient carrying the G2019S mutation of LRRK2.
[0228] In a further embodiment, the compounds outlined in formula I, Ia, Ib, Ic, Id, A or Aa above, or pharmaceutically acceptable salts thereof, or compositions comprising said compounds, may be used in the treatment of cancer or immune-related disorders.
[0229] In some embodiments, the cancer disease may be present in the brain, lung, kidney, and spleen, or blood organs, such as kidney cancer, lung cancer, skin cancer, and papillary renal cancer, and thyroid cancer.
[0230] In some embodiments, the immune-related disorder may be, in one embodiment, Crohn's disease, ulcerative colitis, tuberculosis, or leprosy.
[0231] According to one embodiment of the present invention, treatment may be performed in patients with increased LRRK2 kinase activity or harboring one or more mutations of LRRK2 such as G2019S, I2020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, I2020T or Y2189C.
[0232] In one embodiment, the compounds of the present invention are administered in an amount of about 0.001 mg / kg to about 100 mg / kg of body weight per day. In particular, the daily dosage may range from 0.01 mg / kg to about 50 mg / kg of body weight per day. The exact dosage will depend on the frequency and mode of administration; the sex, age, weight, and general condition of the subject being treated; the nature and severity of the condition being treated; any concomitant illnesses being treated; the desired effect of treatment; and other factors known to those skilled in the art.
[0233] Typical oral dosages for adults range from 1 to 1000 mg / day of a compound of the invention, or a pharmaceutically acceptable salt thereof, such as, for example, 1 to 500 mg / day.
[0234] The compounds of the present invention, or pharmaceutically acceptable salts thereof, may be administered alone as pure compounds or in combination with pharmaceutically acceptable carriers or excipients, either in single or multiple doses. Pharmaceutical compositions according to the present invention may be administered in any form, for example, as described in Remington: The Science and Practice of Pharmacy, 22 nd Edition, Pharmaceutical Press, 2012. In the present context, "excipient," "carrier," "diluent," "adjuvant," etc. are used interchangeably and are intended to have the same meaning.
[0235] All references cited herein, including publications, patent applications, and patents, are incorporated herein by reference in their entirety, notwithstanding any incorporation of specific documents otherwise provided elsewhere herein, to the same extent as if each reference were individually and specifically indicated as incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
[0236] e. List of items Below, items of the present invention are disclosed, the first item being designated I1, the second item being designated I2, and so on.
[0237] I1. Formula A, [ka] (Wherein R1 is CH2R4 or R4; R2 is C1-C3 alkyl, isotopically labeled C1-C3 alkyl, C3-C6 cycloalkyl, or C1-C3 haloalkyl; R3 is halogen, cyano, O—C1-C3 haloalkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, or C1-C3 alkyl; R4 is a 4-7 membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen, C1-C3 alkyl, C1-C3 cyanoalkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl; Each heterocycle or cycloalkyl is unsubstituted or substituted with one, two, or three groups independently selected from the group consisting of cyano, deuterium, halo, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, O-C1-C3 haloalkyl, O-C1-C3 alkyl, or C1-C3 haloalkyl. or a pharmaceutically acceptable salt thereof.
[0238] I2. wherein the compound has the formula Aa, [ka] or a pharmaceutically acceptable salt thereof.
[0239] I3. The compound according to any one of items I1-I2, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from C1-C3 alkyl, isotopically labeled C1-C3 alkyl, or C3-C6 cycloalkyl.
[0240] I4. The compound according to any one of items I1 to I3, or a pharmaceutically acceptable salt thereof, wherein R2 is an isotopically labeled C1-C3 alkyl.
[0241] I5. A compound according to any one of items I1 to I4, or a pharmaceutically acceptable salt thereof, wherein R2 is -CD3.
[0242] I6. A compound according to any one of paragraphs I1 to I5, or a pharmaceutically acceptable salt thereof, wherein R3 is halogen.
[0243] I7. The compound according to any one of paragraphs I1 to I5, or a pharmaceutically acceptable salt thereof, wherein R3 is chloro.
[0244] I8. The compound according to any one of items I1 to I7, or a pharmaceutically acceptable salt thereof, wherein R4 is a 4-6 membered heterocycle having one oxygen atom, and the 4-6 membered heterocycle is unsubstituted or substituted with one group selected from the list consisting of cyano, deuterium, halo, C1-C3 alkyl, isotopically labeled C1-C3 alkyl, or C1-C3 haloalkyl.
[0245] I9. In the formula, R4 is [ka] The compound according to any one of items I1 to I8, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
[0246] I10. The compound according to any one of paragraphs I1 to I9, or a pharmaceutically acceptable salt thereof, wherein R4 is unsubstituted tetrahydro-2H-pyran-4-yl.
[0247] I11. A compound according to claim 1 selected from the list below, or a pharmaceutically acceptable salt thereof. [ka] [ka]
[0248] I12. A pharmaceutical composition comprising a compound according to any one of I1-I11 and one or more pharmaceutically acceptable carriers or diluents.
[0249] I13. A compound according to any one of paragraphs I1 to I11, or a pharmaceutically acceptable salt thereof, for use in therapy.
[0250] I14. A compound according to any one of paragraphs I1 to I11, or a pharmaceutically acceptable salt thereof, for use in treating a disease of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, or Parkinson's disease.
[0251] I15. The compound according to any one of items I1 to I11, or a pharmaceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, or Parkinson's disease in a patient carrying the G2019S mutation of LRRK2.
[0252] I16. A compound according to any one of paragraphs I1 to I11, or a pharmaceutically acceptable salt thereof, for use in treating a disease or disorder characterized by increased LRRK2 kinase activity; or by expression of one or more mutant forms of LRRK2 selected from G2019S, I2020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, I2020T, and Y2189C; or by LRRK2 non-coding mutants alone or in combination selected from rs76904798-T and Rs1491942-G.
[0253] I17. Use of a compound according to any one of paragraphs I1 to I11 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or disorder of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, or Parkinson's disease.
[0254] I18. The use according to item I17, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, or Parkinson's disease in patients carrying the G2019S mutation of LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
[0255] I19. A method for treating a disease or disorder of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, or Parkinson's disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of paragraphs I1 to I11, or a pharmaceutically acceptable salt thereof.
[0256] I20. The use according to item i19, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying the G2019S mutation of LRRK2, or Parkinson's disease in patients carrying only one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G. [Example]
[0257] b. Preparation of compounds of the invention [ka] The compounds of formula I, Ia, Ib, Ic, Id, A, or Aa may be prepared by the methods described below, along with synthetic methods known in the art of organic chemistry or modification methods familiar to those skilled in the art. For example, these methods describe the use of selective protecting groups during the synthesis of the compounds of the present invention. Those skilled in the art will be able to select an appropriate protecting group for a particular reaction. Methods for protecting and deprotecting such groups are well known in the art and are described in Watts and Green et al., Protective Groups in Organic Synthesis, 2006, 4 th Edition, Wiley Interscience, New York. The starting materials used herein are commercially available or may be prepared by routine methods known in the art, for example, as described in standard reference texts such as "Compendium of Organic Synthetic Methods, Vol. I-XII" (published by Wiley Interscience). Preferred methods include, but are not limited to, those described below. The schemes are representative of methods useful for synthesizing the compounds of the invention. They are not intended to limit the scope of the invention in any way.
[0258] Method 1: [ka] Briefly, compounds of formula I can be prepared according to Scheme 1. Compounds of formula I can be prepared in a one-pot procedure by reducing intermediates of type III with iron and ammonium chloride in a suitable solvent, such as a mixture of ethanol and water, as described, for example, for Example 1. Alternatively, intermediates of type III can be reduced using, for example, sodium dithionite in the presence of a base, such as potassium bicarbonate, in a solvent, such as a mixture of water and tetrahydrofuran, to give aminopyrazole intermediates of type II. As detailed in Example 16, intermediates of type II can be cyclized in the presence of a base, such as potassium fluoride, and a solvent, such as dimethyl sulfoxide, to give compounds of formula I.
[0259] Method 2: [ka] Alternatively, the compound of formula I can be a compound of formula I′ (i.e., R 3 Compounds of formula I can be prepared from intermediates of type I' (where M is, for example, Bpin, B(OH)2, Sn(n-Bu)3 or SnMe3, ZnBr, or ZnCl) according to Scheme 2. Compounds of formula I can be prepared by utilizing a cross-coupling reaction between intermediates of type I' and organometallic alkyl intermediates IV (where M is, for example, Bpin, B(OH)2, Sn(n-Bu)3 or SnMe3, ZnBr, or ZnCl). Couplings include, but are not limited to, Negishi-type cross-coupling reactions. The reaction can be carried out by reacting intermediates of type I' with organozinc intermediates IV (where M is, for example, ZnBr or ZnCl) in the presence of a catalyst such as di-μ-iodobis(tri-t-butylphosphino)dipalladium(I) and a suitable solvent such as a mixture of toluene and tetrahydrofuran, as described for Example 7.
[0260] Method 3: [ka] Nitropyrazole intermediates of type III can be prepared according to Scheme 3, starting from pyrazolopyrimidine intermediates of type X. Intermediates of type X are reacted with an alcohol such as IX (where Pg1 is, for example, TBS) under Mitsunobu-type conditions, for example, using diisopropyl azodicarboxylate and triphenylphosphine, in a solvent such as tetrahydrofuran, to give intermediates of type VIII. Intermediates of type VIII (where Pg1 is, for example, TBS) can be converted to alcohol intermediates of type VII using an acid, such as aqueous hydrochloric acid, in a suitable solvent, for example, a mixture of tetrahydrofuran and water, as described in the synthesis of 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol.
[0261] Alcohol intermediates of type VII can be reacted with intermediates of type V under Mitsunobu-type conditions using, for example, diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran to give intermediates of type III, as detailed for example in the synthesis of 3,6-dichloro-1-(3-((5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine.
[0262] Alternatively, intermediates of type VII can be converted to intermediates of type VI (where LG1 is, for example, OT) using p-toluenesulfonyl chloride in the presence of a suitable base, such as triethylamine, in a suitable solvent, such as dichloromethane. Intermediates of type VI can be reacted with intermediates of type V in the presence of a base, such as potassium carbonate, in a solvent, such as N,N-dimethylformamide, to give intermediates of type III, as described, for example, in the synthesis of 3,6-dichloro-1-(3-((5-methyl-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine.
[0263] Method 4: [ka] An alternative method for preparing nitropyrazole intermediates of type III starting from pyrazole intermediates of type V is described in Scheme 4. Intermediates of type XIII can be prepared from intermediates of type V through a Mitsunobu-type reaction with an alcohol such as XIV (where PG2 is, for example, TBS) using, for example, diisopropyl azodicarboxylate and triphenylphosphine in a suitable solvent such as tetrahydrofuran. Alternatively, intermediates of type XIII can be prepared from intermediates of type V through alkylation with intermediates of type XV (where, for example, LG2 is OT and PG2 is TBS) in the presence of a base such as cesium carbonate in a suitable solvent such as N,N-dimethylformamide. Intermediates of type XIII (where PG2 is, for example, TBS) can be converted to intermediates of type XI using, for example, aqueous HCl in a solvent such as tetrahydrofuran.
[0264] Intermediates of type XIII (wherein PG2 is, for example, TBS) can be prepared by R 2 It is understood that modified form XIII can be converted to another intermediate form: for example, modified form XIII (wherein R 2 = cyclopropyl and PG2 = TBS), can be reacted with lithium diisopropylamide and a base such as N-fluorobis(phenylsulfonyl)amine in a suitable solvent such as tetrahydrofuran to give intermediates of type XIII (wherein R 2 = 1-fluorocyclopropyl and PG2 = TBS).
[0265] Intermediates of type XIII are R 2 It is further understood that the compound of formula XIII may be converted to a modified intermediate of formula XI, for example, formula XIII (wherein R 2The intermediate (R = CH3 and PG2 = TBS) can be converted to form XI (where R = CH3 and PG2 = TBS) through reaction with a base such as potassium tert-butoxide in hexadeuterodimethyl sulfoxide as described for the synthesis of 3,6-dichloro-1-(3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine. 2 =CD3) intermediate.
[0266] Finally, intermediates of type XI are reacted with pyrazolopyrimidine intermediates of type X using, for example, a Mitsunobu-type reaction with 1-(azodicarbonyl)-dipiperidine and tributylphosphine in a solvent such as tetrahydrofuran, as detailed in the synthesis of (±)-3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine, to give intermediates of type III.
[0267] Alternatively, intermediates of type XI can be reacted with, for example, methanesulfonyl chloride in the presence of a base such as triethylamine in a suitable solvent such as dichloromethane to give intermediates of type XII (wherein LG3 is OM). Intermediates of type XII can be converted to intermediates of type III through reaction with pyrazolopyrimidine intermediates of type X in the presence of a base such as N,N-diisopropylethylamine, an additive such as sodium iodide, in a suitable solvent such as N,N-dimethylformamide, as described for the synthesis of 3,6-dichloro-1-(3-((1,5-dimethyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine.
[0268] Method 5: [ka] Intermediates of type V can be prepared through a two-step sequence using alkylation followed by hydrolysis according to Scheme 5. Intermediates of type XIX can be converted to intermediates of type XVI using Mitsunobu-type reaction conditions, for example, with di-tert-butyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran in the presence of an alcohol intermediate such as XVII, as described for the synthesis of 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine.
[0269] Alternatively, intermediates of type XIX can be reacted with intermediates such as type XVIII (where LG4 is, for example, a halogen) in the presence of a suitable base such as potassium carbonate in a solvent such as acetonitrile, as described for the synthesis of 1-(3-((1-((2-oxabicyclo[2.1.1]hexan-4-yl)methyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine to give intermediates of type XVI.
[0270] Intermediates of type XVI can be converted to intermediates of type V using a base such as potassium hydroxide in a suitable solvent such as water, as detailed in the synthesis of 3,6-dichloro-1-(3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine.
[0271] Method 6: [ka] An alternative method for preparing intermediates of type XVI is described in Scheme 6. Intermediates of type XXIII can be reacted with alkylating agents of type XVIII (where LG4 is, for example, a halogen) in the presence of a base such as cesium carbonate in a solvent such as N,N-dimethylformamide to give intermediates of type XXII. Intermediates of type XXII can be modified to intermediates of type XXI using, for example, iodine and a base such as lithium bis(trimethylsilyl)amide in a suitable solvent such as tetrahydrofuran. Intermediates of type XXI can be converted to intermediates of type XVI (where M is, for example, Bpin, B(OH)2, Sn(n-Bu)3, SnMe3, or ZnBr) by reaction with reagents of type XX. Coupling reactions include, but are not limited to, Suzuki-Miyaura cross-coupling reactions. The reaction can be mediated using a boronic acid where M=B(OH)2 in the presence of a catalyst system consisting of, for example, tris(dibenzylideneacetone)dipalladium(0) and tricyclohexylphosphine, and a base such as potassium carbonate, in a suitable solvent such as N,N-dimethylformamide, as described for 3,6-dichloro-1-(3-((5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine.
[0272] Method 7: [ka] An alternative method for preparing intermediates of type XIII (where R2 is, for example, Me or Et) is shown in Scheme 7. Intermediates of type XIII (where Pg2 is, for example, TBS) can be prepared by the synthesis of 2-(tributyl-λ)-3,6-dichloro-1-(3-((5-methyl-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine as described in the synthesis of the intermediate cis-3,6-dichloro-1-(3-((5-methyl-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine. 5
[0044] Alternatively, intermediates of type XIII can be prepared by reaction of pyrazole intermediates such as XXIV with an alkylating agent of type XVIII (where LG4 is, for example, OT or Br) in the presence of a base such as potassium carbonate in a suitable solvent such as N,N-dimethylformamide, as detailed in the synthesis of trans-3-((1-(4-fluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol.
[0273] Intermediates of type XXIV (where Pg2 is, for example, TBS) can be synthesized from alcohols such as XXV using, for example, tert-butyldimethylsilyl chloride in the presence of a base such as imidazole and a catalyst such as 4-dimethylaminopyridine in a suitable solvent such as dichloromethane. Alcohol intermediates such as XXV can be prepared from nitropyrazoles such as XXVI (where Pg3 is, for example, 2-tetrahydropyranyl) by treatment with an acid such as aqueous hydrochloric acid in a suitable solvent such as methanol.
[0274] Alcohol intermediates of type XXVI can be prepared by reacting chloro intermediates of type XXVIII with propane-1,3-diols XXVII in the presence of a base such as, for example, cesium fluoride in a solvent such as N,N-dimethylacetamide.
[0275] Chloro intermediates such as XXVIII (where Pg3 is, for example, 2-tetrahydropyranyl) can be prepared from nitropyrazole intermediate XXIX (where Pg3 is, for example, 2-tetrahydropyranyl) using a strong base such as, for example, lithium bis(trimethylsilyl)amide and an electrophile such as, for example, hexachloroethane in a suitable solvent such as tetrahydrofuran.
[0276] Nitropyrazole intermediates of type XXIX (where Pg3 is, for example, 2-tetrahydropyranyl) can be prepared from pyrazoles such as XXX using 3,4-dihydro-2H-pyran in the presence of an acid such as, for example, paratoluenesulfonic acid monohydrate in a suitable solvent such as, for example, tetrahydrofuran. A general synthetic sequence for preparing XXIV is described, for example, in the preparation of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole.
[0277] Method 8: [ka] Alternatively, compounds of Formula I can be prepared from compounds of Formula XXXII according to Scheme 8. Compounds of Formula I can be prepared, for example, by copper-mediated coupling between intermediates of type XXXII and intermediates of type XXXI (where M is, for example, B(OH)). Examples of coupling include, but are not limited to, Chang-Lam type coupling. The reaction can be carried out by reacting intermediates of type XXXII with boronic acid intermediate XXXI (where M = B(OH)) under an oxygen atmosphere in a suitable solvent such as 1,2-dichloroethane in the presence of a copper salt such as copper(II) acetate, a base such as pyridine, and a drying agent such as 4 Å molecular sieves, as described for Examples 39 and 40.
[0278] Method 9: [ka] Intermediates such as XXXII may be prepared according to Scheme 9. Intermediates of type XXXII may be prepared in a one-pot procedure, for example, by reducing intermediates of type XXXIII (where Pg3 is, for example, 2-tetrahydropyranyl) with iron and ammonium chloride in a suitable solvent, for example, a mixture of ethanol and water.
[0279] Nitropyrazole intermediates such as XXXIII can be prepared by reaction of a pyrazolopyrimidine such as X with an alcohol such as XXVI (where Pg3 is, for example, 2-tetrahydropyranyl) using Mitsunobu-type like reaction conditions, for example, diisopropyl azodicarboxylate and triphenylphosphine, in a solvent such as tetrahydrofuran.
[0280] The general synthetic sequence of Scheme 9 was described, for example, in the synthesis of the intermediate 8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine.
[0281] Method 10: [ka] Alternatively, compounds of formula I can be prepared according to Scheme 10. Bromo intermediates of type XXXIV can be reacted with organometallic species such as XX (where M is, for example, Bpin, B(OH)2, Sn(n-Bu)3 or SnMe3, Zn, ZnBr, or ZnCl). Couplings include, but are not limited to, Negishi-type cross-couplings. The reaction can be carried out by reacting intermediates of type XXXIV with an organozinc species such as (CD3)2Zn in the presence of a catalyst such as bis[tris(tert-butyl)phosphine]palladium, a base such as lithium bis(trimethylsilyl)amide, in a suitable solvent such as tetrahydrofuran, as described for Example 50.
[0282] Bromo intermediates such as XXXIV can be prepared from pyrazoles such as XXXV using a brominating agent such as N-bromosuccinimide in a suitable solvent such as tetrahydrofuran. Intermediates of type XXXV can be synthesized from nitropyrazole intermediates such as XXXVI using a one-pot reduction and cyclization procedure. The reduction and subsequent cyclization can be carried out, for example, using iron in the presence of ammonium chloride in a suitable solvent such as a mixture of ethanol and water. Nitropyrazole intermediates such as XXXVI can be synthesized, for example, by reaction of pyrazolopyrimidines such as X with alcohols such as XXXVII using Mitsunobu-like reaction conditions. Mitsunobu-like coupling can be carried out using diisopropyl azodicarboxylate in the presence of triphenylphosphine in a suitable solvent such as tetrahydrofuran. The synthesis of intermediates such as XXXIV is exemplified by the preparation of 3-bromo-8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine.
[0283] Method 11: [ka] A method for preparing intermediates of type XXXVII is shown in Scheme 11. Alcohol intermediates of type XXXVII can be prepared from nitropyrazole intermediates of type XXXVIII (where Pg3 is, for example, TBS) using tetra-n-butylammonium fluoride in a suitable solvent such as tetrahydrofuran. Nitropyrazole intermediates of type XXXVIII can be prepared by reacting 2-(tributyl-λ)-4-(4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol as described in the synthesis of the intermediate 3-((1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol. 5 XXXIX can be synthesized from a pyrazole intermediate such as XXXIX and an alcohol such as XVII under Mitsunobu-type reaction conditions using (-phosphanylidene)acetonitrile in a solvent such as toluene.
[0284] Intermediates of type XXXIX (where Pg3 is, for example, TBS) can be synthesized from alcohols such as XL using, for example, tert-butyldimethylsilyl chloride in the presence of a base such as imidazole and a catalyst such as 4-dimethylaminopyridine in a suitable solvent such as dichloromethane. Alcohol intermediates such as XL can be prepared from nitropyrazoles such as XLI (where Pg4 is, for example, 2-tetrahydropyranyl) by treatment with an acid such as aqueous hydrochloric acid in a suitable solvent such as methanol.
[0285] Alcohol intermediates of type XLI can be prepared by reacting chloro intermediates of type XLII with propane-1,3-diols XXVII in the presence of a base such as, for example, cesium fluoride in a solvent such as N,N-dimethylacetamide.
[0286] Chloro intermediates such as XLII (where Pg4 is, for example, 2-tetrahydropyranyl) can be prepared from nitropyrazole intermediate XLIII (where Pg4 is, for example, 2-tetrahydropyranyl) using a strong base such as, for example, lithium bis(trimethylsilyl)amide and an electrophile such as, for example, hexachloroethane in a suitable solvent such as tetrahydrofuran.
[0287] Abbreviation Abbreviations used in the experiments include, but are not limited to: Boc: tert-butyloxycarbonyl; Brij-35: polyoxyethylene (23) lauryl ether; C: Celsius; CPME: cyclopentyl methyl ether; cPr: cyclopropyl; dba: dibenzylideneacetone; DBAD: di-tert-butyl azodicarboxylate; DCM: dichloromethane; DIAD: diisopropyl azodicarboxylate; DIPEA: N,N-diisopropylethylamine; DMA: N,N-dimethylacetamide; DMF: N'N-dimethylformamide; DMSO: dimethyl sulfoxide; DTT: dithiothreitol; EGTA: ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid; Et: ethyl; E tOAc: ethyl acetate; g: gram; h: hour; HMDS: hexamethyldisilazane; L: liter; LDA: lithium diisopropylamide; M: molar concentration; Me: methyl; mg: milligram; mL: milliliter; mmol: millimole; Ms: methanesulfonyl; n-Bu: n-butyl; NFSI: N-fluorobenzenesulfonimide; NMR: nuclear magnetic resonance; Ph: phenyl; Pin: pinacol; PG: protecting group; SFC: supercritical fluid chromatography; TBS: tert-butyl(dimethyl)silyl; TEA: triethylamine; THF: tetrahydrofuran; THP: tetrahydropyran; TMS: trimethylsilyl; Tris: trisaminomethane; Ts: toluenesulfonyl.
[0288] chemical name Chemical names for the present examples were generated using ChemDraw version 20.0.0.41 from PerkinElmer Informatics, Inc.
[0289] Analysis method LC-MS method Method A: LC-MS was performed in positive ion mode on an Agilent LC1200-MS6110 UPLC-MS or UPLC-MS consisting of an Agilent LC1200 with a column manager, binary solvent manager, sample organizer, PDA detector (operating at 220 & 254 nM), ELS detector, and MS6110 equipped with APPI. LC conditions: The column was an Xtimate C18 2.1 x 30 mm, 3 μm column operated at 50 °C with a binary gradient consisting of water + 0.037% trifluoroacetic acid (A) and acetonitrile + 0.018% trifluoroacetic acid (B) at 1.2 mL / min. Retention times (t R ) is based on the UV trace at 220 & 254nm and is displayed in minutes. Gradient: 0.00 min 10% B 0.9 minutes 80%B 1.5 minutes 80%B 1.51 minutes 10%B 2.00 minutes 10%B Total execution time: 2.0 minutes
[0290] Method B: LC-MS was performed in positive ion mode on an Agilent LC1200-MS6150 or LC1200-MS6110 UPLC-MS consisting of an Agilent LC1200 containing a column manager, a binary solvent manager, a sample organizer, a PDA detector (operating at 220 & 254 nM), an ELS detector, and an MS6150 or MS6110 equipped with an APPI source. LC conditions: The column was a Merck, RP-18e 25 x 3.0 mm column operated at 50 °C with a binary gradient consisting of water + 0.037% trifluoroacetic acid (A) and acetonitrile + 0.018% trifluoroacetic acid (B) at 1.5 mL / min. Retention times (t R ) is based on the UV trace at 220 & 254nm and is displayed in minutes. Gradient: 0.00 min 5% B 0.7 minutes 95%B 1.1 minutes 95%B 1.11 minutes 5%B 1.5 minutes 5%B Total running time: 1.5 minutes
[0291] Method C: LC-MS was performed in positive ion mode on an Agilent Prime-6125B UPLC-MS consisting of an Agilent Prime containing a column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nM), ELS detector, and a 6125B equipped with an APPI source. LC conditions: The column was an Agilent Poroshell 120EC-C18 1.9 μm; 3.0 × 30 mm column operated at 50 °C with a binary gradient consisting of water + 0.037% trifluoroacetic acid (A) and acetonitrile + 0.018% trifluoroacetic acid (B) at 1.5 mL / min. Retention times (t R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 0.00 min 5% B 1.20 minutes 80%B 2.5 minutes 95%B 2.51 minutes 5%B 3.00 minutes 5%B Total execution time: 3.0 minutes
[0292] Method D: LC-MS was performed in positive ion mode on an Agilent Prime-6125B UPLC-MS consisting of an Agilent Prime containing a column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nM), ELS detector, and a 6125B equipped with an APPI source. LC conditions: The column was an Agilent Poroshell 120EC-C18 1.9 μm; 3.0 × 30 mm column operated at 50 °C with a binary gradient consisting of water + 0.037% trifluoroacetic acid (A) and acetonitrile + 0.018% trifluoroacetic acid (B) at 1.5 mL / min. Retention times (t R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 0.00 min 0%B 1.20 minutes 30%B 2.5 minutes 95%B 2.51 minutes 0%B 3.00 minutes 0%B Total execution time: 3.0 minutes
[0293] Method E: LC-MS was performed in positive ion mode on a Waters Aquity UPLC-MS consisting of a column manager, a binary solvent manager, a sample organizer, a PDA detector (operating at 254 nM), an ELS detector, and a Waters Aquity SQD-MS equipped with an APPI source. LC conditions: The column was an Acquity UPLC BEH C18 1.7 μm; 2.1 × 50 mm, operated at 60 °C with a binary gradient consisting of water + 0.05% trifluoroacetic acid (A) and acetonitrile + 5% water + 0.035% trifluoroacetic acid (A) at 1.2 ml / min. Retention times (t R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 0.00 min 10% B 1.00 minutes 100%B 1.01 minutes 10%B 1.15 minutes 10%B Total running time: 1.15 minutes
[0294] Method F: LC-MS was performed in positive ion mode on a Waters Aquity UPLC-MS consisting of a column manager, a binary solvent manager, a sample organizer, a PDA detector (operating at 254 nM), an ELS detector, and a Waters Aquity TQD-MS equipped with an APPI source. LC conditions: The column was an Acquity UPLC BEH C18 1.7 μm; 2.1 × 50 mm, operated at 60 °C with a binary gradient consisting of water + 0.05% trifluoroacetic acid (A) and acetonitrile + 5% water + 0.05% trifluoroacetic acid (A) at 1.2 ml / min. Retention times (t R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 0.00 min 10% B 1.00 minutes 100%B 1.01 minutes 10%B 1.15 minutes 10%B Total running time: 1.15 minutes
[0295] Method G: LC-MS was performed in positive ion mode on an Agilent Prime-6125B UPLC-MS consisting of an Agilent Prime containing a column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nM), ELS detector, and a 6125B equipped with an APPI source. LC conditions: The column was an Agilent Poroshell 120 EC-C18 1.9 μm; 3.0 × 30 mm column operated at 30 °C with a binary gradient consisting of water + 0.05% NH3.H2O (A) and acetonitrile (B) at 1.5 mL / min. Retention times (t R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 0.00 min 5% B 1.20 minutes 80%B 2.5 minutes 95%B 2.51 minutes 5%B 3.00 minutes 5%B Total execution time: 3.0 minutes
[0296] Method H: Method PHQA: LC-MS was performed on a Shimadzu LCMS-2020. The PDA detector was operated with ESI+ from 190 to 400 nM, with a mass scan range of 90 to 900 (m / z). The column was an EVO C18 1.9 μm; 3.0 × 50 mm column operated at 40 °C with a binary gradient consisting of water (A) and water + 5 mM NH4HCO3 in acetonitrile (B) at 1.2 mL / min. Retention times (t R ) is based on a UV trace at 254 nm and is expressed in minutes. Gradient: 0.0 min 10% B 2.0 minutes 95%B 2.6 minutes 95%B 2.7 minutes 10%B Total running time: 2.8 minutes
[0297] Method I: LC-MS was performed in positive ion mode on a Shimadzu LC-20AD; LCMS-2020 consisting of a Shimadzu LC-20AD containing a column manager, binary solvent manager, sample organizer, PDA detector (operating at 220 & 254 nM), ELS detector, and MS6150 equipped with an APPI source. LC conditions: The column was a Chromolith® Flash RP-18e 25-3 mm operated at 50 °C with a binary gradient consisting of water + 0.037% trifluoroacetic acid (A) and acetonitrile + 0.018% trifluoroacetic acid (B) at 1.5 mL / min. Retention times (t R ) is based on the UV trace at 220 & 254nm and is displayed in minutes. Gradient: 0 min 5% B 0.4 minutes 95%B 0.7 minutes 95%B 0.71 minutes 5%B 1.0 min 5%B Total execution time: 1.0 min
[0298] Method J: LC-MS was performed in positive ion mode on a Shimadzu LC20-MS2010 UPLC-MS, consisting of a Shimadzu LC20 containing a column manager, binary solvent manager, sample organizer, PDA detector (operating at 220 & 254 nm), ELS detector, and MS2010 equipped with an APPI source. LC conditions: The column was an Xtimate, C18, 2.1 x 30 mm, 3 μm, operated at 50 °C with a binary gradient consisting of water + 0.037% trifluoroacetic acid (A) and acetonitrile + 0.018% trifluoroacetic acid (B) at 0.8 mL / min. Retention times (t R ) is based on the UV trace at 220 & 254nm and is displayed in minutes. Gradient: 0.00 min 10% B 1.35 minutes 80%B 2.25 minutes 80%B 2.26 minutes 10%B 3 minutes 10%B Total running time: 3 minutes
[0299] Method K: LC-MS was performed in positive ion mode on a Shimadzu LC20-MS2010 UPLC-MS, consisting of a Shimadzu LC20 containing a column manager, binary solvent manager, sample organizer, PDA detector (operating at 220 & 254 nm), ELS detector, and MS2010 equipped with an APPI source. LC conditions: The column was an Xtimate, C18, 2.1 x 30 mm, 3 μm, operated at 50 °C with a binary gradient consisting of water + 0.037% trifluoroacetic acid (A) and acetonitrile + 0.018% trifluoroacetic acid (B) at 0.8 mL / min. Retention times (t R ) is based on the UV trace at 220 & 254nm and is displayed in minutes. Gradient: 0.00 min 0%B 1.35 minutes 60%B 2.25 minutes 60%B 2.26 minutes 0%B 3 minutes 0%B Total running time: 3 minutes
[0300] NMR 1 H NMR spectra were recorded at 600 MHz on a Bruker 600-Avance-III spectrometer, at 500 MHz on a Bruker 500-Avance DRX spectrometer, at 400 MHz on a Bruker Avance AV-III-400 or Varian MR400 spectrometer, and at 300 MHz on a Bruker Avance III HD.
[0301] Chemical shift values are expressed in ppm relative to tetramethylsilane. The following abbreviations or combinations thereof are used for the multiplicity of NMR signals: br = broad, d = doublet, m = multiplet, q = quartet, quint = quintet, s = singlet, and t = triplet.
[0302] c. Preparation of reagents Reagent: Bis(methyl-d3)zinc in THF-dibutyl ether-toluene [ka] To a mixture of magnesium turnings (3.51 g, 145 mmol) and n-butyl ether (39.0 mL) was added DIBAL-H (1.00 mL, 1.00 molar, 1.00 mmol) in toluene at room temperature. The mixture was stirred for 15 minutes, and then iodomethane-d3 (0.62 mL, 10 mmol) was added. The mixture was then heated to 40 °C and stirred for 15 minutes. Additional iodomethane-d3 (5.6 mL, 90 mmol) was then added dropwise over 30 minutes. The mixture was stirred at 40 °C for 1.5 hours. The mixture was cooled, and an aliquot was subjected to iodometric titration (I2 in 2-MeTHF; slow addition of Grignard reagent) to determine a concentration of 1.38 M.
[0303] Under N2, THF (4.40 mL) was added to dried zinc(II) bromide (2.20 g, 9.77 mmol). This was stirred for 10 minutes. Next, n-butyl ether (4.40 mL) was slowly added to form a white suspension. Next, D3CMgI (1.38 M in n-Bu2O) (14.2 mL, 1.38 M, 19.6 mmol) was slowly added over 5 minutes at approximately 5 °C (ice-water cooling) to form a white suspension. The mixture was stirred at room temperature for 30 minutes. Next, toluene (5.52 mL) was added, and the suspension was stirred for 15 minutes. The mixture was filtered under an inert atmosphere, and the filtrate was used in the subsequent reaction. The concentration = 0.71 M was determined by iodometric titration (I2 in 2-MeTHF).
[0304] d. Preparation of intermediates Intermediate: 3,6-Dichloro-1H-pyrazolo[3,4-d]pyrimidine [ka] Three reactions were carried out in parallel: To a solution of 6-chloro-1H-pyrazolo[3,4-d]pyrimidine (8 g, 51.8 mmol) in MeCN (240 mL) was added 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione (7.14 g, 36.23 mmol). The mixture was stirred at 85° C. for 24 hours. The reaction mixture was concentrated under reduced pressure. The residues from the three reactions were combined and purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 80:20) to give 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (4.3 g) of sufficient purity for the subsequent step. 1 H NMR (DMSO-d 6, 400MHz)δ 14.55(br s,1H),9.29(s,1H).
[0305] Intermediate: 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol [ka] To a solution of 3-((tert-butyldimethylsilyl)oxy)propan-1-ol (4.4 g, 23.1 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (5.24 g, 27.7 mmol), and PPh3 (12.1 g, 46.2 mmol) in THF (45 mL) was added dropwise DIAD (9.35 g, 46.2 mmol) at 0 °C. The mixture was stirred at 20 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 95:5 to 90:10) to give 1-(3-((tert-butyldimethylsilyl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (4.4 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.97(s,1H),4.53(t,J=6.8Hz,2H),3.66(t,J=5.6Hz,2H),2.20-2.12(m,2H),0.88(s,9H),0.01(s,6H).
[0306] To a solution of 1-(3-((tert-butyldimethylsilyl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (7 g, 19 mmol) in THF (20 mL) was added HCl (16 mL, 12 M in HO). The mixture was stirred at 20 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was treated with saturated aqueous NaHCO, final pH 7, and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 to 50:50) to give 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (2.1 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 9.00(s,1H),4.59(t,J=6.8Hz,2H),3.66(q,J=5.6Hz,2H),2.20-2.10(m,3H).
[0307] Intermediate: 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl 4-methylbenzenesulfonate [ka] To a solution of 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (580 mg, 2.35 mmol) in DCM (10 mL) was added TEA (713 mg, 7.04 mmol) and TsCl (671 mg, 3.52 mmol). The mixture was stirred at 15 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl 4-methylbenzenesulfonate (800 mg). 1H NMR(CDCl3,400MHz)δ 8.95(s,1H),7.75(d,J=8.0Hz,2H),7.33(d,J=8.0Hz,2H),4.47(t,J=6.8Hz,2H),4.09(t,J=6.0Hz,2H),2.45(s,3H),2.37-2.29(m,2H).
[0308] Intermediate: 3-(3-bromo-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol [ka] A solution of DIAD (1.96 g, 1.89 mL, 9.71 mmol) in THF (65 mL) was cooled to 0 °C. PPh3 (2.55 g, 9.71 mmol) was added in small portions, and the mixture was stirred for 15 min. Next, 3-bromo-6-chloro-1H-pyrazolo[3,4-d]pyrimidine (1.60 g, 6.85 mmol) was added in small portions, followed by a solution of 3-((tert-butyldimethylsilyl)oxy)propan-1-ol (1.09 g, 5.71 mmol) in THF (10 mL). The cooling bath was allowed to expire with stirring overnight. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give 3-bromo-1-(3-((tert-butyldimethylsilyl)oxy)propyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidine (2.17 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,600MHz)δ 8.89(s,1H),δ 4.54(t,J=6.9Hz,2H),3.65(t,J=5.8Hz,2H),2.15(m,2H),0.88(s,9H),0.01(s,6H).
[0309] To a dry flask was added 3-bromo-1-(3-((tert-butyldimethylsilyl)oxy)propyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidine (1.00 g, 2.46 mmol) and THF (25 mL). The flask was stoppered and the atmosphere was replaced with argon. HCl (3 M in CPME) (3.02 mL, 9.1 mmol) was added and the mixture was stirred at 50 °C overnight. The reaction mixture was diluted with water (10 mL), the pH was adjusted with saturated aqueous potassium carbonate (pH ∼11), and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 to 20:80) to give 3-(3-bromo-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (650 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,600MHz)δ 8.91(s,1H),4.60(t,J=6.6Hz,2H),3.65(q,J=5.8Hz,2H),2.18-2.13(m,2H),2.11(t,J=5.8Hz,1H).
[0310] Intermediate: 3,6-dichloro-1-(3-((1,5-dimethyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 1,5-dimethyl-1H-pyrazol-3-ol hydrochloride (5 g, 33.7 mmol, HCl salt) in H2SO4 (40 mL) was added KNO3 (4.08 g, 40.4 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h. The reaction mixture was poured into ice water (200 mL) and adjusted to pH 5-6 with saturated aqueous NaOH. The mixture was extracted with EtOAc (3 × 200 mL), and the combined organic layers were concentrated to give 1,5-dimethyl-4-nitro-1H-pyrazol-3-ol (2.8 g) as a solid of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 3.72(s,3H),2.61(s,3H).
[0311] To a solution of 1,5-dimethyl-4-nitro-pyrazol-3-ol (500 mg, 3.18 mmol), 3-[tert-butyl(dimethyl)silyl]oxypropan-1-ol (727 mg, 3.82 mmol), and PPh3 (1.09 g, 4.14 mmol) in THF (10 mL) was added dropwise DIAD (837 mg, 4.14 mmol) at 0 °C. The mixture was stirred at 15 °C for 16 h. The mixture was concentrated. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 70:30 to 60:40) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1,5-dimethyl-4-nitro-1H-pyrazole (700 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.38(t,J=6.0Hz,2H),3.82(t,J=6.0Hz,2H),3.69(s,3H),2.60(s,3H),2.07-1.97(m,2H),0.89(s,9H),0.05(s,6H).
[0312] To a solution of tert-butyl-[3-(1,5-dimethyl-4-nitro-pyrazol-3-yl)oxypropoxy]-dimethyl-silane (560 mg, 1.70 mmol) in THF (5 mL) was added saturated aqueous HCl (12 M, 1.42 mL). The reaction mixture was stirred at 10° C. for 16 h. The solvent was removed under reduced pressure to give 3-((1,5-dimethyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (365.7 mg) of sufficient purity for the subsequent step. LC-MS (Method A) (m / z) = 216.2 (MH). + t R =0.42 minutes.
[0313] To a solution of 3-(1,5-dimethyl-4-nitro-pyrazol-3-yl)oxypropan-1-ol (200 mg, 0.93 mmol) in DCM (5 mL) was added MsCl (266 mg, 2.32 mmol) and TEA (282 mg, 2.79 mmol) at 0 °C. The reaction mixture was stirred at 15 °C for 16 h. The reaction mixture was diluted with water (10 mL) and extracted with DCM (3 × 10 mL). The combined organic layers were washed with brine (3 × 10 mL), dried over Na SO , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 70:30 to 60:40) to give 3-((1,5-dimethyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl methanesulfonate (150 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.67-4.40(m,4H),3.69(s,3H),3.03(s,3H),2.60(s,3H),2.30-2.24(m,2H).
[0314] To a solution of 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (170 mg, 0.90 mmol) in DMF (2 mL) was added 3-((1,5-dimethyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl methanesulfonate (264 mg, 0.90 mmol), NaI (135 mg, 0.90 mmol), and DIPEA (581 mg, 4.50 mmol). The reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (3×10 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 60:40 → 50:50) to give 3,6-dichloro-1-(3-((1,5-dimethyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (100 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.95(s,1H),4.65(t,J=6.0Hz,2H),4.32(t,J=6.0Hz,2H),3.64(s,3H),2.58(s,3H),2.50-2.44(m,2H).
[0315] Intermediate: 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 5-chloro-3-methyl-4-nitro-1H-pyrazole (10.8 g, 66.85 mmol), tetrahydro-2H-pyran-4-ol (13.66 g, 133.7 mmol), and PPh3 (21.04 g, 80.22 mmol) in THF (100 mL) was added dropwise a solution of DBAD (18.47 g, 80.22 mmol) in THF (40 mL) at 0 °C. The resulting mixture was stirred at 20 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified twice by chromatography on silica gel (eluent: heptane: EtOAc 100:0 to 20:80) to give 3-chloro-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (11 g) of sufficient purity for the next step. 1 H NMR (CDCl 3, 400MHz)δ 4.35-4.26(m,1H),4.17-4.13(m,2H),3.56-3.49(m,2H),2.62(s,3H),2.38-2.26(m,2H),1.83-1.78(m,2H).
[0316] 3-Chloro-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (2.5 g, 10.2 mmol) and KOH (9 g, 160 mmol) in HO (40 mL) were heated at 140° C. for 8 h. The mixture was adjusted to pH ∼3 with aqueous HCl (12 M). The precipitate was filtered. The filter cake was dried to give 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (2.2 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.44(s,1H),4.23-4.16(m,1H),4.13-4.09(m,2H),3.52-3.45(m,2H),2.64(s,3H),2.37-2.26(m,2H),1.76-1.72(m,2H).
[0317] To a solution of DIAD (4.16 g, 20.6 mmol), a solution of 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (3.6 g, 15 mmol), 3-((tert-butyldimethylsilyl)oxy)propan-1-ol (3.62 g, 19.0 mmol), and PPh (5.40 g, 20.6 mmol) in THF (50 mL) was added dropwise at 0 °C. The mixture was stirred at 20 °C for 40 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 → 80:20) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (4 g) of sufficient purity for the next step. 1 H NMR (CDCl 3, 400MHz)δ 4.40(t,J=6.4Hz,2H),4.27-4.17(m,1H),4.16-4.11(m,2H),3.52(t,J=6.4Hz,2H),3.59-3.43(m,2 H),2.63(s,3H),2.38-2.20(m,2H),2.04-1.99(m,2H),1.80-1.70(m,2H),0.88(s,9H),0.04(s,6H).
[0318] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (4 g, 10 mmol) in THF (40 mL) was added HCl (12 M, 8.34 mL, 100 mmol). The mixture was stirred at 20 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The reaction mixture was diluted with water (50 mL), the pH was adjusted to 9-10 using saturated aqueous Na2CO3, and extracted with EtOAc (3 × 100 mL). The combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 → 20:80) to give 3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (1.4 g) of sufficient purity for the next step. 1 H NMR (CDCl 3, 400MHz)δ 4.50(t,J=6.0Hz,2H),4.28-4.17(m,1H),4.17-4.12(m,2H),3.91-3.78(m,2H),3.57 -3.46(m,2H),2.65(s,3H),2.36-2.23(m,2H),2.11-2.05(m,2H),1.81-1.73(m,2H).
[0319] To a solution of 3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (1.4 g, 4.91 mmol) in DCM (20 mL) was added MsCl (1.41 g, 12.31 mmol) and TEA (1.49 g, 14.7 mmol) at 0° C. The mixture was stirred at 20° C. for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with DCM (3×100 mL). The combined organic layers were washed with brine (3×100 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 → 20:80) to give 3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl methanesulfonate (1.5 g) of sufficient purity for the next step. 1 H NMR (CDCl 3, 400MHz)δ 4.49-4.42(m,4H),4.27-4.17(m,1H),4.16-4.11(m,2H),3.58-3.47(m ,2H),3.04(s,3H),2.65(s,3H),2.36-2.22(m,4H),1.80-1.72(m,2H).
[0320] To a solution of 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (810 mg, 4.29 mmol) in DMF (20 mL) was added 3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl methanesulfonate (1.5 g, 4.13 mmol), NaI (619 mg, 4.13 mmol), and DIPEA (2.67 g, 20.6 mmol). The mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (3×100 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 to 60:40) to give 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy) propyl)-1H-pyrazolo[3,4-d]pyrimidine (840 mg) of sufficient purity for the next step. 1 H NMR (CDCl 3, 400MHz)δ 8.96(s,1H),4.65(t,J=6.4Hz,2H),4.35(t,J=6.4Hz,2H),4.23-4.15(m,1H),4.12-4.07(m,2 H),3.54-3.46(m,2H),2.63(s,3H),2.51-2.43(m,2H),2.25-2.14(m,2H),1.76-1.69(m,2H).
[0321] Intermediate: (±)-3,6-Dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a dry flask fitted with a stir bar and stoppered with a septum was added DIAD (2.69 mL, 13.8 mmol) and the atmosphere was replaced with argon. THF (200 mL) was added and the solution was cooled to 0 °C. PPh3 (on resin, loading: 1.6 mmol / g) (3.62 g, 13.8 mmol, using 8.625 g of resin) was then added and the solution was stirred under argon for 5 min. 3-Chloro-5-methyl-4-nitro-1H-pyrazole (1.80 g, 11.1 mmol) was added, followed by a solution of tetrahydro-2H-pyran-3-ol (1.71 g, 16.7 mmol) in THF (10 mL). The mixture was allowed to warm to room temperature and stirred for 4 h. The reaction was diluted with THF and filtered, washing with THF. The filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 to 25:75) to give (±)-3-chloro-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazole (600 mg) of sufficient purity for the next step. 1 H NMR(CDCl3,600MHz)δ 4.27-4.22(m,1H),4.01-3.92(m,2H),3.73(t,J=11.1Hz,1H),3.48-3.42(m ,1H),2.68(s,3H),2.32-2.23(m,1H),2.11-2.05(m,1H),1.89-1.78(m,2H).
[0322] To a vial was added (±)-3-chloro-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazole (725 mg, 2.95 mmol), potassium hydroxide (1.16 g, 20.7 mmol), and water (11.7 mL, 649 mmol). The vial was capped, and the reaction mixture was heated at 152 °C for 3 h using a microwave reactor. The mixture was cooled to room temperature and diluted with water (50 mL). The mixture was washed with EtOAc (10 mL). The aqueous phase was then acidified by slow addition of 2 M aqueous HCl, and the mixture was extracted with EtOAc (3 × 100 mL). The combined organic phases were washed with saturated NaCl, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give (±)-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-ol (510 mg) as a solid of sufficient purity for the next step. 1 H NMR(CDCl3,600MHz)δ 4.21-4.15(m,1H),3.99-3.95(m,1H),3.93-3.89(m,1H),3.75(t,J=10.7Hz,1H),3.46-3.40 (m,1H),2.69(s,1H),2.64(s,3H),2.31-2.22(m,1H),2.06-1.99(m,1H),1.88-1.79(m,2H).
[0323] To a dry flask was added 3-((tert-butyldimethylsilyl)oxy)propyl 4-methylbenzenesulfonate (1.45 g, 4.20 mmol), DMF (15 mL), and (±)5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-ol (510 mg, 2.24 mmol). After flushing the flask with argon, cesium carbonate (1.40 g, 4.30 mmol) was added portionwise. The reaction was stirred at room temperature for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified twice by chromatography on silica gel (eluent: heptane: EtOAc 100:0 → 25:75) to give (±)-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazole (401 mg) of sufficient purity for the next step. 1 H NMR(CDCl3,600MHz)δ 4.38(t,J=6.3Hz,2H),4.18-4.11(m,1H),3.99-3.95(m,1H),3.93-3.88(m,1H),3.80(t,J=6.0Hz,2H),3.70(t,J=10.7Hz) ,1H),3.46-3.40(m,1H),2.62(s,3H),2.26-2.17(m,1H),2.05-1.97(m,3H),1.85-1.79(m,2H),0.88(s,9H),0.04(s,6H).
[0324] To a dry flask was added (±)-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazole (400 mg, 1.00 mmol) and DCM (10 mL). The flask was stoppered and the atmosphere was replaced with argon. HCl (3 M in CPME) (2.67 mL, 8.01 mmol) was added and the mixture was heated briefly and then stirred at room temperature for 1 h. HCl (3 M in CPME) (2.67 mL, 8.01 mmol) was added and the flask was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The reaction mixture was diluted with water (10 mL) and adjusted to pH ∼11 with saturated aqueous potassium carbonate. The mixture was extracted with EtOAc (3 × 50 mL) and the combined organics were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 → 20:80) to give (±)-3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (248 mg) of sufficient purity for the next step. 1 H NMR(CDCl3,600MHz)δ 4.52-4.44(m,2H),4.16(tt,J=11.0,4.3Hz,1H),3.99-3.95(m,1H),3.94-3.88(m,1H),3.86-3.80(m,2H),3.69(t,J=11 .2Hz,1H),3.47-3.41(m,1H),2.63(s,3H),2.55-2.50(m,1H),2.24-2.16(m,1H),2.09-2.00(m,3H),1.88-1.79(m,2H).
[0325] A solution of 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (201 mg, 1.06 mmol) and (±)-3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (243 mg, 0.852 mmol) in THF (25 mL) was thoroughly degassed with argon in a dry vial. The vial was stoppered, and 1,1-(azodicarbonyl)-dipiperidine (484 mg, 1.92 mmol) and tributylphosphine (476 μL, 1.92 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with MeOH (0.5 mL) and diluted with EtOAc (25 mL). Celite was added, and the mixture was concentrated under reduced pressure. The residue was purified twice by chromatography on silica gel (eluent: heptane: EtOAc 100:0 to 20:80) to give (±)-3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy) propyl)-1H-pyrazolo[3,4-d]pyrimidine (244 mg) as a solid pure enough for the next step. 1 H NMR(CDCl3,600MHz)δ 8.95(s,1H),4.68-4.60(m,2H),4.34(t,J=5.8Hz,2H),4.16-4.10(m,1H),3.99-3.94(m,1H),3.91-3.86(m,1H),3.62(t,J=1 0.7Hz,1H),3.43-3.37(m,1H),2.61(s,3H),2.46(p,J=6.2Hz,2H),2.17-2.09(m,1H),2.01-1.96(m,1H),1.84-1.78(m,2H).
[0326] Intermediate: 6-chloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] A solution of DIAD (218 μL, 1.12 mmol) in THF (1 mL) was cooled to 0° C. under an argon atmosphere. PPh3 (294 g, 1.12 mmol) was added, and the mixture was stirred for 10 min. Next, 6-chloro-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine (156 mg, 0.701 mmol) was added, followed by a solution of 3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (160 mg, 0.561 mmol, prepared as described above) in THF (0.25 mL). The reaction mixture was stirred at 0° C. for 2 min and then at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 → 20:80) to give 6-chloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine (190 mg) as a solid of sufficient purity for the subsequent step. 1 H NMR(CDCl3,600MHz)δ 9.12(s,1H),4.76(t,J=6.5Hz,2H),4.38(t,J=5.8Hz,2H),4.21-4.14(m,1H),4.12-4.07(m 2H),3.52-3.46(m,2H),2.61(s,3H),2.52(p,J=6.2Hz,2H),2.23-2.16(m,2H),1.75-1.69(m,2H).
[0327] Intermediate: 3,6-dichloro-1-(3-((5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] A mixture of 3-chloro-4-nitro-1H-pyrazole (10 g, 68 mmol), 4-bromotetrahydro-2H-pyran (22.37 g, 135.6 mmol), and CsCO (55.22 g, 169.5 mmol) in DMF (100 mL) was degassed and purged with N (×3), and then the mixture was stirred at 80 °C for 16 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (4 × 200 mL). The combined organic layers were washed with brine (3 × 300 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 → 70:30) to give 3-chloro-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (8.7 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.22(s,1H),4.38-4.28(m,1H),4.15(dd,J=3.2,10.8Hz,2H),3.59-3.49(m,2H),2.19-2.00(m,4H).
[0328] Three reactions were carried out in parallel on the same scale. To a solution of 3-chloro-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (2.2 g, 9.5 mmol) in THF (100 mL) was added LiHMDS (28.49 mL, 1 M in THF) dropwise at −78 °C. After stirring at −78 °C for 0.5 h, a solution of I (7.23 g, 28.5 mmol) in THF (20 mL) was added dropwise. The reaction mixture was stirred at −78 °C for 1.5 h. The reaction was quenched with saturated aqueous NH Cl (50 mL) and extracted with EtOAc (5 × 50 mL). The combined organic layers were washed with saturated aqueous Na SO (3 × 50 mL), dried over Na SO and concentrated under reduced pressure. The residues from the three reactions were combined and purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 to 70:30) to give 3-chloro-5-iodo-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (8.6 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 4.68-4.58(m,1H),4.17-4.14(m,2H),3.60-3.51(m,2H),2.36-2.23(m,2H),1.90(dd,J=2.4,12.8Hz,2H).
[0329] Four reactions were carried out in parallel on the same scale. A mixture of 3-chloro-5-iodo-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (1.15 g, 3.22 mmol), cyclopropylboronic acid (553 mg, 6.43 mmol), Pd(dba) (185 mg, 0.20 mmol), PCy (90 mg, 0.32 mmol), and KCO (1.33 g, 9.65 mmol) in DMF (10 mL) was stirred at 140 °C for 2 h using a microwave reactor. The reaction mixture was quenched with water (40 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3 × 60 mL), dried over NaSO, and concentrated under reduced pressure. The residues from the four reactions were combined and purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 to 70:30) followed by preparative HPLC (instrument: Gilson GX-281 liquid handler, Shimadzu LC-8A; column: mobile phase A: water (NH3H2O + NH4HCO3), mobile phase B: MeCN, gradient: 26% to 56% B in 10 min, then hold at 100% for 2 min; flow rate (mL / min): 60; column temperature 30 °C, wavelength 220 nm 254 nm basic conditions) to give 3-chloro-5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (2 g) in sufficient purity for the next step in four reactions. 1 H NMR(CDCl3,400MHz)δ 4.77-4.68(m,1H),4.15(dd,J=4.0,11.2Hz,2H),3.58-3.49(m,2H),2.41-2.28(m ,2H),1.92-1.83(m,1H),1.83-1.75(m,2H),1.34-1.27(m,2H),0.81-0.75(m,2H).
[0330] A mixture of 3-chloro-5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (2.9 g, 10.67 mmol) and KOH (8.98 g, 160.10 mmol) in HO (50 mL) was degassed and purged with N (×3), then the mixture was stirred at 140 °C for 16 h. The extracted mixture was acidified to pH = 3 with concentrated HCl and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (3 × 150 mL), dried over NaSO, and concentrated under reduced pressure to give 5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (1.13 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.62(br s,1H),4.71-4.61(m,1H),4.14(dd,J=5.2,12.0Hz,2H),3.57-3.47(m,2H),2.42-2.29(m,2H),1.87-1.78 (m,1H),1.74(dd,J=3.2,12.8Hz,2H),1.35-1.28(m,2H),0.91-0.84(m,2H).LC-MS(Method C)(m / z)=254.2(MH) + t R =1.59 minutes.
[0331] To a solution of 5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (200 mg, 0.79 mmol), 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (195 mg, 0.79 mmol, prepared as above), and PPh3 (621 mg, 2.37 mmol) in THF (10 mL) was added dropwise DIAD (479 mg, 2.37 mmol) at 0 °C. The mixture was stirred at 20 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 to 70:30) to give 3,6-dichloro-1-(3-((5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (140 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 428.1 (MH). + t R =0.87 minutes.
[0332] Intermediate: 1-(3-((1-((2-oxabicyclo[2.1.1]hexan-1-yl)methyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine [ka] A mixture of 1-(iodomethyl)-2-oxabicyclo[2.1.1]hexane (17.93 g, 80.02 mmol), 3-chloro-5-methyl-4-nitro-1H-pyrazole (10.8 g, 66.9 mmol), and K2CO3 (27.7 g, 201 mmol) in MeCN (350 mL) was stirred at 70 °C for 16 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 70:30) to give 1-((2-oxabicyclo[2.1.1]hexan-1-yl)methyl)-3-chloro-5-methyl-4-nitro-1H-pyrazole (8.4 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.40(s,2H),3.74(s,2H),2.98-2.92(m,1H),2.71(s,3H),1.87-1.79(m,2H),1.48-1.44(m,2H).
[0333] To a solution of 1-((2-oxabicyclo[2.1.1]hexan-1-yl)methyl)-3-chloro-5-methyl-4-nitro-1H-pyrazole (1 g, 3.88 mmol) in HO (80 mL) was added KOH (4.35 g, 77.6 mmol). The mixture was stirred at 120 °C for 23 h. Then, additional KOH (1.58 g, 28.2 mmol) was added, and the mixture was stirred at 140 °C for 40 h. The mixture was adjusted to pH ∼2 with concentrated aqueous HCl and extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure to give 1-((2-oxabicyclo[2.1.1]hexan-1-yl)methyl)-5-methyl-4-nitro-1H-pyrazol-3-ol (880 mg) of sufficient purity for the subsequent step. 1 H NMR(DMSO-d6,400MHz)δ 11.37(s,1H),4.30(s,2H),3.63(s,2H),2.86(t,J=6.4Hz,1H),2.53(s,3H),1.875-1.75(m,2H),1.40-1.27(m,2H).
[0334] To a solution of 1-((2-oxabicyclo[2.1.1]hexan-1-yl)methyl)-5-methyl-4-nitro-1H-pyrazol-3-ol (200 mg, 0.84 mmol) and 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (248 mg, 1.00 mmol, prepared as described above) in THF (6 mL) was added DIAD (686 mg, 3.39 mmol) and PPh3 (877 mg, 3.34 mmol). The mixture was stirred at 20 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give 1-(3-((1-((2-oxabicyclo[2.1.1]hexan-1-yl)methyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (230 mg) of sufficient purity for the subsequent step.
[0335] f. Intermediate: 3,6-dichloro-1-(3-((5-methyl-1-((3-methyloxetan-3-yl)methyl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 3-chloro-5-methyl-4-nitro-1H-pyrazole (10 g, 61.9 mmol) in MeCN (100 mL) was added 3-(iodomethyl)-3-methyl-oxetane (14.44 g, 68.1 mmol) and K2CO3 (25.7 g, 186 mmol). The reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 to 75:25) to give 3-chloro-5-methyl-1-((3-methyloxetan-3-yl)methyl)-4-nitro-1H-pyrazole (6.3 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.73(d,J=6.4Hz,2H),4.44(d,J=6.4Hz,2H),4.29(s,2H),2.67(s,3H),1.28(s,3H).
[0336] To a solution of 3-chloro-5-methyl-1-((3-methyloxetan-3-yl)methyl)-4-nitro-1H-pyrazole (500 mg, 2.04 mmol) in HO (25 mL) was added NaOH (2.44 g, 61.1 mmol). The mixture was stirred at 140 °C for 1.5 h. The reaction mixture was extracted with EtOAc (3 × 100 mL) and the combined organic layers were discarded. The aqueous phase was adjusted to pH = 3 with aqueous HCl (12 M), extracted with EtOAc (3 × 100 mL), dried over NaSO, and concentrated under reduced pressure to give 5-methyl-1-((3-methyloxetan-3-yl)methyl)-4-nitro-1H-pyrazol-3-ol (100 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.78(d,J=6.4Hz,2H),4.37(d,J=6.4Hz,2H),4.22(s,2H),2.59(s,3H),1.22(s,3H).
[0337] To a solution of 5-methyl-1-((3-methyloxetan-3-yl)methyl)-4-nitro-1H-pyrazol-3-ol (140 mg, 0.62 mmol), 3-(3,6-dichloropyrazole[3,4-d]pyrimidin-1-yl)propan-1-ol (152 mg, 0.62 mmol, prepared as described above), and PPh3 (485 mg, 1.85 mmol) in THF (4 mL) was added DIAD (374 mg, 1.85 mmol) at 0 °C. The mixture was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 40:60) and purified by preparative HPLC (instrument: Gilson GX-281 liquid handler, Gilson 322 pump, Gilson 156 UV detector; column: Xtimate C18 150 × 40 mm × 5 μm; mobile phase A: water (NH3H2O), mobile phase B: MeCN; gradient: 38% to 68% B in 8 min, then hold at 100% for 1 min; flow rate (mL / min): 60; column temperature: 30 °C; wavelength: 220 nm). Further purification by HPLC at 254 nm gave 3,6-dichloro-1-(3-((5-methyl-1-((3-methyloxetan-3-yl)methyl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (75 mg) of sufficient purity for the next step. 1 H NMR(CDCl3,400MHz)δ 8.96(s,1H),4.70(d,J=6.4Hz,2H),4.64(t,J=6.4Hz,2H),4.37(d,J=6.4Hz,2H), 4.30(t,J=5.6Hz,2H),4.11(s,2H),2.59(s,3H),2.49-2.44(m,2H),1.22(s,3H).
[0338] g. Intermediate 3,6-dichloro-1-(3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] Under an argon atmosphere, potassium tert-butoxide (28.1 mg, 0.250 mmol) was added to a dry vial containing 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (200 mg, 0.501 mmol) in DMSO-d6 (8 mL). The solution turned deep orange. The reaction mixture was stirred at 30 °C for 72 h. The mixture was diluted with deuterium oxide (10 mL) and extracted with EtOAc (3 × 25 mL). The combined organics were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dried completely by lyophilization to remove residual solvent, yielding 3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (140 mg) of sufficient purity for the next step. 1 H NMR(CDCl3,600MHz)δ4.49(t,J=5.9Hz,2H),4.23-4.17(m,1H),4.13-4.08(m,2H),3.86-3.80(m,2H) ,3.54-3.47(m,2H),2.55(t,J=6.0Hz,1H),2.33-2.23(m,2H),2.10-2.03(m,2H),1.78-1.73(m,2H).
[0339] A solution of DIAD (113 μL, 0.583 mmol) in THF (7 mL) was cooled to 0° C. under an argon atmosphere. PPh (153 mg, 0.583 mmol) (on resin, approximately 3 mmol / g: 194 mg = 0.583 mmol was used) was added, and the mixture was stirred for 10 min. Next, 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (118 mg, 0.624 mmol) was added, followed by a solution of 3-((5-(methyl-d)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (120 mg, 0.416 mmol) in THF (1.5 mL). The reaction mixture was stirred at 0° C. for 2 min and then at room temperature overnight. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 20:80) to give 3,6-dichloro-1-(3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (133 mg) as a solid of sufficient purity for the subsequent step. 1 H NMR(CDCl3,600MHz)δ8.95(s,1H),4.64(t,J=6.4Hz,2H),4.35(t,J=5.8Hz,2H),4.20-4.13(m,1H ),4.12-4.07(m,2H),3.53-3.44(m,2H),2.51-2.44(m,2H),2.23-2.14(m,2H),1.76-1.68(m,2H).
[0340] h. Intermediate: 3,6-dichloro-1-(3-((5-methyl-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 3-chloro-4-nitro-1H-pyrazole (5 g, 33.9 mmol) in DMF (50 mL) was added diethyl 2-bromo-2-methylmalonate (17.16 g, 67.79 mmol) and K2CO3 (9.39 g, 68.0 mmol) and stirred at 100 °C for 12 h. The mixture was diluted with HO (50 mL) and extracted with EtOAc (2 × 50 mL). The organic phase was washed with brine (2 × 50 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 70:30) to give diethyl 2-(3-chloro-4-nitro-1H-pyrazol-1-yl)-2-methylmalonate (7.25 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.60(s,1H),4.33(q,J=7.2Hz,4H),2.12(s,3H),1.31(t,J=7.2Hz,6H).
[0341] To a solution of diethyl 2-(3-chloro-4-nitro-1H-pyrazol-1-yl)-2-methylmalonate (3.6 g, 11.3 mmol) in MeOH (80 mL) at 0 °C, NaBH (854 mg, 22.6 mmol) was added in small portions, and the reaction was stirred at 0 °C for 1 h. The mixture was concentrated under reduced pressure. The residue was diluted with HO (10 mL), saturated aqueous NH Cl (10 mL), and extracted with EtOAc (3 × 20 mL). The organic phase was washed with brine (20 mL), dried over Na SO , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 20:80) to give 2-(3-chloro-4-nitro-1H-pyrazol-1-yl)-2-methylpropane-1,3-diol (1.55 g) of sufficient purity for the next step. 1 H NMR(CDCl3,400MHz)δ 8.48(s,1H),4.01(d,J=4.4Hz,4H),2.83-2.72(m,2H),1.53(s,3H).
[0342] To a solution of 2-(3-chloro-4-nitro-1H-pyrazol-1-yl)-2-methylpropane-1,3-diol (1.55 g, 6.58 mmol) in DCM (20 mL) was added TsCl (1.32 g, 6.91 mmol) and TEA (998 mg, 9.87 mmol), and the reaction was stirred at 20 °C for 12 h. The reaction was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give 2-(3-chloro-4-nitro-1H-pyrazol-1-yl)-3-hydroxy-2-methylpropyl 4-methylbenzenesulfonate (1.5 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.22(s,1H),7.65(d,J=8.4Hz,2H),7.32(d,J=8.4Hz,2H),4.40(d,J=10.8Hz,1H),4.27(d,J=10.8Hz,1H),3.95(s,2H),2.64(br s,1H),2.46(s,3H),1.62(s,3H).
[0343] To a solution of 2-(3-chloro-4-nitro-1H-pyrazol-1-yl)-3-hydroxy-2-methylpropyl 4-methylbenzenesulfonate (1.1 g, 2.8 mmol) in THF (20 mL) was added NaH (170 mg, 4.25 mmol, 60% in mineral oil) at 0 °C, and the reaction was stirred at 70 °C for 2 h. The mixture was quenched with HO (20 mL) at 0 °C and extracted with EtOAc (2 × 20 mL). The combined organic phases were washed with brine (20 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40) to give 3-chloro-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazole (360 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.32(s,1H),5.13(d,J=6.4Hz,2H),4.68(d,J=6.8Hz,2H),1.99(s,3H).
[0344] To a solution of trimethylsulfoxonium iodide (1.76 g, 8.00 mmol) in DMSO (7 mL) was added t-BuOK (897 mg, 7.99 mmol) at 25 °C, and the reaction was stirred at 25 °C for 1 h. Next, a solution of 3-chloro-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazole (870 mg, 4.00 mmol) in DMSO (3 mL) was added dropwise at 35 °C, and the mixture was stirred at 35 °C for 12 h. The mixture was diluted with HO (10 mL) and extracted with EtOAc (4 × 10 mL). The organic phase was washed with brine (10 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40) to give 3-chloro-5-methyl-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazole (605 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 232.0 (MH). + t R =0.69 minutes.
[0345] A mixture of 3-chloro-5-methyl-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazole (600 mg, 2.59 mmol) in a solution of NaOH (1.20 g, 30 mmol) in HO (15 mL) was stirred at 100° C. for 4 h. The reaction was cooled to room temperature (20° C.) and acidified to pH 5 with saturated aqueous KHSO. The solid was filtered, washed with HO (2 × 1 mL), and dried to give 5-methyl-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazol-3-ol (405 mg) of sufficient purity for the next step, which was used directly. 1 H NMR(CDCl3,400MHz)δ 8.40(br s,1H),5.19(d,J=6.8Hz,2H),4.59(d,J=7.2Hz,2H),2.46(s,3H),1.87(s,3H).
[0346] 5-Methyl-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazol-3-ol (150 mg, 0.7 mmol), 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl 4-methylbenzenesulfonate (283 mg, 0.71 mmol, prepared as described above), and KCO (292 mg, 2.11 mmol) in DMF (3 mL) were placed in a sealed tube, and the reaction was stirred at 85 °C for 2 h. The mixture was diluted with HO (3 mL) and extracted with EtOAc (2 × 3 mL). The organic phase was washed with brine (2 × 3 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 50:50) to give 3,6-dichloro-1-(3-((5-methyl-1-(3-methyloxetan-3-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (201 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.96(s,1H),5.11(d,J=6.4Hz,2H),4.65(t,J=6.4Hz,2H),4.54(d,J=7.2H z,2H),4.31(t,J=5.6Hz,2H),2.51-2.44(m,2H),2.41(s,3H),1.80(s,3H).
[0347] i. j. Intermediate: 3,6-dichloro-1-(3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] A mixture of dihydro-2H-pyran-4(3H)-one (17 g, 170 mmol) in THF (200 mL) was degassed and purged with N (×3), and lithium aluminum deuteride (9.67 g, 255 mmol) was added portionwise at 0 °C, after which the mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched with water (10 mL), followed by 10% aqueous NaOH (30 mL) and water (10 mL). The mixture was filtered, and the filtrate was concentrated to give tetrahydro-2H-pyran-4-d-4-ol (17.5 g) of sufficient purity for the next step. 1 H NMR(CDCl3,400MHz)δ 3.99-3.91(m,2H),3.48-3.39(m,2H),1.94-1.86(m,2H),1.61-1.49(m,2H).
[0348] To a solution of tetrahydro-2H-pyran-4-d-4-ol (15 g, 145 mmol), TEA (22.08 g, 218 mmol), and N,N-dimethylmethanamine hydrochloride (1.39 g, 14.5 mmol) in DCM (450 mL) was added TsCl (33.3 g, 175 mmol) at 0 °C. The mixture was stirred at 20 °C for 17 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 80:20) to give tetrahydro-2H-pyran-4-yl-4-d 4-methylbenzenesulfonate (30.9 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 7.81(d,J=8.4Hz,2H),7.35(d,J=8.4Hz,2H),3.93-3.80(m,2H),3.52-3.43(m,2H),2.45(s,3H),1.89-1.82(m,2H),1.79-1.70(m,2H).
[0349] To a solution of 5-chloro-3-methyl-4-nitro-1H-pyrazole (16 g, 99.0 mmol) and tetrahydro-2H-pyran-4-yl-4-d 4-methylbenzenesulfonate (30.9 g, 120 mmol) in DMF (300 mL) was added K2CO3 (41.1 g, 297 mmol). The mixture was stirred at 80 °C for 20 h. The reaction mixture was concentrated under reduced pressure. The residue was purified three times by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 80:20) to give 3-chloro-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazole (11 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.18-4.12(m,2H),3.57-3.49(m,2H),2.70(s,3H),2.38-2.28(m,2H),1.85-1.79(m,2H).
[0350] To a solution of 3-chloro-5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazole (11 g, 44.6 mmol) in HO (150 mL) was added KOH (25 g, 446 mmol). The mixture was stirred at 140 °C for 22 h. The mixture was acidified (pH = 3) with aqueous HCl (12 M). The precipitate was filtered. The filter cake was dried to give 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-ol (8 g). The filtrate was extracted with EtOAc (3 × 300 mL). The combined organic layers were washed with brine (3 x 300 mL), dried over NaSO, and concentrated to give 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-ol (2 g). The two raw materials were combined to give 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-ol (10 g) of sufficient purity for the next step. 1H NMR(CDCl3,400MHz)δ 11.37(br s,1H),3.97-3.90(m,2H),3.50-3.42(m,2H),2.59(s,3H),1.99-1.89(m,2H),1.79-1.70(m,2H).
[0351] To a solution of 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-ol (6.0 g, 26 mmol) in DMSO-d (240 mL) was added t-BuOK (3.25 g, 28.9 mmol). The mixture was stirred at 30 °C for 64 h. The mixture was diluted with deuterium oxide (100 mL) and adjusted to pH = 3 with aqueous HCl (2 M). The aqueous phase was extracted with EtOAc (6 × 300 mL). The combined organic layers were washed with brine (2 × 200 mL), dried over NaSO, and concentrated. Water (100 mL) was added to the residue, and the mixture was lyophilized to give 5-(methyl-d)-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-ol (5 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 11.36(br s,1H),3.97-3.89(m,2H),3.51-3.41(m,2H),1.99-1.89(m,2H),1.79-1.69(m,2H).LC-MS:t R =1.653 min (Method D), m / z=232.1[M+H] + .
[0352] To a solution of 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl 4-methylbenzenesulfonate (760 mg, 1.89 mmol, prepared as described above) in DMSO-d (20 mL) was added KCO (288 mg, 2.08 mmol) and 5-(methyl-d)-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-ol (438 mg, 1.89 mmol). The mixture was stirred at 80 °C for 1 h. The reaction mixture was diluted with aqueous HCl (2 M), pH = 6–7, and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (3 × 40 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give 3,6-dichloro-1-(3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl-4-d)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (540 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.94(s,1H),4.64(t,J=6.4Hz,2H),4.34(t,J=6.0Hz,2H),4.10-4.05(m,2H) ,3.53-3.44(m,2H),2.50-2.42(m,2H),2.22-2.12(m,2H),1.76-1.67(m,2H).
[0353] k. Intermediate: 3,6-dichloro-1-(3-((5-(1-fluorocyclopropyl)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] A solution of DIAD (576 μL, 2.96 mmol) in THF (60 mL) was cooled to 0 °C under an argon atmosphere. PPh3 (approximately 3 mmol / g on resin) (777 mg, 2.96 mmol, 1.0 g of resin was used) was added in small portions, and the mixture was stirred for 15 min. Next, 5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (500 mg, 1.97 mmol, prepared as described above) was added, followed by a solution of 3-((tert-butyldimethylsilyl)oxy)propan-1-ol (376 mg, 1.97 mmol) in THF (1 mL). The cooling bath was removed, and the reaction mixture was stirred at room temperature for 3 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 65:35) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (518 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,600MHz)δ 4.66-4.59(m,1H),4.38(t,J=6.3Hz,2H),4.15-4.09(m,2H),3.79(t,J=6.1Hz,2H),3.55-3.48(m,2H),2.34-2.25(m,2H), 2.04-1.98(m,2H),1.85-1.79(m,1H),1.74-1.68(m,2H),1.26-1.21(m,2H),0.88(s,9H),0.78-0.73(m,2H),0.04(s,6H).
[0354] A solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-cyclopropyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (318 mg, 0.747 mmol), lithium chloride (158 mg, 3.74 mmol, dried overnight in a vacuum oven at 90° C.), and N-fluorobis(phenylsulfonyl)amine (530 mg, 1.68 mmol) in THF (20 mL) was cooled to −78° C. under an argon atmosphere. LDA (1.5 M in hexanes) (1.74 mL, 2.62 mmol) was added dropwise via syringe, forming a deep orange solution. Immediately thereafter, a solution of N-fluorobis(phenylsulfonyl)amine (707 mg, 2.24 mmol) in THF (2.5 mL) was added over 20 seconds. The orange color was quenched during the addition. The mixture was stirred for 5 minutes. The mixture was quenched with water (approximately 0.1 mL) and concentrated to dryness. The residue was suspended in DCM, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-(1-fluorocyclopropyl)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (204 mg) of sufficient purity for the next step. 1 H NMR(CDCl3,500MHz)δ 4.78-4.70(m,1H),4.43(t,J=6.3Hz,2H),4.17-4.10(m,2H),3.80(t,J=6.0Hz,2H),3.57-3.49(m,2H),2.39-2.2 8(m,2H),2.05-1.98(m,2H),1.83-1.76(m,2H),1.74-1.65(m,2H),1.14-1.07(m,2H),0.88(s,9H),0.05(s,6H).
[0355] To a dried flask was added 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-(1-fluorocyclopropyl)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (204 mg, 0.460 mmol), DCM (20 mL), and hydrochloric acid (3 M in diethyl ether) (1.61 mL, 3.22 mmol). The flask was flushed with argon and stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 0:100) to give 3-((5-(1-fluorocyclopropyl)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (108 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,600MHz)δ 4.78-4.71(m,1H),4.52(t,J=5.9Hz,2H),4.17-4.11(m,2H),3.86(t,J=5.6Hz,2H),3.57-3.51(m,2H),2.38-2.28(m,2H),2.22(br s,1H),2.11-2.05(m,2H),1.84-1.77(m,2H),1.73-1.66(m,2H),1.15-1.08(m,2H).
[0356] A solution of DIAD (121 μL, 0.623 mmol) in THF (15 mL) was cooled to 0 °C under an argon atmosphere. PPh (on resin, approximately 3 mmol / g) (163 mg, 0.623 mmol, using 207 mg of resin) was added, and the mixture was stirred for 2 min. Next, 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (77.5 mg, 0.410 mmol) was added, followed by a solution of 3-((5-(1-fluorocyclopropyl)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (108 mg, 1.0 Eq, 328 μmol) in THF (1 mL). The cooling bath was removed, and the reaction mixture was stirred for 2 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 0:100) to give 3,6-dichloro-1-(3-((5-(1-fluorocyclopropyl)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (129 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,600MHz)δ 8.95(s,1H),4.75-4.68(m,1H),4.65(t,J=6.4Hz,2H),4.41-4.36(m,2H),4.13-4.08(m,2H),3.56-3.49 (m,2H),2.50-2.44(m,2H),2.27-2.18(m,2H),1.81-1.75(m,2H),1.73-1.66(m,2H),1.15-1.09(m,2H).
[0357] l. Intermediate: 3,6-dichloro-1-(3-((5-ethyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a dry flask was added 3-bromo-4-nitro-1H-pyrazole (14.00 g, 72.93 mmol) and DMF (anhydrous) (150 mL). CsCO (59.4 g, 182 mmol) was added, followed by 4-bromooxane (24.07 g, 146 mmol). The mixture was stirred at 80 °C for 16 h. The mixture was cooled to room temperature, and water (120 mL) and EtOAc (150 mL) were added. The phases were separated, and the organic phase was washed with aqueous NHCl (2 × 150 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 83:17) to give 3-bromo-4-nitro-1-(oxan-4-yl)pyrazole (9.49 g) of sufficient purity for the subsequent step.
[0358] A mixture of 3-bromo-4-nitro-1-(oxan-4-yl)pyrazole (8.44 g, 30.6 mmol) and KOH (33.76 g, 601.7 mmol) in HO (330 mL) was stirred at 100 °C for 16 h. The mixture was acidified with HCl (aq) to pH = 3, extracted with EtOAc (130 mL × 3), and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 33:67) to give 4-nitro-1-(oxan-4-yl)pyrazol-3-ol (5 g) in sufficient purity for further processing.
[0359] To a solution of 4-nitro-1-(oxan-4-yl)pyrazol-3-ol (5 g, 23 mmol) and 3-[(tert-butyldimethylsilyl)oxy]propan-1-ol (8.93 g, 46.9 mmol) in THF (100 mL) was added PPh3 (12.30 g, 46.9 mmol) in one portion at room temperature under an argon atmosphere. Next, DIAD (9.48 g, 46.9 mmol) was added at 0 °C. The resulting mixture was stirred at room temperature for 2 h. The reaction was quenched with water (15 mL) and extracted with EtOAc (2 × 25 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 83:17) to give 3-{3-[(tert-butyldimethylsilyl)oxy]propoxy}-4-nitro-1-(oxan-4-yl)pyrazole (6 g) of sufficient purity for the next step.
[0360] To a stirred solution of 3-{3-[(tert-butyldimethylsilyl)oxy]propoxy}-4-nitro-1-(oxan-4-yl)pyrazole (500 mg, 1.30 mmol) and 15-crown-5 (3.43 g, 15.6 mmol) in THF (25 mL) was added dropwise LDA (6.48 mL, 13.0 mmol, 2 M) at −78 °C. The mixture was stirred at −78 °C for 60 min. Ethyl iodide (1.01 g, 6.49 mmol) was then added, and the resulting mixture was stirred at −78 °C for 2 h. The reaction was quenched with aqueous NH4Cl (25 mL), and the resulting mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative TLC (eluent: petroleum ether: EtOAc 83:17) to give 3-{3-[(tert-butyldimethylsilyl)oxy]propoxy}-5-ethyl-4-nitro-1-(oxan-4-yl)pyrazole (320 mg) of sufficient purity for the next step.
[0361] To a stirred solution of 3-{3-[(tert-butyldimethylsilyl)oxy]propoxy}-5-ethyl-4-nitro-1-(oxan-4-yl)pyrazole (50 mg, 0.12 mmol) in DCM (0.8 mL) was added dropwise HCl in 1,4-dioxane (0.10 mL, 0.40 mmol, 4 M) at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The residue was purified by preparative TLC (eluent: petroleum ether: EtOAc 33:67) to give 3-{[5-ethyl-4-nitro-1-(oxan-4-yl)pyrazol-3-yl]oxy}propan-1-ol (23 mg) of sufficient purity for the subsequent step.
[0362] To a stirred mixture of 3-{[5-ethyl-4-nitro-1-(oxan-4-yl)pyrazol-3-yl]oxy}propan-1-ol (170 mg, 0.57 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (215 mg, 1.14 mmol), and PPh3 (298 mg, 1.14 mmol) in THF (12 mL) was added dropwise DIAD (230 mg, 1.14 mmol) under an argon atmosphere at 0° C. The resulting mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. The residue was purified by preparative TLC (eluent: petroleum ether: EtOAc 80:20) to give the desired 3,6-dichloro-1-(3-((5-ethyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine product (230 mg) of sufficient purity for the subsequent step.
[0363] Intermediate: 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole [ka] To a solution of 5-methyl-4-nitro-1H-pyrazole (12 g, 94 mmol) in THF (140 mL) was added TsOH—HO (898 mg, 4.7 mmol), and the reaction was stirred at 20° C. for 30 minutes. The reaction was cooled to 0° C., and 3,4-dihydro-2H-pyran (10.2 g, 121 mmol) was added. The mixture was stirred at 20° C. for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 80:20) to give 3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (12 g) of sufficient purity for the subsequent step.
[0364] To a solution of 3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (12 g, 57 mmol) in THF (100 mL) at −65° C. was added LiHMDS (1 M in THF, 62.5 mL) and stirred at −65° C. for 30 minutes. 1,1,1,2,2,2-Hexachloroethane (14.80 g, 62.5 mmol) dissolved in THF (50 mL) was then added and the mixture was stirred at −65° C. for 60 minutes and then warmed to 20° C. over 10 minutes. The mixture was quenched with saturated aqueous NH4Cl (200 mL) at 0° C. and then warmed to 20° C. After stirring for 20 minutes, the mixture was extracted with EtOAc (3×150 mL). The combined organic layers were washed with brine (80 mL) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 90:10) to give 5-chloro-3-methyl-4-nitro-1-tetrahydropyran-2-yl-pyrazole (7.9 g) of sufficient purity for the next step.
[0365] To a solution of 5-chloro-3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (19 g, 77 mmol) in DMA (150 mL) was added CsF (41.1 g, 271 mmol) and propane-1,3-diol (29.4 g, 387 mmol). The mixture was stirred at 50 °C for 16 h. Water (200 mL) was added to the mixture, which was then extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 69:31) to give 3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (13.7 g) of sufficient purity for the subsequent step.
[0366] To a solution of 3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (4 g, 14 mmol) in MeOH (20 mL) was added aqueous HCl (12 M, 14 mL). The mixture was stirred at 20° C. for 16 h and then heated at 60° C. for 2 h. The mixture was concentrated under reduced pressure, and the pH was adjusted to 10 with 4 M aqueous NaOH. The resulting mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0 to 80:20) to give 3-((5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (2.7 g) of sufficient purity for the subsequent step. 1 H NMR (DMSO-d6,400MHz)δ 12.94(br s,1H),4.55(t,J=4.8Hz,1H),4.28(t,J=6.4Hz,2H),3.60-3.49(m,2H),2.47(s,3H),1.92-1.82(m,2H).
[0367] To a solution of 3-((5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (2.7 g, 13 mmol) in DCM (30 mL) was added imidazole (1.46 g, 21.5 mmol), TBSCl (4.05 g, 26.8 mmol), and DMAP (820 mg, 6.71 mmol). The mixture was stirred at 20° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 79:21) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (3.7 g) of sufficient purity for the subsequent step. 1 H NMR(CD3OD,400MHz)δ 4.40(t,J=6.4Hz,2H),3.84(t,J=6.0Hz,2H),2.61(s,3H),2.03(t,J=6.0Hz,2H),0.89(s,9H),0.05(s,6H).
[0368] m. Intermediate: 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-4-nitro-1H-pyrazole 5 [ka] To a solution of 5-ethyl-4-nitro-1H-pyrazole (12.5 g, 88.6 mmol) in THF (150 mL) was added TsOH·HO (843 mg, 4.43 mmol). The mixture was stirred at 25° C. for 15 minutes, and then 3,4-dihydro-2H-pyran (9.54 g, 113 mmol) was added at 0° C. The mixture was stirred at 25° C. for 16 hours. The mixture was concentrated. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 90:10) to give 3-ethyl-4-nitro-1-tetrahydropyran-2-yl-pyrazole (19 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.33(s,1H),5.34-5.30(m,1H),4.13-4.06(m,1H),3.76-3.66(m,1H),2.98(q,J=7.6H z,2H),2.19-2.09(m,1H),2.02-1.96(m,1H),1.77-1.63(m,4H),1.28(t,J=7.6Hz,3H).
[0369] To a solution of 3-ethyl-4-nitro-1-tetrahydropyran-2-yl-pyrazole (19 g, 84.4 mmol) in THF (80 mL) at −65° C. was added LiHMDS (1 M in THF, 92.8 mL) and stirred at −65° C. for 30 min. Next, 1,1,1,2,2,2-hexachloroethane (22 g, 93 mmol) dissolved in THF (60 mL) was added and the mixture was stirred at −65° C. for 2 h and then warmed to 20° C. over 10 min. The mixture was quenched with saturated aqueous NH4Cl (200 mL) at 0° C., warmed to 20° C. for 20 min, and extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine (3×80 mL) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 95:5) to give 5-chloro-3-ethyl-4-nitro-1-tetrahydropyran-2-yl-pyrazole (17 g) of sufficient purity for the next step. 1 H NMR(CDCl3,400MHz)δ 5.52(dd,J=2.8,10.0Hz,1H),4.13-4.03(m,1H),3.76-3.64(m,1H),2.98(q,J=7.2Hz,2H),2.5 1-2.36(m,1H),2.22-2.10(m,1H),1.95-1.85(m,1H),1.81-1.60(m,3H),1.29(t,J=7.2Hz,3H).
[0370] To a solution of 5-chloro-3-ethyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (12 g, 46 mmol) and propane-1,3-diol (17.58 g, 231.1 mmol) in DMA (150 mL) was added CsF (21.06 g, 138.6 mmol). The mixture was stirred at 50° C. for 16 hours. The mixture was diluted with water (200 mL) and extracted with EtOAc (4×150 mL). The combined organic layers were washed with brine (4×100 mL) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 60:40) to give 3-((3-ethyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (14 g) of sufficient purity for the subsequent step.
[0371] To a solution of 3-((3-ethyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (14 g, 47 mmol) in MeOH (140 mL) was added concentrated aqueous HCl (24 mL, 12 M). The mixture was stirred at 60° C. for 3 h. The mixture was cooled to 0° C., the pH was adjusted to 8 using NaOH, and then the mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 10:90) to give 3-((5-ethyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (8.5 g) of sufficient purity for the subsequent step. 1 H NMR (DMSO-d 6 ,400MHz)δ 12.95(br s,1H),4.54(br,1H),4.29(t,J=6.8Hz,2H),3.54(t,J=6.0Hz,2H),2.89(q,J=7.6Hz,2H),1.92-1.83(m,2H),1.20(t,J=7.6Hz,3H).
[0372] To a solution of 3-((5-ethyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (8.5 g, 40 mmol) in DCM (70 mL) was added DMAP (1.45 g, 11.9 mmol), imidazole (4.30 g, 63.2 mmol), and TBSCl (11.9 g, 79.0 mmol). The mixture was stirred at 25 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 10:90) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-4-nitro-1H-pyrazole 5 (8.5 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.40(t,J=6.4Hz,2H),3.83(t,J=6.0Hz,2H),3.04(q,J=7.6Hz,2H),2.09-1.99(m,2H),1.33(t,J=7.6Hz,3H),0.88(s,9H),0.05(s,6H).
[0373] Intermediate: 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole [ka] To a solution of 4-nitro-1H-pyrazole (10 g, 88 mmol) in THF (100 mL) were added 3,4-dihydro-2H-pyran (22.3 g, 265 mmol) and TsOH·HO (841 mg, 4.4 mmol). The mixture was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 90:10) to give 4-nitro-1-tetrahydropyran-2-yl-pyrazole (17 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.37(s,1H),8.10(s,1H),5.41(dd,J=9.2Hz,2.8Hz,1H),4.10-4.06(m,1H), 3.80-3.70(m,1H),2.16-2.10(m,1H),2.05-1.90(m,2H),1.80-1.60(m,3H).
[0374] To a solution of 4-nitro-1-tetrahydropyran-2-yl-pyrazole (15 g, 76 mmol) in THF (150 mL) was added LiHMDS (1 M in THF, 83.7 mL) dropwise at −78° C. After the addition, the mixture was stirred at this temperature for 0.5 h, and then 1,1,1,2,2,2-hexachloroethane (19.81 g, 83.7 mmol) in THF (50 mL) was added dropwise at −78° C. The resulting mixture was stirred at 20° C. for 1.5 h. The reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) at 0° C. and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 90:10) to give 5-chloro-4-nitro-1-tetrahydropyran-2-yl-pyrazole (11.4 g) of sufficient purity for the next step. 1 H NMR(CDCl3,400MHz)δ 8.21(s,1H),5.57(dd,J=2.8,9.6Hz,1H),4.15-3.98(m,1H),3.77-3.64(m,1H),2.50-2 .35(m,1H),2.24-2.10(m,1H),1.99-1.91(m,1H),1.80-1.60(m,2H),1.60-1.52(m,1H).
[0375] To a solution of 5-chloro-4-nitro-1-tetrahydropyran-2-yl-pyrazole (10 g, 43 mmol) in DMA (150 mL) was added CsF (26.23 g, 172.7 mmol) and propane-1,3-diol (16.42 g, 215.9 mmol). The mixture was stirred at 50 °C for 15 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine (5 × 300 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40) to give 3-((4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (6.7 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.03(s,1H),5.45(dd,J=2.8,9.2Hz,1H),4.68-4.62(m,1H),4.55-4.48(m,1H),4.10-4.03(m,1H),3.92(t,J =6.0Hz,2H),3.74-3.65(m,1H),2.47-2.29(m,1H),2.18-2.13(m,1H),2.13-2.07(m,2H),1.76-1.57(m,4H).
[0376] To a solution of 3-((4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (19.8 g, 73.0 mmol) in MeOH (200 mL) was added concentrated aqueous HCl (12 M, 73 mL). The mixture was stirred at 60° C. for 16 h. The mixture was concentrated under reduced pressure and the pH was adjusted to 10 with 4 M aqueous NaOH. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (10 v% MeOH) 100:0 to 50:50) to give 3-((4-nitro-1H-pyrazol-5-yl)oxy)propan-1-ol (10.5 g) of sufficient purity for the subsequent step. LC-MS (Method K) (m / z) = 187.7 (MH). + t R =0.96 minutes.
[0377] To a solution of 3-((4-nitro-1H-pyrazol-5-yl)oxy)propan-1-ol (10.5 g, 56.1 mmol), imidazole (6.11 g, 89.8 mmol), and DMAP (3.43 g, 28.1 mmol) in DCM (200 mL) was added TBSCl (16.91 g, 112.2 mmol). The mixture was stirred at 20° C. for 12 h. The mixture was concentrated. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (10% MeOH) 100:0 to 50:50) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (13.6 g) of sufficient purity for the subsequent step. 1H NMR (CDCl3,400MHz)δ 8.20(s,1H),4.46(t,J=6.0Hz,2H),3.86(t,J=5.6Hz,2H),2.11-2.07(m,2H),0.91(s,9H),0.11-0.03(m,6H).
[0378] Intermediate: cis-3,6-dichloro-1-(3-((5-methyl-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of cis-2-methyltetrahydro-2H-pyran-4-ol (2 g, 17.2 mmol), 4-nitrobenzoic acid (3.31 g, 19.8 mmol), and PPh3 (6.77 g, 25.8 mmol) in THF (50 mL) was added a solution of DIAD (5.22 g, 25.8 mmol) at 0 °C. The mixture was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 90:10) to give trans-2-methyltetrahydro-2H-pyran-4-yl 4-nitrobenzoic acid (6.5 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.32(d,J=6.8Hz,2H),8.24(d,J=6.8Hz,2H),5.52-5.41(m,1H),3.99-3.84(m,3H) ),2.04-1.91(m,2H),1.90-1.81(m,1H),1.71-1.63(m,1H),1.22(d,J=6.4Hz,3H).
[0379] To a solution of trans-2-methyltetrahydro-2H-pyran-4-yl 4-nitrobenzoate (6.5 g, 24 mmol) in THF (50 mL) and MeOH (50 mL) was added aqueous NaOH (2 M, 37 mL). The mixture was stirred at 20° C. for 2 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 40:60) to give trans-2-methyltetrahydro-2H-pyran-4-ol (1.3 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.25-4.19(m,1H),3.93-3.84(m,2H),3.81-3.74(m,1H),1.89-1.80(m,1H),1.66-1.63(m,1H),1.58-1.50(m,2H),1.15(d,J=6.4Hz,3H).
[0380] A solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (1 g, 3.17 mmol) in toluene (20 mL) was treated with trans-2-methyltetrahydro-2H-pyran-4-ol (553 mg, 4.76 mmol) and 2-(tributyl-λ 5-phosphanylidene)acetonitrile (3.06 g, 12.68 mmol) was added. The mixture was stirred at 110° C. for 15 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 40:60) to give cis-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (1 g) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 414.3 (MH). + t R =1.10 minutes.
[0381] A solution of cis-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (1.0 g, 2.4 mmol) in HCl / 1,4-dioxane (4 M, 10 mL) was stirred at 20° C. for 15 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give cis-3-((5-methyl-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (430 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz,)δ 4.50(t,J=6.0Hz,2H),4.29-4.19(m,1H),4.13-4.05(m,1H),3.85(t,J=5.2Hz,2H),3.61-3.51(m,2H),2.65(s,3H),2 .61-2.49(m,1H),2.30-2.16(m,1H),2.12-2.06(m,2H),2.01-1.89(m,1H),1.84-1.70(m,2H),1.28(d,J=6.0Hz,3H).
[0382] To a solution of cis-3-((5-methyl-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (412 mg, 1.38 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (260 mg, 1.38 mmol), and PPh3 (1.08 g, 4.13 mmol) in THF (20 mL) was added DIAD (835 mg, 4.13 mmol) at 0 °C. The mixture was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40) to give cis-3,6-dichloro-1-(3-((5-methyl-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (500 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.95(s,1H),4.65(t,J=6.4Hz,2H),4.35(t,J=6.0Hz,2H),4.25-4.15(m,1H),4.12-4.07(m,1H),3.61-3.48(m,2H),2.62(s ,3H),2.52-2.42(m,2H),2.20-2.08(m,1H),1.91-1.80(m,1H),1.79-1.73(m,1H),1.72-1.67(m,1H),1.27(d,J=6.0Hz,3H).
[0383] n. Intermediate: 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl-1,1,2,2,3,3-d6)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a stirred mixture of 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (200 mg, 1.05 mmol) and propane-d-1,3-diol (130 mg, 1.58 mmol) in THF (2 mL) was added PPh (555 mg, 2.11 mmol) and DIAD (427 mg, 2.11 mmol) in portions at 0 °C under an argon atmosphere. The resulting mixture was stirred at room temperature for 2 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 50:50) to give 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1,1,2,2,3,3-d-1-ol (124.8 mg) of sufficient purity for the subsequent step. 1 H NMR(DMSO-d6,400MHz)δ 9.30(s,1H),4.53(s,1H).
[0384] To a stirred mixture of 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1,1,2,3,3-d-1-ol (700 mg, 2.76 mmol) and 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (754 mg, 3.31 mmol) in THF (10 mL) was added PPh (1.45 g, 5.53 mmol) and DIAD (1.12 g, 5.53 mmol) under an argon atmosphere at 0 °C. The resulting mixture was stirred at room temperature for 2 h. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 50:50) to give 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl-1,1,2,2,3,3-d6)-1H-pyrazolo[3,4-d]pyrimidine (750 mg) of sufficient purity for the subsequent step.
[0385] Intermediate: 3,6-dichloro-1-(3-((5-methyl-1-(3-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine o. [ka] To a solution of 2-(2-methyl-1,3-dioxolan-2-yl)acetohydrazide (5 g, 31 mmol) in MeOH (50 mL) was added 3-methyltetrahydro-4H-pyran-4-one (3.57 g, 31.3 mmol) at 25° C. The mixture was stirred at 25° C. for 1 hour. NaBH3CN (5.89 g, 93.7 mmol) was added to the mixture, and the mixture was stirred at 25° C. for 1 hour. The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (100 mL), washed with saturated aqueous NH4Cl (2 x 50 mL), HO (50 mL), and brine (50 mL), dried over Na2SO4, filtered, and concentrated to give 2-(2-methyl-1,3-dioxolan-2-yl)-N'-(3-methyltetrahydro-2H-pyran-4-yl)acetohydrazide (8.06 g) in sufficient purity for the next step.
[0386] To a solution of 2-(2-methyl-1,3-dioxolan-2-yl)-N'-(3-methyltetrahydro-2H-pyran-4-yl)acetohydrazide (8.06 g, 31 mmol) in EtOH (100 mL) was added TFA (4.63 mL, 62.6 mmol), and the mixture was stirred at 90°C for 12 h. Additional TFA (4.63 mL) was added at 25°C, and the reaction was stirred at 90°C for an additional 12 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 20:80) to give 5-methyl-1-(3-methyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (3.8 g) of sufficient purity for the subsequent step.
[0387] To a solution of 5-methyl-1-(3-methyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (3.8 g, 19 mmol) in H2SO4 (40 mL) was slowly added KNO3 (5.97 g, 59.1 mmol) at 0 °C. The mixture was stirred at 0 °C for 0.5 h. The mixture was poured into ice water (150 mL) and extracted with EtOAc (4 × 50 mL). The organic phase was washed with saturated aqueous NaHCO3 (100 mL), brine (2 × 100 mL), dried over Na2SO4, and concentrated under reduced pressure to give 5-methyl-1-(3-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-ol (2.9 g) of sufficient purity for the subsequent step.
[0388] 3-(3,6-Dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (1.53 g, 6.19 mmol), 5-methyl-1-(3-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-ol (1.5 g, 6.22 mmol), DIAD (3.76 g, 18.6 mmol), and PPh on resin (6.18 g, 18.58 mmol, 3 mmol / g) in THF (30 mL) were stirred for 16 h at 20° C. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 40:60) to give 3,6-dichloro-1-(3-((5-methyl-1-(3-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (1.7 g) of sufficient purity for the subsequent step.
[0389] p. Intermediate: trans-3,6-dichloro-1-(3-((1-(4-fluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 4-fluorocyclohexanol (500 mg, 4.23 mmol, cis:trans = 3:1) in DCM (7 mL) was added TEA (727 mg, 7.18 mmol) and DMAP (52 mg, 0.43 mmol) at 0 °C, followed by TsCl (888 mg, 4.66 mmol). The mixture was stirred at 20 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 80:20) to give cis-4-fluorocyclohexyl 4-methylbenzenesulfonate (720 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 7.80(d,J=8.4Hz,2H),7.34(d,J=8.0Hz,2H),4.72-4.50(m,2H),2.45(s,3H),2.02-1.87(m,4H),1.74-1.57(m,4H).
[0390] To a solution of cis-(4-fluorocyclohexyl) 4-methylbenzenesulfonate (342 mg, 1.25 mmol) and 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (350 mg, 1.11 mmol) in DMF (6 mL) was added K2CO3 (467 mg, 3.38 mmol). The mixture was stirred at 80 °C for 24 h. The mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (3 × 20 mL) and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 60:40) to give trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(4-fluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazole (220 mg) of sufficient purity for the subsequent step. 1H NMR(400MHz,CDCl3)δ 4.75-4.53(m,1H),4.38(t,J=6.4Hz,2H),4.12-3.97(m,1H),3.81(t,J=6.0Hz,2H),2.62(s,3H),2. 37-2.23(m,2H),2.13-1.98(m,4H),1.97-1.88(m,2H),1.76-1.64(m,2H),0.89(s,9H),0.05(s,6H).
[0391] To a solution of trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(4-fluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazole (220 mg, 0.53 mmol) in DCM (1 mL) was added HCl / dioxane (4 M, 5 mL). The mixture was stirred at 20° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0 to 60:40) to give trans-3-((1-(4-fluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (110 mg) of sufficient purity for the subsequent step. 1 H NMR(400MHz,CDCl3)δ 4.76-4.54(m,1H),4.48(t,J=5.6Hz,2H),4.11-3.99(m,1H),3.84(t,J=5.2H z,2H),2.63(s,3H),2.35-2.25(m,2H),2.10-1.90(m,6H),1.71-1.63(m,2H).
[0392] A mixture of trans-3-[1-(4-fluorocyclohexyl)-5-methyl-4-nitro-pyrazol-3-yl]oxypropan-1-ol (100 mg, 0.4 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (63 mg, 0.4 mmol), PPh3 (261 mg, 1.0 mol), and DIAD (201 mg, 1.0 mmol) in THF (1 mL) was stirred for 16 h at 20 °C. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 60:40) to give trans-3,6-dichloro-1-(3-((1-(4-fluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (170 mg) of sufficient purity for the subsequent step.
[0393] q. Intermediate: 3,6-dichloro-1-(3-((1-(4,4-difluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (0.3 g, 0.95 mmol) and 4-bromo-1,1-difluoro-cyclohexane (1.33 g, 6.66 mmol) in DMF (6 mL) was added CsCO (620 mg, 1.90 mmol) at 20 °C. The reaction mixture was stirred at 80 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(4,4-difluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazole (0.32 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 4.41(t,J=6.4Hz,2H),4.19-4.12(m,1H),3.83(t,J=6.0Hz,2H),2.65(s,3H),2. 41-2.24(m,4H),2.08-2.03(m,2H),2.01-1.86(m,4H),0.90(s,9H),0.06(s,6H).
[0394] To a mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(4,4-difluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazole (0.31 g, 0.72 mmol) in THF (5 mL) was added HCl / dioxane (4 M, 5 mL), and the mixture was then stirred at 25° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give 3-((1-(4,4-difluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (0.21 g) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 320.2 (MH). + t R =0.81 minutes.
[0395] To a mixture of 3-((1-(4,4-difluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (0.2 g, 0.63 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (118 mg, 0.63 mmol), and PPh3 (329 mg, 1.25 mmol) in THF (20 mL) was added DIAD (253 mg, 1.25 mmol) at 0 °C. The mixture was stirred at 25 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give 3,6-dichloro-1-(3-((1-(4,4-difluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (0.28 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.97(s,1H),4.66(t,J=6.8Hz,2H),4.36(t,J=5.6Hz,2H),4.13-4.04(m,1 H),2.63(s,3H),2.53-2.43(m,2H),2.36-2.17(m,4H),2.00-1.83(m,4H).
[0396] Intermediate: 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(oxepan-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of hex-5-en-1-ol (9.0 g, 89 mmol) in DCM (150 mL) was added m-CPBA (29.08 g, 135 mmol, 80% purity) at 0 °C. The reaction mixture was stirred at 20 °C for 16 h. The reaction was cooled to 0 °C and quenched with aqueous NaOH (1 M, 140 ml). The reaction mixture was diluted with water (100 mL) and extracted with DCM (3 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 60:40 to 50:50) to give 4-(oxiran-2-yl)butan-1-ol (8 g) of sufficient purity for the subsequent step.
[0397] To a solution of 4-(oxiran-2-yl)butan-1-ol (7.5 g, 65 mmol) in THF (100 mL) was added t-BuOK (8.69 g, 77.5 mmol). The reaction mixture was stirred at 50 °C for 16 h. Water (50 mL) was added to the mixture, and it was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3 × 50 mL), dried over Na SO , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 30:70 → 20:80) to give a mixture of oxepan-3-ol and (tetrahydro-2H-pyran-2-yl)methanol (4 g). The mixture of tetrahydropyran-2-ylmethanol and oxepan-3-ol was dissolved in DCM (40 mL). At 0°C, TEA (5.23 g, 51.65 mmol) and N,N-dimethylmethanamine hydrochloride (329 mg, 3.44 mmol) were added, followed by TsCl (7.88 g, 41.3 mmol). The mixture was stirred at 20°C for 16 h. The solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 to 70:30) to give a mixture of oxepan-3-yl 4-methylbenzenesulfonate and (tetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (5 g). To a solution of 3-chloro-5-methyl-4-nitro-1H-pyrazole (2 g, 12.38 mmol) in DMF (10 mL) was added a mixture of oxepan-3-yl 4-methylbenzenesulfonate and (tetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (4 g). K2CO3 (5.13 g, 37.1 mmol) was added, and the reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (3 × 10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 85:15) to give 3-chloro-5-methyl-4-nitro-1-(oxepan-3-yl)pyrazole (700 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 4.42-4.32(m,1H),4.02-3.94(m,1H),3.92-3.77(m,3H),2.67(s,3H),2.13-2.04(m,2H),1.99-1.86(m,3H),1.72-1.63(m,1H).
[0398] To a solution of 3-chloro-5-methyl-4-nitro-1-(oxepan-3-yl)pyrazole (200 mg, 0.77 mmol) in HO (10 mL) was added KOH (1.1 g, 20 mmol). The reaction mixture was stirred at 155 °C for 16 h using a microwave reactor. The mixture was washed with EtOAc (10 mL). The aqueous phase was adjusted to pH = 2-3, extracted with EtOAc (3 × 10 mL), dried over NaSO, and concentrated under reduced pressure to give 5-methyl-4-nitro-1-(oxepan-3-yl)pyrazol-3-ol (150 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.37-4.24(m,1H),4.02-3.94(m,1H),3.91-3.84(m,1H),3.84-3.78(m,2 H),2.63(s,3H),2.15-2.01(m,2H),1.99-1.84(m,3H),1.72-1.62(m,1H).
[0399] To a solution of 5-methyl-4-nitro-1-(oxepan-3-yl)pyrazol-3-ol (150 mg, 0.62 mmol) in THF (10 mL) was added 3-(3,6-dichloropyrazole[3,4-d]pyrimidin-1-yl)propan-1-ol (169 mg, 0.68 mmol), DIAD (754 mg, 3.73 mmol), and PPh3 on resin (975 mg, 3.73 mmol) at 0° C. The reaction mixture was stirred at 25° C. for 16 h. The solvent was removed. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 70:30 → 60:40) to give 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(oxepan-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (250 mg) of sufficient purity for the subsequent step.1 H NMR(CDCl3,400MHz)δ 8.95(s,1H),4.65(t,J=6.4Hz,2H),4.34(t,J=6.0Hz,2H),4.31-4.23(m,1H),3.86(d,J=7.2Hz,2H),3.8 2-3.78(m,2H),2.60(s,3H),2.50-2.44(m,2H),2.02-1.96(m,2H),1.92-1.79(m,3H),1.69-1.62(m,1H).
[0400] Intermediate: 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(oxepan-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 3-chloro-5-methyl-4-nitro-1H-pyrazole (2 g, 12 mmol) and 4-bromooxepane (2.44 g, 13.6 mmol) in MeCN (50 mL) was added K2CO3 (5.13 g, 37.1 mmol). The mixture was stirred at 80 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 80:20) to give 3-chloro-5-methyl-4-nitro-1-(oxepan-4-yl)-1H-pyrazole (1.2 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.49-4.39(m,1H),3.98-3.91(m,1H),3.90-3.77(m,2H),3.69-3.61(m,1H),2.68(s,3H),2.45-2.35( m,1H),2.35-2.24(m,1H),2.19-2.08(m,1H),2.04-1.96(m,1H),1.96-1.88(m,1H),1.87-1.73(m,1H).
[0401] To a solution of 3-chloro-5-methyl-4-nitro-1-(oxepan-4-yl)-1H-pyrazole (200 mg, 770 μmol) in HO (10 mL) was added KOH (1.12 g, 20.02 mmol). The mixture was stirred at 155 °C for 3 h using a microwave reactor. The mixture was washed with EtOAc (50 mL × 3). The aqueous phase was adjusted to pH = 3 with HCl (12 M) and extracted with EtOAc (100 mL × 3). The combined organic layers were dried over NaSO and concentrated under reduced pressure to give 5-methyl-4-nitro-1-(oxepan-4-yl)-1H-pyrazol-3-ol (200 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 11.31(br s,1H),4.57-4.35(m,1H),3.80-3.69(m,2H),3.66-3.54(m,2H),2.57(s,3H) ,2.14-2.06(m,1H),2.06-1.93(m,2H),1.92-1.84(m,1H),1.83-1.73(m,2H).
[0402] To a solution of 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (280 mg, 1.13 mmol), 5-methyl-4-nitro-1-(oxepan-4-yl)-1H-pyrazol-3-ol (273 mg, 1.13 mmol), and PPh3 on resin (2.26 g, 6.80 mmol, 3 mmol / g) in THF (20 mL) was added DIAD (1.37 g, 6.80 mmol) at 0 °C. The mixture was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(oxepan-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (330 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.99(s,1H),4.65(t,J=6.4Hz,2H),4.35(t,J=6.0Hz,2H),4.32-4.23(m,1H),3.96-3.81(m,2H),3.79-3.71(m,1H),3.69-3.59(m,1) H),2.61(s,3H),2.53-2.42(m,2H),2.34-2.24(m,1H),2.24-2.14(m,1H),2.04-1.98(m,1H),1.95-1.86(m,2H),1.83-1.73(m,1H).
[0403] Intermediate: trans-3,6-dichloro-1-(3-((1-(3-fluorotetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (1.6 g, 5.1 mmol) in toluene (20 mL) was added cis-3-fluorotetrahydropyran-4-ol (914 mg, 7.61 mmol) and 2-(tributyl-λ 5 To the resulting mixture was added trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(3-fluorotetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazole (1.6 g), which was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 80:20) to give trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(3-fluorotetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazole (1.6 g), which was sufficiently pure for the next step. 1H NMR(CDCl3,400MHz)δ 5.00-4.75(m,1H),4.41(t,J=6.4Hz,2H),4.31-4.18(m,2H),4.11-4.04(m,1H),3.82(t,J=6.0Hz,2H),3.56-3.46(m,1 H),3.43-3.34(m,1H),2.66(s,3H),2.57-2.45(m,1H),2.05-1.99(m,2H),1.98-1.89(m,1H),0.89(s,9H),0.05(s,6H).
[0404] A solution of trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(3-fluorotetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazole (1.6 g, 3.8 mmol) in HCl / dioxane (4 M, 10 mL) was stirred at 20° C. for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 40:60) to give trans-3-((1-(3-fluorotetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (850 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 304.2 (MH). + t R =0.73 minutes.
[0405] To a solution of trans-3-((1-(3-fluorotetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (400 mg, 1.32 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (249 mg, 1.32 mmol), and PPh3 (1.04 g, 3.96 mmol) in THF (20 mL) was added DIAD (800 mg, 3.96 mmol) at 0 °C. The mixture was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give trans-3,6-dichloro-1-(3-((1-(3-fluorotetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (450 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 474.2 (MH). + t R =0.92 minutes.
[0406] Intermediate: 3-(8-chloro-3-methyl-4,11,12,13-tetrahydro-2H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1,4,6,8]oxatriazacycloundecin-2-yl)bicyclo[1.1.1]pentane-1-carboxamide [ka] O3-[(3-methoxycarbonylbicyclo[1.1.1]pentane-1-carbonyl)oxy-(2,4,6-trimethylphenyl)-λ in 1,4-dioxane (15 mL) 3A mixture of [-iodanyl]O1-methylbicyclo[1.1.1]pentane-1,3-dicarboxlate (600 mg, 1.03 mmol), 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (300 mg, 0.951 mmol), pentane-2,4-dione (114 mg, 1.14 mmol), thiophene-2-carbonyloxycopper (218 mg, 1.14 mmol), 4,7-diphenyl-1,10-phenanthroline (632 mg, 1.90 mmol), and DBU (145 mg, 0.951 mmol) was degassed and purged with N2 three times, and the mixture was stirred in the dark at 20 °C for 60 h. The reaction mixture was diluted with aqueous NH4Cl (50 mL) and extracted with DCM (3 × 100 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluent: petroleum ether: EtOAc 100:0 to 80:20) to give 3-(3-(3-(tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)bicyclo[1.1.1]pentane-1-carboxylate (300 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.39(t,J=6.4Hz,2H),3.80(t,J=6.4Hz,2H),3.75(s,3H),2.67(s,3H),2.63(s,6H),2.04-1.98(m,2H),0.89(s,9H),0.05(s,6H).
[0407] A solution of methyl 3-(3-(3-(tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)bicyclo[1.1.1]pentane-1-carboxylate (570 mg, 1.30 mmol) in HCl / MeOH (4 M, 10 mL) was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40) to give methyl-3-(3-(3-hydroxypropoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)bicyclo[1.1.1]pentane-1-carboxylate (250 mg) of sufficient purity for the subsequent step. 1 H NMR (DMSO-d 6 ,400MHz)δ 4.53(s,1H),4.28(t,J=6.4Hz,2H),3.66(s,3H),3.53(t,J=6.0Hz,2H),2.63(s,3H),2.61(s,6H),1.94-1.81(m,2H).
[0408] To a solution of methyl-3-(3-(3-hydroxypropoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)bicyclo[1.1.1]pentane-1-carboxylate (240 mg, 0.738 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (139 mg, 0.738 mmol), and PPh3 on resin (736 mg, 2.21 mmol, 3 mmol / g) in THF (10 mL) was added DIAD (448 mg, 2.21 mmol) at 0 °C. The mixture was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 40:60) to give methyl 3-(3-(3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)bicyclo[1.1.1]pentane-1-carboxylate (270 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.96(s,1H),4.65(t,J=6.4Hz,2H),4.33(t,J=6.0Hz,2H),3.75(s,3H),2.66(s,3H),2.60(s,6H),2.51-2.41(m,2H).
[0409] To a solution of methyl 3-(3-(3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)bicyclo[1.1.1]pentane-1-carboxylate (260 mg, 0.524 mmol) in EtOH (40 mL) and HO (8 mL) was added Fe (146 mg, 2.61 mmol) and NH4Cl (140 mg, 2.62 mmol). The mixture was stirred at 80 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give methyl 3-(8-chloro-3-methyl-4,11,12,13-tetrahydro-2H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1,4,6,8]oxatriazacycloundecin-2-yl)bicyclo[1.1.1]pentane-1-carboxylate (100 mg) in sufficient purity for use in the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.65(s,1H),6.82(br s,1H),4.54-4.46(m,2H),4.46-4.38(m,2H),3.74(s,3H),2.61(s,6H),2.33(s,3H),2.01-1.85(m,2H).
[0410] In a sealed flask, NH3 / MeOH (7 M, 15 mL) was added to methyl 3-(8-chloro-3-methyl-4,11,12,13-tetrahydro-2H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1,4,6,8]oxatriazacycloundecin-2-yl)bicyclo[1.1.1]pentane-1-carboxylate (90 mg, 0.209 mmol). The reaction mixture was stirred at 80 °C for 15 h. The reaction mixture was concentrated under reduced pressure to give 3-(8-chloro-3-methyl-4,11,12,13-tetrahydro-2H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1,4,6,8]oxatriazacycloundecin-2-yl)bicyclo[1.1.1]pentane-1-carboxamide (80 mg) of sufficient purity for the subsequent step.
[0411] Intermediate: 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(2-oxaspiro[3.3]heptan-6-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (350 mg, 1.11 mmol), 2-oxaspiro[3.3]heptan-6-ol (152 mg, 1.33 mmol), PPh3 on resin (553 mg, 1.66 mmol, 3 mmol / g), and DIAD (337 mg, 1.66 mmol) in THF (5 mL) was stirred at 20 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 70:30) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(2-oxaspiro[3.3]heptan-6-yl)-1H-pyrazole (295 mg) of sufficient purity for the subsequent step. H NMR(CDCl3,400MHz)δ 4.77(d,J=4.8Hz,4H),4.56-4.49(m,1H),4.41(t,J=6.0Hz,2H),3.82(t,J=6.0Hz,2H),2.87 -2.79(m,2H),2.77-2.69(m,2H),2.56(s,3H),2.07-2.02(m,2H),0.89(s,9H),0.05(s,6H).
[0412] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(2-oxaspiro[3.3]heptan-6-yl)-1H-pyrazole (260 mg, 0.63 mmol) in THF (5 mL) was added TBAF (1 M, 1 mL). The mixture was stirred at 20° C. for 2 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (15 mL×3). The combined organic layers were concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 100:0→0:100) to give 3-((5-methyl-4-nitro-1-(2-oxaspiro[3.3]heptan-6-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (179 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 4.77(d,J=9.2Hz,4H),4.56-4.47(m,3H),3.86(t,J=5.6Hz,2H),2.86-2.78(m,2H),2.77-2.70(m,2H),2.57(s,3H),2.14-2.06(m,2H).
[0413] A mixture of 3-((5-methyl-4-nitro-1-(2-oxaspiro[3.3]heptan-6-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (160 mg, 0.54 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (101.71 mg, 0.54 mmol), PPh3 on resin (3 mmol / g), and DIAD (185 mg, 0.92 mmol) in THF (5 mL) was stirred at 20 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 20:80) to give 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(2-oxaspiro[3.3]heptan-6-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (170 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.96(s,1H),4.77(s,2H),4.72(s,2H),4.66(t,J=6.4Hz,2H),4.52-4.45(m,1 H),4.37(t,J=5.6Hz,2H),2.78-2.69(m,4H),2.55(s,3H),2.50-2.44(m,2H).
[0414] Intermediate: 3,6-dichloro-1-(3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl-1,1,2,2,3,3-d6)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a stirred mixture of 4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (100 mg, 0.469 mmol) and K2CO3 (259 mg, 1.87 mmol) in DMF (3 mL) was added bromo(methoxy)methane (117 mg, 0.938 mmol) in small portions at 0 °C. The resulting mixture was stirred at room temperature for 16 h. The reaction was quenched by the addition of water (100 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 50:50) to give 3-(methoxymethoxy)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (40 mg) of sufficient purity for the next step.
[0415] To a stirred solution of 3-(methoxymethoxy)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (200 mg, 0.777 mmol) in THF (2 mL) was added dropwise LiHMDS (1.55 mL, 1.55 mmol, 1 M in THF) at −78° C. The resulting mixture was stirred at −78° C. for 2 h. DO (4 mL) was added at −78° C. The resulting mixture was diluted with water (100 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 50:50) to give 3-(methoxymethoxy)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-5-d (180 mg) of sufficient purity for the subsequent step.
[0416] To a stirred solution of 3-(methoxymethoxy)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-5-d (50 mg) in THF (1.5 mL) was added dropwise LiHMDS (0.39 mL, 0.39 mmol, 1 M in THF) at −78° C. The resulting mixture was stirred at −78° C. for 1 h. CD3I (113 mg, 0.776 mmol) was added dropwise at −78° C. The resulting mixture was stirred at −78° C. for 2 h, followed by the dropwise addition of DO (2 mL) at −78° C. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 67:33) to give 3-(methoxymethoxy)-5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (40 mg) of sufficient purity for the next step.
[0417] A solution of 3-(methoxymethoxy)-5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (150 mg, 0.547 mmol) and HCl in 1,4-dioxane (4 mL, 16 mmol, 4 M) in DCM (2 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated under reduced pressure to give 5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (101 mg) of sufficient purity for the subsequent step. 1 H NMR(DMSO-d6,400MHz)δ 11.35(s,1H),4.47(tt,J=11.2,4.0Hz,1H),3.96-3.92(m,2H),3.46(t,J=12.0Hz,2H),1.97-1.93(m,2H),1.77-1.74(m,2H).
[0418] To a stirred solution of 5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (95.5 mg, 0.416 mmol) in THF (5 mL), 3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1,1,2,2,3,3-d6-1-ol (70 mg, 0.277 mmol) and PPh3 (145 mg, 0.554 mmol) were added portionwise at room temperature under an argon atmosphere. To the above mixture was added dropwise DIAD (0.11 mL, 0.554 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 50:50) to give 3,6-dichloro-1-(3-((5-(methyl-d3)-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl-1,1,2,2,3,3-d6)-1H-pyrazolo[3,4-d]pyrimidine (110 mg) of sufficient purity for the subsequent step.
[0419] Intermediate: 1-(8-chloro-3-methyl-4,11,12,13-tetrahydro-2H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1,4,6,8]oxatriazacycloundecin-2-yl)cyclopropanecarboxamide [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (600 mg, 1.90 mmol) in DMF (24 mL) was added CsCO (2.48 g, 7.62 mmol) and methyl 2,4-dibromobutanoate (552 mg, 2.12 mmol). The mixture was stirred at 45 °C for 16 h. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine (3 × 15 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 90:10) to give 1-(3-(3-(tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)cyclopropanecarboxylate (440 mg) of sufficient purity for the subsequent step. 1 H NMR(DMSO-d6,400MHz)δ 4.28(t,J=6.0Hz,2H),3.73(t,J=6.0Hz,2H),3.65(s,3H),2.54(s,3H),1.95- 1.85(m,2H),1.86-1.78(m,2H),1.77-1.70(m,2H),0.84(s,9H),0.01(s,6H).
[0420] To methyl 1-(3-(3-(tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)cyclopropanecarboxylate (440 mg, 1.06 mmol) was added HCl / dioxane (4 M, 5 mL), and the mixture was stirred at 20° C. for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: DCM:MeOH 100:0 to 97:3), suspended in water (10 mL), extracted with EtOAc (3×40 mL), and the combined organic layers were dried over NaSO and concentrated under reduced pressure to give methyl 1-(3-(3-hydroxypropoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)cyclopropanecarboxylate (320 mg) of sufficient purity for the subsequent step.
[0421] To a solution of methyl 1-(3-(3-hydroxypropoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)cyclopropanecarboxylate (300 mg, 1.00 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (202 mg, 1.07 mmol), and DIAD (608 mg, 3.01 mmol) in THF (5 mL) was added PPh3 (789 mg, 3.01 mmol) at 0 °C. The mixture was stirred at 20 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 70:30) to give methyl 1-(3-(3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)cyclopropanecarboxylate (230 mg) of sufficient purity for the subsequent step. 1 H NMR(DMSO-d6,400MHz)δ 9.27(s,1H),4.55(t,J=6.4Hz,2H),4.26(t,J=5.6Hz,2H),3.65(s,3H),2.54(s,3H),2.35-2.25(m,2H),1.85-1.77(m,2H),1.70-1.65(m,2H).
[0422] A mixture of methyl 1-(3-(3-(3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propoxy)-5-methyl-4-nitro-1H-pyrazol-1-yl)cyclopropanecarboxylate (190 mg, 0.340 mmol), Fe (95 mg, 1.70 mmol), and NHCl (91 mg, 1.7 mmol) in EtOH (4 mL) and HO (1 mL) was degassed and purged with N three times, after which the mixture was stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 50:50) to give methyl 1-(8-chloro-3-methyl-4,11,12,13-tetrahydro-2H-5,7-(azenometheno)dipyrazolo[3,4-b.5',1'-g][1,4,6,8]oxatriazacycloundecin-2-yl)cyclopropanecarboxylate (63 mg) in sufficient purity for the next step. LC-MS (Method B) (m / z) = 404.2 (MH). + t R =0.79 minutes.
[0423] A mixture of NH3 / MeOH (7 M, 8 mL) and methyl 1-(8-chloro-3-methyl-4,11,12,13-tetrahydro-2H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1,4,6,8]oxatriazacycloundecin-2-yl)cyclopropanecarboxylate (60 mg, 0.15 mmol) in a sealed tube was heated at 80 °C for 2 h using a microwave reactor. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 80:20) to give 1-(8-chloro-3-methyl-4,11,12,13-tetrahydro-2H-5,7-(azenometheno)dipyrazolo[3,4-b.5',1'-g][1,4,6,8]oxatriazacycloundecin-2-yl)cyclopropanecarboxamide (40 mg) in sufficient purity for the next step. LC-MS (Method B) (m / z) = 389.2 (MH). + t R =0.70 minutes.
[0424] Intermediate: 3,6-dichloro-1-(3-((1-((1r,4r)-4-methoxycyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of (1s,4s)-cyclohexane-1,4-diol (2 g, 17 mmol) in water (10 mL) was added KOH (1.06 g, 18.94 mmol) and MeI (3.67 g, 25.8 mmol). The mixture was stirred at 100 °C for 5 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 95:5 to 50:50) to give (1s,4s)-4-methoxycyclohexanol (500 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 3.79-3.69(m,1H),3.38-3.21(m,4H),1.89-1.75(m,2H),1.70-1.62(m,4H),1.58-1.50(m,2H).
[0425] To a solution of (1s,4s)-4-methoxycyclohexanol (400 mg, 3.07 mmol) in DCM (6 mL) was added EtN (684 mg, 6.76 mmol), DMAP (38 mg, 0.31 mmol), and TsCl (820 mg, 4.30 mmol) sequentially at 0 °C. The mixture was warmed to 15 °C and stirred for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give (1s,4s)-4-methoxycyclohexyl 4-methylbenzenesulfonate (350 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 7.80(d,J=8.4Hz,2H),7.33(d,J=8.0Hz,2H),4.65-4.56(m,1H),3.30(s,3H),3.26- 3.18(m,1H),2.45(s,3H),1.94-1.82(m,2H),1.80-1.70(m,2H),1.63-1.56(m,4H).
[0426] A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (400 mg, 1.27 mmol), (1s,4s)-4-methoxycyclohexyl 4-methylbenzenesulfonate (400 mg, 1.41 mmol), and CsCO (826 mg, 2.54 mmol) in DMF (10 mL) was degassed and purged with N × 3, then stirred at 80 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 95:5 to 70:30) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-((1r,4r)-4-fluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazole (240 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.39(t,J=6.0Hz,2H),4.03-3.94(m,1H),3.81(t,J=6.0Hz,2H),3.39(s,3H),3.30-3.20(m,1H),2.62(s,3H),2.28- 2.19(m,2H),2.06-2.04(m,2H),2.02-1.97(m,2H),1.95-1.84(m,2H),1.42-1.30(m,2H),0.89(s,9H),0.05(s,6H).
[0427] A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-((1r,4r)-4-fluorocyclohexyl)-5-methyl-4-nitro-1H-pyrazole (240 mg, 0.56 mmol) in HCl / dioxane (4 M, 5 mL) was degassed and purged with N2 × 3, then the mixture was stirred at 15 °C for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 95:5 → 0:100) to give 3-((1-((1r,4r)-4-methoxycyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (130 mg) of sufficient purity for the subsequent step. 1 H NMR(400MHz,CDCl3)δ 4.50(t,J=6.4Hz,2H),4.06-3.95(m,1H),3.82(t,J=5.6Hz,2H),3.38(s,3H),3.30-3.18(m,1H),2.63( s,3H),2.31-2.17(m,2H),2.10-2.05(m,2H),2.04-1.95(m,2H),1.94-1.82(m,2H),1.43-1.30(m,2H).
[0428] To a solution of 3-((1-((1r,4r)-4-methoxycyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (130 mg, 0.41 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (78 mg, 0.41 mmol), and PPh3 (218 mg, 0.83 mmol) in THF (10 mL) was added dropwise DIAD (168 mg, 0.83 mmol) at 0 °C. The mixture was stirred at 15 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 → 50:50) to give 3,6-dichloro-1-(3-((1-((1r,4r)-4-methoxycyclohexyl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (160 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 484.2 (MH). +t R =0.95 minutes.
[0429] Intermediate: 1-(3-((1-(3-oxabicyclo[3.1.0]hexan-6-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine [ka] To 2-(3-oxabicyclo[3.1.0]hexan-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (950 mg, 4.52 mmol) in THF (20 mL) and HO (5 mL) was added sodium periodate (2.91 g, 13.6 mmol) and stirred at 20 °C for 30 min. Next, aqueous HCl (1 M, 5 mL) was added and stirred at 20 °C for 12 h. The reaction was filtered, and the filter cake was washed with THF (20 mL × 2). The filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc (30 mL), washed with brine (10 mL), dried over NaSO, and concentrated under reduced pressure to give 3-oxabicyclo[3.1.0]hexan-6-ylboronic acid (579 mg) of sufficient purity for the subsequent step.
[0430] A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (700 mg, 2.22 mmol), 3-oxabicyclo[3.1.0]hexan-6-ylboronic acid (579 mg, 4.53 mmol), Cu(OAc) (613 mg, 3.37 mmol), and 4Å MS (700 mg) in DCE (50 mL) was stirred under oxygen (15 psi) at 65° C. for 36 h. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give 1-(3-oxabicyclo[3.1.0]hexan-6-yl)-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (730 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 398.2 (MH). + t R =0.96 minutes.
[0431] To a solution of 1-(3-oxabicyclo[3.1.0]hexan-6-yl)-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (700 mg, 1.76 mmol) in THF (5 mL) was added TBAF (1 M in THF, 2.64 mL) at 0° C., and the reaction was stirred at 20° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 0:100) to give 3-((1-(3-oxabicyclo[3.1.0]hexan-6-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (310 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.46(t,J=5.6Hz,2H),4.18-4.11(m,2H),3.87-3.79(m,4H),3.18(t,J=2.0H z,1H),2.66(s,3H),2.64-2.59(m,1H),2.39-2.35(m,2H),2.09-2.05(m,2H).
[0432] To a mixture of 3-((1-(3-oxabicyclo[3.1.0]hexan-6-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (300 mg, 1.06 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (210 mg, 1.11 mmol), and PPh3 (555 mg, 2.12 mmol) in THF (10 mL) was added DIAD (428 mg, 2.12 mmol) at 0 °C, and the reaction was stirred at 20 °C for 12 h. The reaction was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give 1-(3-((1-(3-oxabicyclo[3.1.0]hexan-6-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (250 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 454.1 (MH). + t R =0.78 minutes.
[0433] Intermediate: 8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]-triazacycloundecine [ka] 3-((3-Methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propan-1-ol (2 g, 7.0 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.32 g, 7.01 mmol), PPh3 (2.76 g, 10.52 mmol), and DIAD (2.13 g, 10.52 mmol) in THF (20 mL) were stirred at 15 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30). The crude product was dissolved in a mixture of 40 mL of EtOAc and 20 mL of petroleum ether at 50 °C for 20 min. The mixture was cooled to 20° C., filtered, and the filter cake was dried to give 3,6-dichloro-1-(3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (2.3 g) of sufficient purity for further steps. 1 H NMR(CDCl3,400MHz)δ 9.01(s,1H),5.43(dd,J=2.8,10.4Hz,1H),4.70(t,J=6.8Hz,2H),4.59-4.46(m,1H),4.44-4.34(m,1H),4.08-4.00(m,1H),3.74-3 .60(m,1H),2.57-2.47(m,5H),2.43-2.31(m,1H),2.17-2.06(m,1H),1.93-1.79(m,1H),1.78-1.67(m,2H),1.27(d,J=6.4Hz,1H).
[0434] To a solution of 3,6-dichloro-1-(3-((3-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (2.3 g, 5.0 mmol) in EtOH (300 mL) was added Fe (1.41 g, 25.2 mmol), followed by a solution of NH4Cl (1.35 g, 25.2 mmol) in HO (20 mL). The mixture was stirred at 80 °C for 32 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0:→ 0:100 followed by DCM: MeOH 100:0→ 90:10) to give 8-chloro-3-methyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]-triazacycloundecine (500 mg) of sufficient purity for the next step. 1 H NMR(DMSO-d6,400MHz)δ 11.68(br s,1H),9.33(s,1H),8.77(s,1H),4.44-4.24(m,4H),2.18(s,3H),1.82-1.72(m,2H).LC-MS(Method C)(m / z)=306.1(MH) + t R =1.19 minutes.
[0435] Intermediate: 3,6-dichloro-1-(3-((1-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-ol (5 g, 38 mmol) in DCM (150 mL) was added PPh (30.2 g, 115 mmol) and CBr (19.11 g, 57.61 mmol). The mixture was stirred at 20 °C for 16 h. The reaction mixture was poured into MTBE (100 mL) and filtered. The filter cake was washed with MTBE (50 mL), and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 91:9) to give (2R,4S,6S)-4-bromo-2,6-dimethyltetrahydro-2H-pyran (2.6 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.73-4.68(m,1H),4.05-4.01(m,2H),1.99-1.94(m,2H),1.72-1.67(m,2H),1.22(d,J=6.0Hz,6H).
[0436] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (500 mg, 1.59 mmol) in DMF (15 mL) was added (2R,4s,6S)-4-bromo-2,6-dimethyltetrahydro-2H-pyran (461 mg, 2.38 mmol) and K2CO3 (659 mg, 4.77 mmol). The mixture was stirred at 80 °C for 16 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with brine (3 × 40 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 40:60) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazole (410 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 4.40(t,J=6.4Hz,2H),4.29-4.18(m,1H),3.81(t,J=6.0Hz,2H),3.63-3.58(m,2H),2.62(s,3H),2.05 -1.99(m,2H),1.95-1.83(m,2H),1.79-1.71(m,2H),1.28(d,J=6.4Hz,6H),0.89(s,9H),0.05(s,6H).
[0437] 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazole (400 mg, 0.935 mmol) was dissolved in HCl / dioxane (4 M, 3 mL) and stirred at 20° C. for 2 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 55:45) to give 3-((1-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (223 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.51(t,J=6.0Hz,2H),4.32-4.22(m,1H),3.86(t,J=5.6Hz,2H),3.70-3.55(m, 2H),2.65(s,3H),2.14-2.06(m,2H),1.95-1.73(m,4H),1.30(d,J=6.0Hz,6H).
[0438] To a solution of 3-((1-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (208 mg, 0.664 mmol) and 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (125 mg, 0.664 mmol) in THF (6 mL) was added PPh3 (522 mg, 1.99 mmol). The mixture was cooled to 0 °C, and DIAD (403 mg, 1.99 mmol) was added. The resulting mixture was stirred at 20 °C for 12 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 75:25) to give 3,6-dichloro-1-(3-((1-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (170 mg).
[0439] Intermediate: 3,6-dichloro-1-(3-((1-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 2,2-dimethyltetrahydropyran-4-ol (250 mg, 1.92 mmol) in toluene (20 mL) was added 2-(tributyl-λ 5To the reaction mixture were added 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (550 mg, 1.74 mmol). The mixture was stirred at 110° C. for 15 hours. The solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 70:30) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazole (230 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z)=428.2 (MH). + t R =1.11 minutes.
[0440] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazole (450 mg, 1.05 mmol) in THF (8 mL) was added TBAF (1 M, 1.58 mL) at 25° C. The resulting solution was stirred at 25° C. for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 to 30:70) to give 3-((1-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (285 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.51(t,J=6.0Hz,2H),4.45-4.33(m,1H),3.99-3.75(m,4H),2.66(s,3H),2.61-2 .52(m,1H),2.31-2.16(m,1H),2.12-2.07(m,3H),1.81-1.67(m,2H),1.33(s,6H).
[0441] To a solution of 3-((1-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (275 mg, 0.878 mmol) and 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (166 mg, 0.878 mmol) in THF (15 mL) was added PPh3 (691 mg, 2.63 mmol) at 5 °C, followed by DIAD (532 mg, 2.63 mmol). The resulting mixture was stirred at 25 °C for 12 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 40:60) to give 3,6-dichloro-1-(3-((1-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (210 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.96(s,1H),4.66(t,J=6.4Hz,2H),4.42-4.34(m,3H),3.97-3.87(m,1H),3.83-3.71(m,1H),2.64(s ,3H),2.53-2.45(m,2H),2.20-2.09(m,1H),2.03-1.93(m,1H),1.77-1.63(m,2H),1.35-1.30(m,6H).
[0442] Intermediate: 1-(3-((1-(8-oxabicyclo[3.2.1]octan-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine [ka] 8-oxabicyclo[3.2.1]octan-3-ol (609 mg, 4.76 mmol), tert-butyl-dimethyl-[3-[(5-methyl-4-nitro-1H-pyrazol-3-yl)oxy]propoxy]silane (1.0 g, 3.17 mmol), and 2-(tributyl-λ)- 5 -phosphanylidene)acetonitrile (3.06 g, 12.7 mmol) was stirred at 110° C. for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 75:25) to give 1-(8-oxabicyclo[3.2.1]octan-3-yl)-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (1.7 g) of sufficient purity for the subsequent step.
[0443] To 1-(8-oxabicyclo[3.2.1]octan-3-yl)-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (1.5 g, 2.5 mmol, approximately 70 mol% purity) in THF (35 mL) was slowly added TBAF (1 M in THF, 6.17 mL). The mixture was stirred at 25° C. for 16 h. The reaction mixture was extracted with EtOAc (50 mL×3). The combined organic layers were washed with brine (50 mL×2), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 50:50) to give 3-((1-(8-oxabicyclo[3.2.1]octan-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (370 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 4.57-4.56(m,1H),4.51-4.46(m,3H),4.45-4.38(m,1H),3.86-3.83(m,2H),2.63-2.61(m,3H),2.46-2.37(m,2H), 2.13-2.06(m,2H),2.04-1.98(m,1H),1.96-1.93(m,2H),1.91-1.86(m,1H),1.84-1.80(m,1H),1.70-1.66(m,1H).
[0444] To a solution of 3-((1-(8-oxabicyclo[3.2.1]octan-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (325 mg, 1.04 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (197 mg, 1.04 mmol), and PPh3 (821 mg, 3.13 mmol) in THF (14 mL) was added DIAD (633 mg, 3.13 mmol) at 0 °C. The mixture was stirred at 25 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 50:50) to give 1-(3-((1-(8-oxabicyclo[3.2.1]octan-3-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (620 mg) of sufficient purity for the subsequent step. LC-MS (Method I) (m / z) = 482.0 (MH). + t R =0.55 minutes.
[0445] Intermediate: 3,6-Dichloro-1-[1,1-dideuterio-3-(5-methyl-4-nitro-1-tetrahydropyran-4-yl-pyrazol-3-yl)oxy-propyl]pyrazolo[3,4-d]pyrimidine [ka] To a solution of ethyl 3-hydroxypropanoate (5 g, 42 mmol) in THF (60 mL) was added TsOH .HO (403 mg, 2.12 mmol) was added and stirred at 20° C. for 30 min. Then, 3,4-dihydro-2H-pyran (4.56 g, 54.2 mmol) was added at 0° C., and the mixture was stirred at 20° C. for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 92:8) to give ethyl 3-((tetrahydro-2H-pyran-2-yl)oxy)propanoate (7.3 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.64(t,J=2.8Hz,1H),4.20-4.13(m,2H),4.05-3.95(m,1H),3.89-3.65(m,1H),3.55-3.45(m,1H),3.57-3.47 (m,1H),2.61(t,J=6.4Hz,2H),1.87-1.75(m,1H),1.74-1.65(m,1H),1.62-1.48(m,4H),1.27(t,J=7.2Hz,3H).
[0446] A solution of ethyl 3-((tetrahydro-2H-pyran-2-yl)oxy)propanoate (7.85 g, 38.8 mmol) in THF (50 mL) was added dropwise to a solution of LiAlD (2.95 g, 77.6 mmol) in THF (80 mL) at 0 °C, and the mixture was then stirred at 20 °C for 2 h. The reaction mixture was quenched with water (2 mL), followed by 10% aqueous NaOH (2 mL) and water (2 mL). The mixture was then filtered, and the filtrate was concentrated under reduced pressure to give 1,1-dideuterio-3-tetrahydropyran-2-yloxy-propan-1-ol (6.28 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.60(t,J=2.8Hz,1H),3.99-3.84(m,2H),3.65-3.50(m,2H),2.49-2.23(m,1H),1.89-1.70(m,4H),1.62-1.52(m,4H).
[0447] To a solution of 1,1-dideuterio-3-tetrahydropyran-2-yloxy-propan-1-ol (3.09 g, 19.1 mmol) in THF (180 mL) was added 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (3 g, 16 mmol), PPh3 (12.49 g, 47.62 mmol), and DIAD (9.63 g, 47.6 mmol) at 0 °C. The mixture was stirred at 20 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 80:20) to give 3,6-dichloro-1-(1,1-dideuterio-3-tetrahydropyran-2-yloxy-propyl)pyrazolo[3,4-d]pyrimidine (4.2 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.97(s,1H),4.50(t,J=3.6Hz,1H),3.82-3.74(m,2H),3.51-3.41(m,1H),3. 38-3.25(m,1H),2.22(t,J=6.0Hz,2H),1.79-1.65(m,2H),1.61-1.49(m,4H).
[0448] To 3,6-dichloro-1-(1,1-dideuterio-3-tetrahydropyran-2-yloxy-propyl)pyrazolo[3,4-d]pyrimidine (4.1 g, 12 mmol) in MeOH (100 mL) was added concentrated aqueous HCl (12 M, 10 mL) and stirred at 20 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 79:21) to give 3,3-dideuterio-3-(3,6-dichloropyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (2.6 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.99(s,1H),3.65(t,J=6.0Hz,2H),2.30(br,1H),2.14(t,J=6.0Hz,2H).
[0449] To a solution of 3,3-dideuterio-3-(3,6-dichloropyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (200 mg, 0.803 mmol) in THF (15 mL) was added 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (182 mg, 0.803 mmol), DIAD (487 mg, 2.41 mmol), and PPh3 (632 mg, 2.41 mmol) at 0° C. The mixture was stirred at 20° C. for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 35:65) to give 3,6-dichloro-1-[1,1-dideuterio-3-(5-methyl-4-nitro-1-tetrahydropyran-4-yl-pyrazol-3-yl)oxy-propyl]pyrazolo[3,4-d]pyrimidine (680 mg) of sufficient purity for the subsequent step.
[0450] Intermediate: 3,6-Dichloro-1-[3,3-dideuterio-3-(5-methyl-4-nitro-1-tetrahydropyran-4-yl-pyrazol-3-yl)oxy-propyl]pyrazolo[3,4-d]pyrimidine [ka] DIAD (1.33 g, 6.60 mmol) was added to a solution of 5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (500 mg, 2.20 mmol), 1,1-dideuterio-3-tetrahydropyran-2-yloxy-propan-1-ol (428 mg, 2.64 mmol), and PPh (1.73 g, 6.60 mmol) in THF (20 mL) at 0° C. The mixture was stirred at 20° C. for 15 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 65:35) to give 3-(1,1-dideuterio-3-tetrahydropyran-2-yloxy-propoxy)-5-methyl-4-nitro-1-tetrahydropyran-4-yl-pyrazole (1 g) of sufficient purity for the next step. All material was dissolved in MeOH (10 mL) and aqueous HCl (12 M, 5 mL) was added. The mixture was stirred at 20 °C for 15 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 0:100) followed by preparative HPLC (instrument: Gilson GX-281 liquid handler, Gilson 322 pump, Gilson 156 UV detector, column: Xtimate C18 150 × 40 mm × 10 μm, mobile phase: A: water (NH₃·H₂O + NH₄HCO₃), mobile phase B: MeCN, gradient: 25% to 55% B in 8 min, flow rate (mL / min): 55, column temperature: 35 °C, wavelength: 220 nm, 254 nm) to give 3,3-dideuterio-3-(5-methyl-4-nitro-1-tetrahydropyran-4-yl-pyrazol-3-yl)oxy-propan-1-ol (260 mg) of sufficient purity for further processing. 1 H NMR(CDCl3,400MHz)δ 4.28-4.18(m,1H),4.17-4.09(m,2H),3.92-3.78(m,2H),3.58-3.45(m,2H),2.65(s, 3H),2.57-2.48(m,1H),2.38-2.22(m,2H),2.06(t,J=5.6Hz,2H),1.81-1.72(m,2H).
[0451] DIAD (450 mg, 2.23 mmol) was added to a solution of 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (140 mg, 0.741 mmol), 3,3-dideuterio-3-(5-methyl-4-nitro-1-tetrahydropyran-4-yl-pyrazol-3-yl)oxy-propan-1-ol (235 mg, 0.812 mmol), and PPh (583 mg, 2.22 mmol) in THF (20 mL) at 0° C. The mixture was stirred at 20° C. for 15 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 60:40) to give 3,6-dichloro-1-[3,3-dideuterio-3-(5-methyl-4-nitro-1-tetrahydropyran-4-yl-pyrazol-3-yl)oxy-propyl]pyrazolo[3,4-d]pyrimidine (700 mg) of sufficient purity for the subsequent step.
[0452] Intermediate: 3,6-dichloro-1-(3-((1-(3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 3-methyltetrahydropyran-4-one (5 g, 44 mmol) and TEA (8.87 g, 87.6 mmol) in DCM (50 mL) was added TMSOTf (14.6 g, 65.7 mmol) at 0 °C. The mixture was stirred at 0 °C for 2 h. The reaction mixture was quenched with saturated aqueous NaCl (15 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by distillation (temperature: 80 °C, pressure: 0.26 mbar) to give trimethyl((5-methyl-3,6-dihydro-2H-pyran-4-yl)oxy)silane (6.7 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 4.03-3.98(m,2H),3.84-3.80(m,2H),2.20-2.11(m,2H),1.51(s,3H),0.20(s,9H).
[0453] To a solution of trimethyl((5-methyl-3,6-dihydro-2H-pyran-4-yl)oxy)silane (6.7 g, 36 mmol) in CHCN (70 mL) was added Selectfluor (15.29 g, 43.15 mmol) at 0 °C. The mixture was stirred at 0 °C for 2 h. The reaction mixture was diluted with saturated aqueous NaCl (150 mL) and extracted with EtO (4 × 50 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The residue was purified by distillation (temperature: 25 °C, pressure: 20 mbar) to give 3-fluoro-3-methyltetrahydro-4H-pyran-4-one (3.9 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.00-3.93(m,2H),3.92-3.88(m,1H),3.73-3.69(m,1H),2.89-2.80(m,1H),2.62-2.58(m,1H),1.55-1.46(m,3H).
[0454] To a solution of 2-(2-methyl-1,3-dioxolan-2-yl)acetohydrazide (1.3 g, 8.12 mmol) and 3-fluoro-3-methyltetrahydro-4H-pyran-4-one (2.15 g, 16.2 mmol) in MeOH (30 mL) was added AcOH (975 mg, 16.2 mmol). The reaction mixture was stirred at 20 °C for 1 h. NaBHCN (1.53 g, 24.4 mmol) was added, followed by stirring at 60 °C for 15 h. The mixture was concentrated under reduced pressure, and the residue was diluted with EtOAc (50 mL), washed with HO (20 mL) and brine (20 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give N'-(3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-2-(2-methyl-1,3-dioxolan-2-yl)acetohydrazide (1.65 g) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 277.2 (MH). + t R=0.57 minutes.
[0455] To a solution of N'-(3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-2-(2-methyl-1,3-dioxolan-2-yl)acetohydrazide (1.62 g, 5.86 mmol) in EtOH (20 mL) was added TFA (2.67 g, 23.5 mmol) and the reaction was stirred at 90 °C for 15 hours. TFA (2.7 g, 24 mmol) was added to the mixture and the reaction was stirred at 90 °C for an additional 16 hours. The mixture was concentrated under reduced pressure to give 1-(3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-5-methyl-1H-pyrazol-3-ol (1.9 g). All material was dissolved in HSO (20 mL) and KNO (2.95 g, 29.2 mmol) was added at 0 °C and the reaction was stirred at 0 °C for 0.5 hours. The mixture was poured into ice water (100 mL) and extracted with EtOAc (4 × 50 mL). The combined organic phase was washed with brine (50 mL), dried over Na SO , and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluent: petroleum ether: EtOAc (10v% MeOH) 100:0 → 70:30) to obtain 1-(3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-ol (0.14 g) of sufficient purity for the next step. 1 H NMR(CDCl3,400MHz)δ 8.47(br s,1H),4.46-4.37(m,1H),4.21-4.14(m,1H),3.94-3.89(m,1H),3.60-3.52(m,1H),3.51-3.4 6(m,1H),2.70(d,J=1.6Hz,3H),2.67-2.65(m,1H),1.99-1.92(m,1H),1.36(d,J=23.6Hz,3H).
[0456] To a mixture of 3-(3,6-dichloropyrazole[3,4-d]pyrimidin-1-yl)propan-1-ol (0.12 g, 0.49 mmol), 1-(3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-ol (126 mg, 0.49 mmol), and PPh3 (382 mg, 1.46 mmol) in THF (20 mL) was added DIAD (295 mg, 1.46 mmol) at 0° C. The mixture was stirred at 20° C. for 12 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40, repeated twice) to give 3,6-dichloro-1-(3-((1-(3-fluoro-3-methyltetrahydro-2H-pyran-4-yl)-5-methyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (0.2 g) of sufficient purity for the subsequent step. LC-MS (Method J) (m / z) = 488.0 (MH). + t R =1.64 minutes.
[0457] Intermediate: 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (600 mg, 1.90 mmol) and CsCO (1.86 g, 5.71 mmol) in DMF (10 mL) was added 4-(bromomethyl)tetrahydro-2H-pyran (511 mg, 2.85 mmol). The mixture was stirred at 80 °C for 16 h. The reaction mixture was diluted with EtOAc (50 mL) and extracted with HO (3 × 40 mL). The combined organic layers were washed with brine (50 mL), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 70:30) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazole (480 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.38(t,J=6.0Hz,2H),4.01-3.97(m,2H),3.85-3.79(m,4H),3.41-3.33(m,2H),2.61(s,3H),2.23 -2.11(m,1H),2.07-1.99(m,2H),1.59-1.49(m,2H),1.44-1.32(m,2H),0.88(s,9H),0.04(s,6H).
[0458] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazole (470 mg, 1.14 mmol) in THF (7 mL) was added TBAF (1 M in THF, 1.70 mL). The mixture was stirred at 25° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 40:60) to give 3-((5-methyl-4-nitro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazol-3-yl)oxy)propan-1-ol (300 mg) of sufficient purity for the subsequent step. 1H NMR(400MHz,CDCl3)δ4.50(t,J=6.0Hz,2H),4.01-3.97(m,2H),3.87-3.79(m,4H),3.40-3.34(m ,2H),2.61(s,3H),2.22-2.12(m,1H),2.10-2.05(m,2H),1.55-1.48(m,2H),1.44-1.32(m,2H).
[0459] To 3-((5-methyl-4-nitro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazol-3-yl)oxy)propan-1-ol (290 mg, 0.97 mmol) and 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (183 mg, 0.97 mmol) in THF (7 mL) was added PPh3 (762 mg, 2.91 mmol) and DIAD (588 mg, 2.91 mmol). The mixture was stirred at 25 °C for 16 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (690 mg) of sufficient purity for the subsequent step.
[0460] Intermediate: 3-bromo-8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (2.8 g, 9.3 mmol) and cis-4-methoxycyclohexan-1-ol (1.81 g, 13.9 mmol) in toluene (60 mL) was added 2-(tributyl-λ 5To the reaction mixture was added 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazole (2.54 g) of sufficient purity for the next step. 1 H NMR(CDCl3,400MHz)δ 8.01(s,1H),4.42(t,J=6.4Hz,2H),4.01-3.91(m,1H),3.82(t,J=6.0Hz,2H),3.40(s,3H),3.30-3.20(m,1 H),2.27-2.28(m,4H),2.07-2.01(m,2H),1.83-1.70(m,2H),1.48-1.34(m,2H),0.89(s,9H),0.05(s,6H).
[0461] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazole (2.4 g, 5.8 mmol) in THF (50 mL) was added TBAF (1 M in THF, 8.7 mL) and stirred at 20° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (MeOH 10 v%) 100:0 to 50:50) to give 3-((1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (1.7 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.03(s,1H),4.51(t,J=6.0Hz,2H),4.02-3.93(m,1H),3.85(t,J=5.6Hz,2H),3.39(s,3H),3. 29-3.20(m,1H),2.28-2.18(m,4H),2.14-2.06(m,2H),1.84-1.71(m,2H),1.47-1.36(m,2H).
[0462] To a mixture of 3-((1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (1.7 g, 5.7 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.07 g, 5.68 mmol), and PPh3 (4.47 g, 17.0 mmol) in THF (120 mL) was added DIAD (3.45 g, 17.0 mmol) at 0 °C. The mixture was stirred at 20 °C for 11 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40) to give 3,6-dichloro-1-(3-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (1.24 g) of sufficient purity for the subsequent step. LC-MS (Method J) (m / z) = 470.0 (M−H). + t R =1.60 minutes.
[0463] To a mixture of 3,6-dichloro-1-(3-((1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (1.24 g, 2.64 mmol) and NH4Cl (705 mg, 13.2 mmol) in a mixture of EtOH (150 mL) and HO (15 mL) was added Fe (736 mg, 13.2 mmol) at 20 °C. The reaction mixture was stirred at 80 °C for 16 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (10% MeOH v / v) 100:0 → 50:50) to give 8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (0.8 g) of sufficient purity for the subsequent step. LC-MS (Method J) (m / z) = 404.0 (M−H). + t R =1.40 minutes.
[0464] A solution of NBS (463 mg, 2.60 mmol) in THF (10 mL) was added dropwise to 8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (0.7 g, 1.73 mmol) in THF (70 mL) at 5° C. over 0.5 h. The mixture was stirred at 5° C. for 0.5 h and concentrated under reduced pressure. The residue was diluted with EtOAc (100 mL), washed with brine (50 mL × 3), dried, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (DCM 10v%) 100:0 → 50:50) and preparative SFC (instrument: Thar 200, column: DAICEL CHIRALCEL OJ-H Purification was carried out using a column (250 × 30 mm, 5 μm column, mobile phase: supercritical CO₂ / EtOH (0.1% NH₃.HO, v%) = 80 / 20, flow rate: 60 mL / min, column temperature: 38 °C, nozzle pressure: 100 bar, nozzle temperature: 60 °C, evaporator temperature: 20 °C, trimmer temperature: 25 °C, wavelength: 220 nm) to give 3-bromo-8-chloro-2-((1r,4r)-4-methoxycyclohexyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (0.26 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.62(s,1H),6.79(s,1H),4.43(t,J=4.4Hz,2H),4.36(t,J=4.8Hz,2H),4.15-4.04(m,1H),3.31(s,3H),3 .24-3.12(m,1H),2.26-2.09(m,2H),2.04-1.80(m,6H),1.39-1.24(m,2H).LC-MS(Method C)(m / z)=484.1(MH) + t R =1.69 minutes.
[0465] Intermediates: (+)-cis-8-chloro-2-(2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine and (-)-cis-8-chloro-2-(2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (5 g, 16.6 mmol) and trans-2-methyltetrahydro-2H-pyran-4-ol (2.31 g, 19.9 mmol) in toluene (150 mL) was added 2-(tributyl-λ 5 To the reaction mixture was added cis-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (4.6 g) of sufficient purity for the subsequent step.
[0466] To a solution of cis-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (4.6 g, 11.5 mmol) in THF (90 mL) was added TBAF (1 M in THF, 17.3 mL). The mixture was stirred at 20° C. for 2 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 0:100) to give cis-3-((1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (3 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.05(s,1H),4.51(t,J=6.0Hz,2H),4.25-4.13(m,2H),3.85(t,J=5.6Hz,2H),3.63-3.47(m,2H),2 .19-2.13(m,1H),2.11-2.06(m,3H),2.00-1.88(m,1H),1.71-1.59(m,1H),1.29(d,J=6.4Hz,3H).
[0467] To a solution of cis-3-((1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (3.25 g, 11.4 mmol) and 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (2.15 g, 11.4 mmol) in THF (250 mL) was added PPh3 (8.96 g, 34.2 mmol) at 5 °C, followed by DIAD (6.91 g, 34.2 mmol). The resulting mixture was stirred at 20 °C for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give cis-3,6-dichloro-1-(3-((1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (2.75 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.97(s,1H),8.03(s,1H),4.67(t,J=6.4Hz,2H),4.38(t,J=6.0Hz,2H),4.19-4.12(m,2H),3.62-3.51(m,2H),2.53-2.45(m,2H),2.15-2.10(m,1H),2.08-2.01(m,1H),1.97-1.84(m,1H),1.67-1.62(m,1H),1.30(d,J=6.8Hz,3H).
[0468] To a suspension of cis-3,6-dichloro-1-(3-((1-(2-methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (1.87 g, 4.10 mmol) in EtOH (200 mL) and HO (50 mL) was added Fe (1.14 g, 20.5 mmol) and NHCl (1.10 g, 20.5 mmol). The mixture was stirred at 80 °C for 16 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The material was suspended in DCM (100 mL), filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (MeOH 10% v / v) 80:20 → 20:80) to give cis-8-chloro-2-(2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (1.1 g). Cis-8-chloro-2-(2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (1.5 g) was purified by preparative SFC (instrument: Berger MultiGram II, column: DAICEL CHIRALPAK AD Separation was performed using a column of 250 × 30 mm, 10 μm column, mobile phase: supercritical CO₂ / EtOH (0.1% NH₃.H₂O, v%) = 45 / 55, flow rate: 80 mL / min, column temperature: 38 °C, nozzle pressure: 100 bar, nozzle temperature: 60 °C, evaporator temperature: 20 °C, trimmer temperature: 25 °C, wavelength: 220 nm to give: (+)-cis-8-chloro-2-(2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (500 mg). 1H NMR(CDCl3,400MHz)δ 8.66(s,1H),7.27(s,1H),7.06(br s,1H),4.54-4.47(m,2H),4.47-4.41(m,2H),4.23-4.10(m,2H),3.62-3.51(m,2H),2.18-2.12(m,1H),2.1 0-2.04(m,1H),2.03-1.87(m,3H),1.71-1.60(m,1H),1.28(d,J=6.0Hz,3H).LC-MS(Method C)(m / z)=390.2(MH) + t R = 1.43 min. Chiral analytical SFC conditions (instrument: Waters UPCC with PDA detector, column: Chiralpak AD-3 50 × 4.6 mm i.d., 3 μm, mobile phase: A: CO2, B: ethanol (0.05% DEA), gradient: 5% to 40% B in 2 min, hold 40% for 1.2 min, then hold 5% B for 0.8 min, flow rate: 4 mL / min, column temperature: 35 °C, ABPR: 1500 psi, run time: 4 min, wavelength: 220 nm), ee > 99%, t R =2.39 minutes.
number
number
[0469] Intermediate: 3-bromo-8-chloro-2-((2R,4R) or (2S,4S)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, Peak 1 [ka] To a solution of (+)-cis-8-chloro-2-(2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (520 mg, 1.33 mmol) in THF (19 mL) was added a solution of NBS (268 mg, 1.51 mmol) in THF (4 mL) over 13 minutes at room temperature. The mixture was stirred at room temperature for 1 hour. Water (5 mL) was slowly added at room temperature, and the reaction mixture was then concentrated under reduced pressure to remove most of the THF. The mixture was filtered, and the filter cake was washed with water, dried, and then concentrated under reduced pressure to give 3-bromo-8-chloro-2-((2R,4R) or (2S,4S)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b.5',1'-g][1]oxa[4,6,8]triazacycloundecine, peak 1 (559 mg), of sufficient purity for the next step.
[0470] Intermediate: 3-bromo-8-chloro-2-((2R,4R) or (2S,4S)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, Peak 2 [ka] To a solution of (-)-cis-8-chloro-2-(2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo was added a solution of [3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (475 mg, 1.22 mmol) in THF (19 mL) over 13 min, followed by a solution of NBS (239 mg, 1.34 mmol) in THF (4 mL) at room temperature. The mixture was stirred at room temperature for 1 h. Water (5 mL) was slowly added at room temperature, and the reaction mixture was concentrated to remove most of the THF. The mixture was filtered, and the filter cake was washed with water, dried, and then concentrated to give 3-bromo-8-chloro-2-((2R,4R) or (2S,4S)-2-methyltetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b.5',1'-g][1]oxa[4,6,8]triazacycloundecine, peak 2 (473 mg), pure enough for the next step.
[0471] Intermediate: 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1H-pyrazole (900 mg, 2.85 mmol) in toluene (30 mL) was added 2-(tributyl-λ 5(4-phosphanylidene)acetonitrile (2.75 g, 11.4 mmol) and 4-oxaspiro[2.5]octan-7-ol (439 mg, 3.42 mmol, prepared in a manner similar to that described in Mathur, A. et al. J. Org. Chem., 2017, 82, 10376-10387) were added. The mixture was stirred at 110 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 → 80:20) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazole (600 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z)=426.2(MH) + t R =1.11 minutes.
[0472] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-methyl-4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazole (590 mg, 1.39 mmol) in THF (10 mL) was added TBAF (1 M in THF, 2.08 mL). The mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 50:50) to give 3-((5-methyl-4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (400 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 312.1 (MH). + t R =0.77 minutes.
[0473] To a solution of 3-((5-methyl-4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (390 mg, 1.25 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (237 mg, 1.25 mmol), and PPh3 (986 mg, 3.76 mmol) in THF (20 mL) at 0 °C was added DIAD (760 mg, 3.76 mmol). The mixture was stirred at 20 °C for 15 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40) to give 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (500 mg) of sufficient purity for the subsequent step.
[0474] Intermediate: trans-3,6-dichloro-1-(3-((5-ethyl-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] A solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-4-nitro-1H-pyrazole (1 g, 3.0 mmol), cis-3-fluorotetrahydro-2H-pyran-4-ol (547 mg, 4.55 mmol), and 2-(tributylphosphoranylidene)acetonitrile (2.93 g, 12.1 mmol) in toluene (40 mL) was stirred at 110° C. for 15 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 95:5 to 80:20) to give trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (950 mg) of sufficient purity for the subsequent step.1 H NMR(CDCl3,400MHz)δ 5.07-4.83(m,1H),4.42(t,J=6.4Hz,2H),4.34-4.15(m,2H),4.13-4.02(m,1H),3.82(t,J=6.0Hz,2H),3.55-3.46(m,1H),3.44-3.34 (m,1H),3.15-2.98(m,2H),2.55-2.42(m,1H),2.09-2.00(m,2H),1.95-1.86(m,1H),1.28(t,J=7.6Hz,3H),0.89(s,9H),0.05(s,6H).
[0475] To a solution of trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (950 mg, 2.20 mmol) in THF (15 mL) was added TBAF (3.30 mL, 1 M in THF) at 0° C., and the reaction was stirred at 25° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 95:5 to 50:50) to give trans-3-((5-ethyl-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (600 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 5.06-4.83(m,1H),4.50(t,J=6.0Hz,2H),4.34-4.16(m,2H),4.13-4.04(m,1H),3.88(t,J=5.6Hz,2H),3.56-3.46(m,1H) ),3.44-3.34(m,1H),3.21-2.94(m,2H),2.55-2.40(m,1H),2.18-2.02(m,2H),1.97-1.87(m,1H),1.28(t,J=7.6Hz,3H).
[0476] To trans-3-((5-ethyl-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (600 mg, 1.89 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (357 mg, 1.89 mmol), and PPh3 (992 mg, 3.78 mmol) in THF (20 mL) was added dropwise DIAD (765 mg, 3.78 mmol) at 0° C. The mixture was stirred at 25° C. for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 → 50:50) to give trans-3,6-dichloro-1-(3-((5-ethyl-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (830 mg) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 488.1 (MH). + t R =0.94 minutes.
[0477] Intermediate: 3,6-dichloro-1-(3-((5-ethyl-1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine [ka] A mixture of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-4-nitro-1H-pyrazole (1 g, 3.0 mmol), cis-4-methoxycyclohexanol (790 mg, 6.07 mmol), and 2-(tributylphosphoranylidene)acetonitrile (2.93 g, 12.1 mmol) in toluene (40 mL) was stirred at 110° C. for 15 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 95:5 to 80:20) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazole (700 mg) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 4.39(t,J=6.4Hz,2H),4.03-3.91(m,1H),3.82(t,J=6.4Hz,2H),3.39(s,3H),3.33-3.20(m,1H),3.03(q,J=7.6Hz,2H),2. 30-2.19(m,2H),2.15-2.01(m,4H),1.91-1.81(m,2H),1.46-1.34(m,2H),1.26(t,J=6.8Hz,3H),0.89(s,9H),0.05(s,6H).
[0478] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-5-ethyl-1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazole (700 mg, 1.59 mmol) in THF (15 mL) was added TBAF (2.38 mL, 1 M in THF) at 0° C., and the reaction was stirred at 30° C. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether:EtOAc 95:5 to 50:50) to give 3-((5-ethyl-1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (500 mg) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 4.50(t,J=6.0Hz,2H),4.05-3.93(m,1H),3.83(t,J=5.6Hz,2H),3.39(s,3H),3.31-3.19(m,1H),3.04(q,J=7 .6Hz,2H),2.30-2.20(m,2H),2.09-2.04(m,4H),1.93-1.83(m,2H),1.42-1.32(m,2H),1.27(t,J=7.2Hz,3H).
[0479] To a solution of 3-((5-ethyl-1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (500 mg, 1.53 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (289 mg, 1.53 mmol), and PPh3 (801 mg, 3.05 mmol) in THF (20 mL) was added dropwise DIAD (618 mg, 3.05 mmol) at 0 °C. The mixture was stirred at 25 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 80:20 → 50:50) to give 3,6-dichloro-1-(3-((5-ethyl-1-((1r,4r)-4-methoxycyclohexyl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (1 g) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 498.1 (MH). + t R =0.97 minutes.
[0480] Intermediate: 3-bromo-8-chloro-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (6 g, 20 mmol) and oxepan-4-ol (3.47 g, 29.9 mmol) in toluene (120 mL) was added 2-(tributyl-λ 5 To the reaction mixture was added 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1-(oxepan-4-yl)-1H-pyrazole (7.2 g, 79.6 mmol). The mixture was stirred at 110° C. for 15 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 30:70) to give 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1-(oxepan-4-yl)-1H-pyrazole (7.2 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.04(s,1H),4.47-4.37(m,2H),4.29-4.20(m,1H),3.94-3.79(m,4H),3.77-3.67(m,2H),2. 30-2.10(m,4H),2.05-1.99(m,2H),1.95-1.79(m,2H),0.91-0.87(m,9H),0.09-0.02(m,6H)
[0481] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1-(oxepan-4-yl)-1H-pyrazole (7.4 g, 18.5 mmol) in THF (150 mL) was added TBAF (1 M in THF, 28 mL) and stirred at 20° C. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (MeOH 10 v%) 100:0 to 50:50) to give 3-((4-nitro-1-(oxepan-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (5.1 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.06(s,1H),4.51(t,J=6.0Hz,2H),4.31-4.19(m,1H),3.94-3.80(m,4H),3.77-3.67(m,2H),2.58(br s,1H),2.31-2.06(m,6H),1.94-1.79(m,2H).
[0482] To a mixture of 3-((4-nitro-1-(oxepan-4-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (1.7 g, 6.0 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.13 g, 6.0 mmol), and PPh3 (4.69 g, 17.9 mmol) in THF (100 mL) was added DIAD (3.61 g, 17.9 mmol) at 0 °C. The mixture was stirred at 20 °C for 16 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 40:60) to give 3,6-dichloro-1-(3-((4-nitro-1-(oxepan-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (3.3 g) of sufficient purity for the subsequent step. LC-MS (Method J) (m / z) = 455.9 (M−H). + t R =1.54 minutes.
[0483] To a mixture of 3,6-dichloro-1-(3-((4-nitro-1-(oxepan-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (3.5 g, 7.7 mmol) and NH4Cl (1.02 g, 19.1 mmol) in EtOH (150 mL) and HO (30 mL) was added Fe (1.07 g, 19.1 mmol) at 20 °C. The mixture was stirred at 80 °C for 16 h, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (DCM 10% by volume) 100:0 to 50:50) to give 8-chloro-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (1.5 g) of sufficient purity for the subsequent step. 1 H NMR(DMSO-d6,400MHz)δ 9.63(s,1H),8.84(s,1H),7.53(s,1H),4.53-4.37(m,4H),4.35-4.25(m,1H),3.88-3.74(m,2H) ,3.74-3.59(m,2H),2.21-2.11(m,2H),2.09-2.01(m,2H),2.0-1.88(m,2H),1.87-1.75(m,2H).
[0484] A solution of NBS (685 mg, 3.85 mmol) in THF (5 mL) was added dropwise to 8-chloro-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (1 g, 2.6 mmol) in THF (50 mL) at 25 °C. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (50 mL). The organic phase was washed with brine (20 mL × 3), dried, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (DCM 10 v%) 100:0 to 80:20) to give 3-bromo-8-chloro-2-(oxepan-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.8 g) of sufficient purity for the subsequent step. 1 H NMR(400MHz,CDCl3)δ 8.63(s,1H),6.90-6.71(m,1H),4.50-4.39(m,3H),4.38-4.32(m,2H),3.88-3.76(m,2H),3.75-3.66(m,1H),3 .65-3.56(m,1H),2.36-2.23(m,1H),2.23-2.13(m,1H),2.13-2.02(m,1H),2.0-1.9(m,3H),1.88-1.73(m,2H).
[0485] Intermediate: 3-bromo-8-chloro-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] A solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (0.56 g, 1.84 mmol) in toluene (11 mL) was treated with tetrahydro-2H-pyran-3-ol (0.261 mL, 2.76 mmol) and 2-(tributyl-λ 5 To the reaction mixture was added 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazole (412 mg) of sufficient purity for the next step.
[0486] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazole (412 mg, 0.930 mmol) in THF (15.1 mL) was added aqueous HCl (0.80 mL, 12 M, 9.6 mmol). The mixture was stirred at room temperature for 30 min. The mixture was concentrated under reduced pressure, adjusted to pH = 8-9 by adding saturated aqueous NaHCO3, and extracted with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 → 0:100) to give 3-((4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (261 mg) of sufficient purity for the subsequent step.
[0487] To the reaction vessel was added DIAD (355 μL, 1.83 mmol) and the atmosphere was replaced with argon. THF (12 mL) was added and the solution was cooled to 0° C. Next, triphenylphosphine (on resin, loading: 1.6 mmol / g) (1.18 g, 1.89 mmol) was added and the solution was stirred under argon for 5 minutes. At this point, 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (223 mg, 1.09 mmol) was added, followed by the addition of 3-((4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (261 mg, 0.914 mmol) as a solution in THF (4 mL). The mixture was allowed to warm to room temperature and stirred overnight at room temperature. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane: EtOAc 100:0 → 0:100) to give 3,6-dichloro-1-(3-((4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (498 mg) of sufficient purity for the subsequent step.
[0488] To a solution of 3,6-dichloro-1-(3-((4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (430 mg, 0.914 mmol) in EtOH (130 mL) and HO (10 mL) was added Fe (570 mg, 10.2 mmol) and NHCl (500 mg, 9.35 mmol). The mixture was stirred at 60 °C overnight, followed by stirring at 80 °C for 23 h. The reaction mixture was filtered through Celite and then concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: heptane:EtOAc 100:0 to 0:100) to give 8-chloro-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (214 mg) of sufficient purity for the subsequent step.
[0489] To a solution of 8-chloro-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (532 mg, 1.37 mmol) in THF (19 mL) was added NBS (276 mg, 1.55 mmol) as a solution in THF (4 mL) over 13 minutes at room temperature. The mixture was stirred at room temperature for 1 hour. Water (5 mL) was slowly added at room temperature, and the reaction mixture was then concentrated under reduced pressure to remove most of the THF. The mixture was filtered, and the filter cake was washed with water and dried to give 3-bromo-8-chloro-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (492 mg) of sufficient purity for the subsequent step.
[0490] Intermediate: 8-chloro-2-((3R,4S) or (3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, Peak 1 and 8-Chloro-2-((3R,4S) or (3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, Peak 2 [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (6 g, 20 mmol) and cis-3-fluorotetrahydro-2H-pyran-4-ol:trans-3-fluorotetrahydro-2H-pyran-4-ol (cis / trans = 3:1, 3.59 g, 29.9 mmol) in toluene (120 mL) was added 2-(tributyl-λ5 To the resulting solution was added trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (5.6 g), which was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 30:70) to give trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (5.6 g), which was sufficiently pure for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 8.12(s,1H),4.93-4.72(m,1H),4.44(t,J=6.4Hz,2H),4.27(dd,J=5.6,11.6Hz,1H),4.12-4.04(m,2H),3.83(t,J=5.6Hz,2H) ),3.55-3.45(m,1H),3.43-3.34(m,1H),2.44-2.33(m,1H),2.18-2.09(m,1H),2.06-2.00(m,2H),0.89(s,9H),0.05(s,6H).
[0491] To a solution of trans-3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (5.47 g, 13.6 mmol) in THF (100 mL) was added TBAF (1 M in THF, 20 mL) and stirred at 20° C. for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (MeOH 10% v / v) 100:0 to 50:50) to give trans-3-((1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (3.6 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.14(s,1H),4.93-4.71(m,1H),4.51(t,J=6.0Hz,2H),4.27(dd,J=5.2,11.2Hz,1H),4.21-4.14(m,1H),4.10-4.04(m,1H) ),3.87(t,J=6.0Hz,2H),3.55-3.45(m,1H),3.43-3.33(m,1H),2.43-2.33(m,1H),2.18-2.13(m,1H),2.12-2.07(m,2H).
[0492] To trans-3-((1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propan-1-ol (3.6 g, 135 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (2.35 g, 12.5 mmol), and PPh3 (9.79 g, 37.3 mmol) in THF (200 mL) was added DIAD (7.55 g, 37.3 mmol) at 0° C. The mixture was stirred at 20° C. for 11 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (MeOH, 10% v / v) 100:0 → 50:50) to give trans-3,6-dichloro-1-(3-((1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (3 g) of sufficient purity for the subsequent step. LC-MS (Method J) (m / z) = 482.0 (M+Na). + t R =1.54 minutes.
[0493] To trans-3,6-dichloro-1-(3-((1-(3-fluorotetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (3 g, 6.5 mmol) and NHCl (1.74 g, 32.6 mmol) in a mixture of EtOH (600 mL) and HO (100 mL) was added Fe (1.82 g, 32.6 mmol) at 20 °C. The mixture was stirred at 80 °C for 16 h. Additional Fe (1.82 g) and NHCl (1.74 g) were added and stirred at 80 °C for an additional 16 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (DCM, 10 v%) 100:0 → 50:50) to give trans-8-chloro-2-(3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (1.6 g). trans-8-chloro-2-(3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (1.6 g) was separated using preparative SFC (instrument: Thar SFC Prep 200, column: DAICEL CHIRALPAK AD 250 x 30 mm, 10 μm, mobile phase: supercritical CO2 / ETOH (0.1% NH3.H2O, v%) = 50 / 50, flow rate: 200 mL / min, column temperature: 38 °C, nozzle pressure: 100 bar, nozzle temperature: 60 °C, evaporator temperature: 20 °C, trimmer temperature: 25 °C, wavelength: 220 nm) to give: 8-Chloro-2-((3R,4S) or (3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, peak 1 (0.62 g), of sufficient purity for subsequent steps. LC-MS (Method B) (m / z) = 394.1 (M−H). + t R= 0.77 min. Chiral analytical SFC conditions (instrument: Waters UPCC with PDA detector, column: Chiralpak AD-3 50 × 4.6 mm i.d., 3 μm, mobile phase: A: CO2, B: ethanol (0.05% DEA), isocratic solvent: 40% B, flow rate: 4 mL / min, column temperature: 35 °C, ABPR: 1500 psi, run time: 4 min, wavelength: 220 nm), ee > 99%, t R =1.42 minutes. and the corresponding enantiomers 8-Chloro-2-((3R,4S) or (3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, peak 2 (0.53 g), of sufficient purity for the next step. LC-MS (Method B) (m / z) = 394.1 (M−H). + t R = 0.77 min. Chiral analytical SFC conditions (instrument: Waters UPCC with PDA detector, column: Chiralpak AD-3 50 × 4.6 mm i.d., 3 μm, mobile phase: A: CO2, B: ethanol (0.05% DEA), isocratic solvent: 40% B, flow rate: 4 mL / min, column temperature: 35 °C, ABPR: 1500 psi, run time: 4 min, wavelength: 220 nm), ee > 99%, t R =1.97 minutes.
[0494] Intermediate: (+)-3-Bromo-8-chloro-2-((3R,4S) or (3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] A solution of NBS (470 mg, 2.64 mmol) in THF (5 mL) was added dropwise to 8-chloro-2-((3R,4S) or (3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, peak 1 (0.52 g, 1.32 mmol) in THF (50 mL) at 20 °C. The mixture was stirred at 20 °C for 1 h. The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (10 mL). The organic phase was washed with brine (5 mL × 2), dried, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (DCM 10% v / v) 100:0 → 50:50) and preparative SFC (instrument: Thar SFC Prep80, column: DAICEL CHIRALCEL OD-H The column was purified using a 250 × 30 mm, 10 μm column, mobile phase: supercritical CO₂ / EtOH (0.1% NH₃.H₂O, v%) = 70 / 30, flow rate: 80 mL / min, column temperature: 38 °C, nozzle pressure: 100 bar, nozzle temperature: 60 °C, evaporator temperature: 20 °C, trimmer temperature: 25 °C, wavelength: 220 nm) to give (+)-3-bromo-8-chloro-2-((3R,4S) or (3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (0.2 g) of sufficient purity for subsequent steps. 1 H NMR(CDCl3,400MHz)δ 8.73(s,1H),6.82(br s,1H),5.09-4.87(m,1H),4.60-4.40(m,5H),4.34-4.26(m,1H),4.12-4.04(m,1H),3.60-3.50 (m,1H),3.49-3.39(m,1H),2.43-2.30(m,1H),2.12-1.95(m,3H).LC-MS(Method C)(m / z)=474.1(MH) + t R= 1.60 min. Chiral analytical SFC conditions (Instrument: Waters UPCC with PDA detector, Column: Chiralpak AD-3 50 × 4.6 mm i.d., 3 μm, Mobile phase: A: CO2, B: Ethanol (0.05% DEA), Gradient: 5% to 40% B in 2 min, hold 40% for 1.2 min, then hold 5% B for 0.8 min, Flow rate: 4 mL / min, Column temperature: 35 °C, ABPR: 1500 psi, Run time: 4 min, Wavelength: 254 nm), ee > 99%, t R =0.78 minutes.
number
[0495] Intermediate: (-)-3-bromo-8-chloro-2-((3R,4S) or (3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] The intermediate was prepared by elution with (+)-3-bromo-NBS (434 mg, 2.44 mmol) in THF (5 mL), 8-chloro-2-((3R,4S or 3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, peak 2 (0.48 g, 1.22 mmol) in THF (50 mL) at 20 °C for 1 h. This compound was prepared in a similar manner to 8-chloro-2-((3R,4S) or (3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, and purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (10% by volume) 100:0 → 50:50) and preparative SFC (instrument: Thar SFC Prep80, column: DAICEL CHIRALCEL OD-H). Subsequent purification using a 250 × 30 mm, 10 μm column, mobile phase: supercritical CO₂ / EtOH (0.1% NH₃.HO, v%) = 70 / 30, flow rate: 80 mL / min, column temperature: 38 °C, nozzle pressure: 100 bar, nozzle temperature: 60 °C, evaporator temperature: 20 °C, trimmer temperature: 25 °C, wavelength: 220 nm) afforded (−)-3-bromo-8-chloro-2-((3R,4S) or (3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.23 g) of sufficient purity for subsequent steps. 1 H NMR(CDCl3,400MHz)δ 8.72(s,1H),6.91(br s,1H),5.09-4.87(m,1H),4.60-4.41(m,5H),4.34-4.25(m,1H),4.12-4.04(m,1H),3.56-3.50 (m,1H),3.49-3.39(m,1H),2.43-2.29(m,1H),2.12-1.95(m,3H).LC-MS(Method C)(m / z)=474.0(MH) + tR = 1.60 min. Chiral analytical SFC conditions (Instrument: Waters UPCC with PDA detector, Column: Chiralpak AD-3 50 × 4.6 mm i.d., 3 μm, Mobile phase: A: CO2, B: Ethanol (0.05% DEA), Gradient: 5% to 40% B in 2 min, hold 40% for 1.2 min, then hold 5% B for 0.8 min, Flow rate: 4 mL / min, Column temperature: 35 °C, ABPR: 1500 psi, Run time: 4 min, Wavelength: 254 nm), ee > 99%, t R =0.99 minutes.
number
[0496] Intermediates: (-)-(R) or (S)-3-bromo-8-chloro-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine and (+)-(R) or (S)-3-bromo-8-chloro-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1H-pyrazole (7.6 g, 25 mmol) and 4-oxaspiro[2.5]octan-7-ol (4.2 g, 33 mmol, prepared in a similar manner as in Mathur, A. et al. J. Org. Chem., 2017, 82, 10376-10387) in toluene (220 mL) was added 2-(tributyl-λ 5To the reaction mixture was added 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazole (6.3 g) of sufficient purity for the subsequent step. 1 H NMR(CDCl3,400MHz)δ 7.99(s,1H),4.37(t,J=6.4Hz,2H),4.32-4.22(m,1H),4.0-3.93(m,1H), 3.77(t,J=6.4Hz,2H),3.64-3.55(m,1H),2.47-2.39(m,1H),2.14-2.02(m ,2H),2.00-1.94(m,2H),1.57-1.52(m,1H),0.96-0.90(m,1H),0.84(s,9 H),0.75-0.66(m,1H),0.60-0.53(m,1H),0.49-0.40(m,1H),0.03(s,6H).
[0497] To a solution of 3-(3-((tert-butyldimethylsilyl)oxy)propoxy)-4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazole (6.3 g, 15 mmol) in THF (120 mL) was added TBAF (1 M in THF, 23 mL) and stirred at 25° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (MeOH 10 v%) 100:0 to 50:50) to give 3-((4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (4.4 g) of sufficient purity for the subsequent step. 1H NMR(CDCl3,400MHz)δ 8.07(s,1H),4.51(t,J=6.0Hz,2H),4.39-4.28(m,1H),4.06-3.99(m,1H),3.86(t ,J=5.6Hz,2H),3.70-3.60(m,1H),2.53-2.45(m,1H),2.22-2.08(m,4H),1.70(br s,1H),1.63-1.57(m,1H),1.01-0.95(m,1H),0.82-0.71(m,1H),0.68-0.58(m,1H),0.54-0.44(m,1H).
[0498] To 3-((4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazol-3-yl)oxy)propan-1-ol (4.3 g, 14.5 mmol), 3,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (2.73 g, 14.5 mmol), and PPh3 (11.4 g, 43.4 mmol) in THF (180 mL) was added DIAD (8.77 g, 43.4 mmol) at 0 °C. The mixture was stirred at 25 °C for 14 hours. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc 100:0 to 60:40) to give 3,6-dichloro-1-(3-((4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (3.3 g) of sufficient purity for the subsequent step. LC-MS (Method B) (m / z) = 468.1 (MH). + t R =0.93 minutes.
[0499] To 3,6-dichloro-1-(3-((4-nitro-1-(4-oxaspiro[2.5]octan-7-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (3.2 g, 6.8 mmol) and NH4Cl (3.20 g, 59.8 mmol) in a mixture of EtOH (320 mL) and HO (60 mL) was added Fe (3.20 g, 57.3 mmol) at 20 °C. The mixture was stirred at 80 °C for 16 h. The mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (DCM 10% v / v) 100:0 → 50:50) to give 8-chloro-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (1.5 g) of sufficient purity for the next step. LC-MS (Method B) (m / z) = 402.1 (M−H). + t R =0.70 minutes.
[0500] A solution of NBS (1.24 g, 6.97 mmol) in THF (20 mL) was added dropwise to a solution of 8-chloro-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (1.4 g, 3.5 mmol) in THF (130 mL) at 25 °C. The mixture was stirred at 25 °C for 1 h. The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (20 mL). The organic phase was washed with brine (3 × 10 mL), dried and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: petroleum ether: EtOAc (DCM 10% by volume) 100:0 to 80:20) to give 3-bromo-8-chloro-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (0.7 g) of sufficient purity for the subsequent step. 3-Bromo-8-chloro-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (0.7 g) was separated by preparative SFC (instrument: SFC150AP, column: DAICEL CHIRALPAK AD 250 × 30 mm, 10 μm, mobile phase: supercritical CO2 / EtOH (0.1% NH3)). 3· HO, v%) = 40 / 60, flow rate: 100 mL / min, column temperature: 38 °C, nozzle pressure: 100 bar, nozzle temperature: 60 °C, evaporator temperature: 20 °C, trimmer temperature: 25 °C, wavelength: 220 nm) to give: (-)-(R) or (S)-3-Bromo-8-chloro-2-(4-oxaspiro[2.5]octan-7-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (0.24 g). 1H NMR(CDCl3,400MHz)δ 8.71(s,1H),7.02(br s,1H),4.60-4.50(m,3H),4.49-4.42(m,2H),4.06-3.99(m,1H),3.72- 3.63(m,1H),2.78-2.69(m,1H),2.40-2.27(m,1H),2.10-2.01(m,2H),1 .98-1.90(m,1H),1.41-1.33(m,1H),1.00-0.93(m,1H),0.81-0.73(m,1 H),0.63-0.56(m,1H),0.52-0.45(m,1H).LC-MS(Method C)(m / z)=482.0(MH) + t R = 1.68 min. Chiral analytical SFC conditions (Instrument: Waters UPCC with PDA detector, Column: Chiralpak AD-3 50 × 4.6 mm i.d., 3 μm, Mobile phase: A: CO2, B: Ethanol (0.05% DEA), Gradient: 5% to 40% B in 2 min, hold 40% for 1.2 min, then hold 5% B for 0.8 min, Flow rate: 4 mL / min, Column temperature: 35 °C, ABPR: 1500 psi, Run time: 4 min, Wavelength: 254 nm), ee > 99%, t R =1.18 minutes.
number
number
[0501] Compounds of the Invention Example 1: 8-chloro-2,3-dimethyl-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] To a solution of 3,6-dichloro-1-(3-((1,5-dimethyl-4-nitro-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (90 mg, 0.23 mmol) in HO (1 mL) and EtOH (5 mL) was added Fe (65 mg, 1.17 mmol) and NHCl (62 mg, 1.17 mmol). The reaction mixture was stirred at 100 °C for 16 h. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (equipment: Gilson GX-281 liquid handler, Gilson 322 pump, Gilson 156 UV detector; column: Phenomenex Gemini-NX C18 75 × 30 mm × 3 μm; mobile phase: A: water (0.05% NH3.H2O v / v + 10 mM NH4HCO3), mobile phase B: MeCN, gradient: 30% to 60% B in 7 min, then hold at 100% for 2 min; flow rate (mL / min): 25; column temperature: 25 °C; wavelength: 220 nm - 254 nm) to give the title compound (30 mg). 1 H NMR(CDCl3,400MHz)δ 8.67(s,1H),6.76(br s,1H),4.54-4.42(m,4H),3.70(s,3H),2.29(s,3H),1.99-1.95(m,2H).LC-MS(Method C)(m / z)=320.2(MH) + t R =1.67 minutes.
[0502] Example 2: 8-chloro-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] The compound was prepared in a manner similar to that of Example 1 using 3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (840 mg, 1.84 mmol), Fe (514 mg, 9.20 mmol), and NH4Cl (492 mg, 9.20 mmol) in EtOH (40 mL) and HO (4 mL) at 100 °C for 15 h, worked up, and purified by preparative HPLC (instrument: Gilson GX-281 liquid handler, Gilson 322 pump, Gilson 156 UV detector; column: Xtimate C18 150 × 40 mm × 5 μm; Mobile phase A: water (0.05% NH3H2O), Mobile phase B: MeCN; Gradient: 28% to 53% B in 6 min, then hold at 100% for 1 min; Flow rate (mL / min): 1; Column temperature: 25 °C; Wavelength: 220 nm - 254 nm). 1 H NMR(CDCl3,400MHz)δ 8.65(s,1H),6.85(br s,1H),4.57-4.35(m,4H),4.17-4.06(m,3H),3.59-3.46(m,2H),2.36-2.21 (m,5H),2.01-1.90(m,2H),1.85-1.77(m,2H).LC-MS(Method C)(m / z)=390.2(MH) + t R =1.79 minutes.
[0503] Example 3: (R) or (S)-8-chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine, Peak 1 and Example 4: (R) or (S)-8-chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine, Peak 2 [ka] The racemic mixture of Examples 3 and 4 was prepared in a manner similar to that of Example 1 using (±)-3,6-dichloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-3-yl)oxy)propyl)-1H-pyrazolo[3,4-d]pyrimidine (218 mg, 0.478 mmol), Fe (133 mg, 2.39 mmol), and NHCl (128 mg, 2.39 mmol) in EtOH (17 mL) and HO (1.7 mL) at 94 °C for 4 h, followed by workup and chromatography on silica gel (eluent: heptane:EtOAc). Purification by 80:20 → 10:90 followed by HPLC purification gave (±)-8-chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (140 mg). The racemic mixture (140 mg) was separated into two enantiomers by preparative chiral SFC (instrument: Berger Multigram II, column: Chiralpak-IA, 250 mm × 20 mm, 5 μm particle size, mobile phase: CO2 / EtOH (96% with 0.1% DEA, v / v) = 60 / 40, flow rate: 50 mL / min, column temperature: 35 °C, pressure: 100 bar), giving: Example 3, Peak 1: (R) or (S)-8-chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5′,1′-g][1]oxa[4,6,8]triazacycloundecine (35 mg). 1H NMR(600MHz,CDCl3)δ 8.66(s,1H),6.52(br s,1H),4.53-4.37(m,4H),4.07(tt,J=11.1,4.4Hz,1H)),3.98-3.91(m,2H),3.69(t,J=10.8Hz,1H),3.48-3.40(m,1H), 2.28(s,3H),2.28-2.18(m,1H),2.09-2.04(m,1H),2.00-1.88(m,2H),1.86-1.78(m,2H).LC-MS(Method E)(m / z)=390.4(MH) + t R = 0.59 min. Chiral analytical SFC conditions (instrument: Aurora SFC Fusion5 / Agilent, column: Chiralpak-IA, 150 × 4.6 mm, particle size: 5 μm, mobile phase: CO2 / EtOH (96% containing 0.1% DEA, v / v) = 60 / 40, isocratic elution: 7 min, flow rate: 4 mL / min, column temperature: 40 °C, UV detection: 254 nm), ee > 99%, t R =1.92 minutes. and the corresponding enantiomers Example 4, Peak 2: Example 4: (R) or (S)-8-chloro-3-methyl-2-(tetrahydro-2H-pyran-3-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine (50 mg). 1 H NMR(600MHz,CDCl3)δ 8.66(s,1H),6.52(br s,1H),4.53-4.37(m,4H),4.07(tt,J=11.1,4.4Hz,1H)),3.98-3.91(m,2H),3.69(t,J=10.8Hz,1H),3.48-3.40(m,1H), 2.28(s,3H),2.28-2.18(m,1H),2.09-2.04(m,1H),2.00-1.88(m,2H),1.86-1.78(m,2H).LC-MS(Method E)(m / z)=390.4(MH) + t R= 0.59 min. Chiral analytical SFC conditions (instrument: Aurora SFC Fusion5 / Agilent, column: Chiralpak-IA, 150 × 4.6 mm, particle size: 5 μm, mobile phase: CO2 / EtOH (96% containing 0.1% DEA, v / v) = 60 / 40, isocratic elution: 7 min, flow rate: 4 mL / min, column temperature: 40 °C, UV detection: 254 nm), ee > 99%, t R =2.53 minutes.
[0504] Example 5: 3-methyl-2-(tetrahydro-2H-pyran-4-yl)-8-(trifluoromethyl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] The compound was prepared in a manner similar to that of Example 1 using 6-chloro-1-(3-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl)oxy)propyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine (95 mg, 0.19 mmol), Fe (54 mg, 0.97 mmol), and NH4Cl (52 mg, 5 eq, 0.97 mmol) in EtOH (15 mL) and HO (1.5 mL) at 85 °C for 72 h, followed by workup and purification by chromatography on silica gel (eluent: heptane:EtOAc 80:20 to 10:90) to give the title compound (42 mg). 1 H NMR(CDCl3,600MHz)δ 8.81(s,1H),6.57(br s,1H),4.60-4.42(m,4H),4.17-4.06(m,3H),3.52(td,J=12.1,2.1Hz,2H ),2.33-2.24(m,2H),2.30(s,3H),2.08-1.94(m,2H),1.84-1.78(m,2H). 19 F NMR(CDCl3,470MHz)δ-61.5(s).LC-MS(Method E)(m / z)=424.4(MH) + t R=0.64 minutes.
[0505] Example 6: 8-Bromo-3-methyl-2-(tetrahydro-2H-pyran-4-yl)-2,4,12,13-tetrahydro-11H-5,7-(azenometheno)dipyrazolo[3,4-b:5',1'-g][1]oxa[4,6,8]triazacycloundecine [ka] A solution of DIAD (87 μL, 0.45 mmol) in THF (5 mL) was cooled to 0 °C. PPh3 (on resin, ca. 3 mmol / g) (118 mg, 0.449 mmol) (using 150 mg of resin (ca. 3 mmol / g) = 0.449 mmol) was added in small portions, and the mixture was stirred for 10 min. 5-Methyl-4-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-ol (60.0 mg, 0.264 mmol, prepared as described above) was then added, followed by a solution of 3-(3-bromo-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propan-1-ol (77.0 mg, 0.26 mmol) in THF (1 mL). The cooling bath was removed, and the reaction mixture was stirred for 2 h. The mixture was filtered, washing with THF, and the filtrate was concentrated to dryness under reduced pressure. The resulting residue was redissolved in ethanol (5 mL) and water (0.5 mL). Fe (73.7 mg, 1.32 mmol) and NH4Cl (70.6 mg, 1.32 mmol) were added, the flask ...
Claims
1. Formula I 【Chemistry 1】 (In the formula, R 1 is CH 2 R 4 Or R 4 and R 2 is C 1 ~C 3 Alkyl, isotopically labeled C 1 ~C 3 Alkyl, C 3 ~C 6 Cycloalkyl, or C 1 ~C 3 haloalkyl; R 3 is halogen, cyano, O-C 1 ~C 3 Haloalkyl, C 1 ~C 3 Haloalkyl, C 3 ~C 6 Cycloalkyl, or C 1 ~C 3 is alkyl; R 4 is a 4-7 membered heterocycle having 1 to 2 heteroatoms independently selected from oxygen and nitrogen; 1 ~C 3 Alkyl, C 1 ~C 3 Cyanoalkyl, C 1 ~C 3 Haloalkyl, or C 3 ~C 6 is cycloalkyl; Or R 4 is a bicyclic 8-membered heterocycle having 1-2 heteroatoms independently selected from oxygen and nitrogen; Each heterocycle or cycloalkyl is unsubstituted or substituted with cyano, deuterium, halogen, C 1 ~C 3 Alkyl, isotopically labeled C 1 ~C 3 Alkyl, O-C 1 ~C 3 Haloalkyl, O-C 1 ~C 3 Alkyl, or C 1 ~C 3 substituted with 1, 2, or 3 groups independently selected from the group consisting of haloalkyl; or a pharma- ceutically acceptable salt thereof.
2. The compound is of formula Ia 【Chemistry 2】 2. The compound of claim 1, which is a compound of the formula:
3. R 2 But, C 1 ~C 3 Alkyl, isotopically labeled C 1 ~C 3 Alkyl or C 3 ~C 6 3. The compound according to claim 1 or 2, or a pharma- ceutically acceptable salt thereof, selected from cycloalkyl.
4. R 2 But -CH 3 , C.H. 2 CH 3 , -CD 3 or cyclopropyl; or cyclopropyl; or a pharma- ceutically acceptable salt thereof.
5. R 2 isotopically labeled C 1 ~C 3 The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.
6. R 2 Ga-CD 3 5. The compound according to any one of claims 1 to 4, wherein:
7. R 3 The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof, wherein is halogen.
8. R 3 The compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, wherein is chloro.
9. R 4 is a 4- to 6-membered heterocyclic ring having one oxygen atom, and the 4- to 6-membered heterocyclic ring is unsubstituted or is substituted with cyano, deuterium, halogen, C 1 ~C 3 Alkyl, isotopically labeled C 1 ~C 3 Alkyl or C 1 ~C 3 9. The compound of any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof, substituted with one group selected from the list consisting of haloalkyl.
10. R 4 is a 4- to 6-membered heterocyclic ring having one oxygen atom, and the 4- to 6-membered heterocyclic ring is unsubstituted or is substituted with cyano, deuterium, halogen, C 1 ~C 3 Alkyl, isotopically labeled C 1 ~C 3 Alkyl or C 1 ~C 3 9. The compound of any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof, substituted with two groups independently selected from the list consisting of haloalkyl.
11. R 4 But -CH 3 , 【Chemistry 3】 【Chemistry 4】 (wherein * indicates the attachment point) 9. The compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:
12. R 4 The compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof, wherein is unsubstituted tetrahydropyran.
13. R 4 The compound according to any one of claims 1 to 8, wherein is unsubstituted tetrahydro-2H-pyran-4-yl, or a pharma- ceutically acceptable salt thereof.
14. 【Chemical 5】 【Chemistry 6】 2. The compound of claim 1, selected from the list of:
15. 【Chemical 7】 【Chemistry 8】 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】 2. The compound of claim 1, selected from the list of:
16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 and one or more pharma- ceutically acceptable carriers.
17. 16. A compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, for use in therapy.
18. 16. A compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, for use in the treatment of a disease of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, or Parkinson's disease.
19. 16. The compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, or Parkinson's disease in a patient carrying the G2019S mutation of LRRK2.
20. 16. A compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, for use in the treatment of a disease or disorder characterized by increased LRRK2 kinase activity; or by expression of one or more mutant forms of LRRK2 selected from G2019S, I2020T, M1646T, G2385R, A419V, N551K, R1398H, K1423K, R1441G, R1441H, R1441C, R1628P, S1647T, Y1699C, I2020T, and Y2189C; or by one or more LRRK2 non-coding mutations selected from rs76904798-T and Rs1491942-G.
21. 16. Use of a compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or disorder of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy, or Parkinson's disease.
22. 22. The use according to claim 21, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, or Parkinson's disease in patients carrying the G2019S mutation of LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
23. 16. A method for treating a disease or disorder of the central nervous system selected from dementia with Lewy bodies, multiple system atrophy or Parkinson's disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof.
24. 24. The method of claim 23, wherein the Parkinson's disease is idiopathic Parkinson's disease, sporadic Parkinson's disease, Parkinson's disease in patients carrying the G2019S mutation of LRRK2, or Parkinson's disease in patients carrying one or more LRRK2 non-coding variants selected from rs76904798-T and Rs1491942-G.
